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Abstract 
The uibiquitous Type II toxin – antitoxin (TA) loci encode two proteins, a toxin and 
an antitoxin. The antitoxin combines with and neutralizes a cognate toxin. Usually, 
the TA genes form an operon that is transcribed by a single promoter located 
upstream of the genes. In most cases, the antitoxin autoregulates the TA operon via 
binding to operator sites in the promoter region. In almost all such cases, the toxin act 
as a co-repressor of transcription as the toxin enhances the DNA binding of the 
antitoxin. Recently, it has been shown that toxins play an additional role in 
stimulating transcription, as the antitoxin and toxin ratio is important for cooperative 
binding of the complex to DNA. The antitoxin is rapidly degraded by cellular 
proteases under conditions of stress and treatment with antibiotics, which leads to 
activation of the toxin. 
The toxins of TAs belong to different gene families. The most abundant TA 
gene family is vapBC that, in some organisms, have expanded into cohorts of genes. 
For example, the major human pathogen Mycobacterium tuberculosis contains at least 
88 TAs, 45 of which are vapBC loci. VapC toxins encoded by vapBC loci are PIN 
domain proteins (PilT N-terminal). Eukaryotic PIN domain proteins are site-specific 
ribonucleases involved in quality control, metabolism and maturation of mRNA and 
rRNA. From in vitro experiments it has been postulated that VapC toxins are RNases 
or DNases but their exact cellular target has remained elusive.  
Here I show that VapC encoded by Shigella flexneri 2a virulence plasmid 
pMYSH6000 and the chromosome of Salmonella enterica serovar Typhimurium LT2 
are site-specific endoribonucleases that specifically cleave tRNA
fMet
 in the anticodon 
stem-loop in vivo and in vitro. Furthermore, I show that VapC dependent depletion of 
tRNA
fMet
 leads to bacteriostatic inhibition of global translation, which surprisingly 
induces low-level initiation of translation at elongator codons that are correctly 
positioned relative to a Shine & Dalgarno sequence.  
I also show that VapC forms a complex with VapB and acts as a co-repressor 
of vapBC transcription. During steady state growth VapB is in excess of VapC. 
However, nutrient stress or treatment with antibiotics leads to Lon protease dependent 
decrease in VapB levels. Furthermore, I show that VapC in excess of VapB directly 
interferes with cooperative DNA binding of the VapBC complex, which is dependent 
on the dimerisation of the VapC toxin. 
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In conclusion, I show that enteric VapCs not only regulate global cellular 
translation by tRNA
fMet
 cleavage, but also regulate vapBC transcription by conditional 
cooperativity. 
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Abbreviations 
A     adenosine 
Amp     ampicillin 
ATP     adenosine triphosphate 
bp     base pair(s) 
BLAST    basic local alignment search tool 
C     cytosine 
ºC    degrees Celsius 
CM     chloramphenicol 
C-terminus    carboxy terminus 
Da     Daltons 
DNase    deoxyribonuclease 
dNTP     deoxynucleotide triphosphate 
EDTA    Ethylenediaminetetraacetic acid 
EF     elongation factor 
EMSA    electrophoretic mobility shift assay 
EtBr    Ethidium Bromide 
FD    Formamide 
G     guanine 
h    hour 
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
His-tag    poly-histidine tag 
HTH     helix turn helix 
IF    initiation factor 
IPTG     isopropylthio-β-D-galactosidase 
IR    inverted repeat 
Kan    kanamycin 
kb     kilobase 
LB     luria bertani 
LHH    looped helix helix 
mi     mRNA interferase 
min    minutes 
mRNA    messenger RNA 
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Native-PAGE    non-denaturing PAGE 
ND     not determined 
NMD     nonsense mediated decay 
NMR     nuclear magnetic resonance 
N-terminus    amino terminus 
MW    molecular weight 
OD     optical density 
ON    over night 
ORF     open reading frame 
PAGE     polyacrylamide gel electrophoresis 
PBS     phosphate buffered saline 
PCR     polymerase chain reaction 
PDB     protein data bank 
PIN     PilT N-terminal domain 
PNK     polynucleotide kinase 
ppGpp    guanosine tetraphosphate 
PSK     post segregational killing 
RHH     ribbon helix helix 
rpm     revolutions per minute 
RNase    ribonuclease 
rRNA     ribosomal RNA 
SDS    Sodium dodecyl sulphate 
σ    sigma factor 
T     thymine 
TA     toxin antitoxin 
Tris    tris-(hydroxymethyl)-aminomethane 
tRNA    transfer RNA 
tRNAse   transfer RNA ribonuclease 
U     uracil 
UTR     untranslated region 
Vap     virulence associated protein 
WT     wild type 
 9 
Introduction 
Prokaryotes have evolved elaborate strategies to inherit unstable plasmids by actively 
preventing loss during cell division. In most cases prokaryotic plasmids contain 
centromere-like gene cassettes that actively segregate plasmids before cell division 
occurs (Gerdes et al., 2004). Others rely on gene cassettes, which selectively restrict 
the reproduction of plasmid-free daughter cells (Jensen and Gerdes, 1995). The latter 
type of system is also referred to as toxin-antitoxin systems (TAs).  
Early genetic screening for genes involved in stabilisation of plasmid R1 revealed a 
small locus named hok/sok (host killing/ suppression of killing) (Gerdes et al., 1986). 
This system is represented by three genes; mok (modulator of killing), hok and sok. 
The mok gene encodes a small peptide, which overlaps with hok reading frame and is 
necessary for hok translation. The sok gene, which is a cis encoded small RNA that 
inhibits Hok synthesis in two ways; indirectly by intefering with mok translation and 
directly by decreasing the stability of hok mRNA in a RNase III dependent manner 
(Thisted and Gerdes, 1992;Gerdes et al., 1992). If continuous synthesis of unstable 
sok mRNA is lost e.g. if the plasmid is not inherited to one of the daughter cells after 
cell division, left over stable hok mRNA will result in Hok synthesis and selective 
killing  of plasmid free cells. This phenotype is also referred to as postseggregational 
killing or PSK. A general trait of all TAs is that they encode an unstable antitoxin and 
a stable toxin, which evidently, if plasmid is resident, will lead to plasmid addiction 
and a PSK phenotype. It is now clear that TAs are not only restricted to mobile 
genetic elements such as plasmids or phages, but are also present on prokaryotic  
chromosomes (Gerdes and Wagner, 2007;Fozo et al., 2010). Hence, chromosomal 
TAs may play other roles. 
TAs come in several forms and have been divided into three different types with 
respect to the nature of their component parts; hok/sok TA system is a type I TA 
(Figure 1A). The second class, Type II TAs, are strictly proteic systems in which the 
antitoxin neutralises the toxin by direct interactions between antitoxin and toxin 
(Gerdes et al., 2005;van Melderen, 2010) (Figure 1B). The third class is type III TAs, 
which are similar to type I having an RNA antitoxin and similar to the type II systems 
in that the antitoxin makes direct interactions with the toxin and hereby neutralizes its 
activity (Figure 1C). Type III TAs are a quite recent discovery and the only well 
described example is plasmid resident ToxIN (ToxN for toxin and ToxI for toxin 
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inhibitor) from Erwinia carotovora Atroseptica (Fineran et al., 2009). The TA locus 
was found to be an efficient abortive infection (Abi) system that gives resistance to 
multiple types of phages, by restricting growth of infected cells. The recent solving of 
ToxIN crystal structure revealed, ToxI as a 36-nucleotide RNA pseudo-knot, which 
makes extensive RNA-protein contacts with ToxN (Blower et al., 2011b). 
Interestingly, the structure also revealed that ToxN is involved in generating ToxI by 
endonuclease activity on a repetitive ToxI precursor.  
Most TA research to date has concerned Type II TAs and will also be the main 
subject of this introduction. Bioinformatic reports from several groups in recent years 
have made it apparent that type II TAs are highly abundant not only on plasmids but 
especially on chromosomes of both bacteria and archaea (Anantharaman and Aravind, 
2003;Pandey and Gerdes, 2005;Makarova et al., 2009). This makes type II TAs far 
more common than either type I or type III TAs. 
Type II TAs have been extensively studied over the years, but their biological roles 
are still not clear and several possibilities have been suggested, which might not be 
 
Figure 1 Overview of Toxin-Antitoxin types. A) Type I TAs encode a small Antisense RNA 
antitoxin which inhibits translation of toxin mRNA as well as promoting the degradation by cellular 
ribonucleases such as RNase III. If synthesis of RNA antitoxin is discontinued toxin is translated 
and actvated. B) Type II TAs are strictly proteic and encode an unstable antitoxin and a stable toxin 
which forms a non-toxic complex. Antitoxin inhibits transcription, which is enhanced by the toxin 
in TA complex. When antitoxin is degraded by cellular proteases, toxin liberated to act on its target. 
C) Type III TAs encode an RNA antitoxin, which is generated from antitoxin repeats and a protein 
toxin. RNA antitoxin neutralises toxin activity by binding to the toxin which also negatively 
regulates transcription. As yet unidentified factor(s) are predicted to degrade or interfere with the 
antitoxin, which in turn actives the toxin. Adapted from (Blower et al., 2011a). 
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exclusive. These include: stress response elements and pathogenesis systems (Gerdes 
et al., 2005;Ramage et al., 2009), persistence (Korch et al., 2003;Keren et al., 
2004;Vazquez-Laslop et al., 2006), quorum sensing and biofilm formation (Kim et 
al., 2009;Wang et al., 2011), protection from phage infection (Hazan and Engelberg-
Kulka, 2004), protection against loss of DNA (Szekeres et al., 2007;Wozniak and 
Waldor, 2009), programmed cell death (Aizenman et al., 1996) and even anti-
addiction modules (Saavedra De et al., 2008). 
Generally, type II TAs constitute a single genetic unit where the toxin gene is 
positioned downstream of the antitoxin gene (Gerdes et al., 2005). In the majority of 
TAs the antitoxin TGA stop-codon overlaps with ATG start-codon of the toxin gene 
in an ATGA sequence (-2bp overlap), however TGATG sequence (-1bp) is also 
frequent. These gene overlaps reflects translational coupling, which has been shown 
for the parD/pem TA-locus of plasmid R1/R100 (Ruiz-Echevarria et al., 1995).  
However, for some families of type II TAs including higBA, hicAB and mqsRA the 
antitoxin gene is positioned downstream of the toxin gene (Pandey and Gerdes, 
2005;Jorgensen et al., 2009;Brown et al., 2009). In these cases antitoxin and toxins 
levels are balanced by rare start codons or an additional promoter.  
The antitoxin gene encodes a proteic antitoxin (~70-150 amino acids), which 
generally contains an N-terminal DNA binding domain that bind in the TA promoter 
region and represses TA operon transcription. Antitoxins generally bind toxins (~90-
440 amino acids) by high affinity interactions between the antitoxin C-terminus and 
the toxin. The TA complex formation usually enhances the affinity of the antitoxin for 
promoter DNA. Generally antitoxins, as opposed to toxins, are unstructured proteins, 
which render them metabolically unstable and prone to proteolysis by cellular 
proteases (summarised in Figure 1B).     
The following chapter, Chapter 1, will be an overview of Type II TA families, 
phylogeny and distribution. Chapter 2 will describe the structures of Type II toxins 
and their molecular targets. Chapter 3 will focus on mechanisms of toxin inactivation 
and how Type II TAs are regulated. The final chapter, Chapter 4, will concern the 
different aspects of Type II TAs function and proposed biological roles.     
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Chapter 1: Families 
Toxin-antitoxin loci: Families, distrubution and phylogeny 
By the development of shotgun sequencing methods, the first bacterial genome was 
sequenced in 1995 (Fleischmann et al., 1995). This led to an explosion in the number 
of sequenced genomes over the last 15 years and now more than 1600 genomes are 
available on National Centre for Biotechnology Information genome homepage 
(http://www.ncbi.nlm.nih.gov/genome). Bioinformatic analysis on vast sequence data 
sets allows new connections and predictions to be made regarding the biology of 
bacteria and archaea. Bioinformatics in particular has been central for the 
understanding of type II TAs and the distribution and phylogeny of chromosomal 
Type II TAs. Even predictions of new TA families have been made possible.   
Type II toxin-antitoxin systems were first discovered as efficient PSK systems, which 
can stabilise mobile genetic elements such as ccd locus of Escherichia coli F-plasmid 
(Ogura and Hiraga, 1983). Several distinct families of plasmid encoded Type II TAs 
have since been identified: parD/pem of R1/R100 (Bravo et al., 1987), vapBC of 
Salmonella Dublin virulence plasmid (Pullinger and Lax, 1992), parDE of RK2 
(Roberts and Helinski, 1992), phd-doc of bacteriophage P1 (Lehnherr et al., 1993), 
higBA of Rts1 (Tian et al., 1996) and relBE of P307 (Gronlund and Gerdes, 1999).   
For parD TA locus of plasmid R1, kis-kid (killing suppressor and determinant), 
chromosomal homologues chpA and chpB (chromosomal homolog of pem) were soon 
after identified in Escherichia coli (Masuda et al., 1993). At present, chpA is 
generally referred to as mazEF (Aizenman et al., 1996). It is now known that chpA 
toxin, ChpAK, more commonly referred to as MazF, does not actually kill the cells 
and MazF-inhibited cells can easily be resuscitated by subsequent chpAI/MazE 
production (Pedersen et al., 2002). Similar early observations were made for relBE of 
plasmid P307, which was found to have chromosomal homologues not only in 
bacteria but also in archaea (Gotfredsen and Gerdes, 1998;Gronlund and Gerdes, 
1999). Observations like these have questioned whether plasmid-resident Type II TAs 
in fact kill plasmid-free cells or, rather, restrict growth when TA resident plasmids are 
lost. Identification of a striking abbundance of TAs on the chromosomes of 
prokaryotes led to the idea that TAs might have other biological roles than stabilising 
DNA (Gerdes, 2000;Anantharaman and Aravind, 2003;Pandey and Gerdes, 2005).  
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To date, at least ten type II TA-families from plasmids and chromosomes have been 
identified, which have been divided according to sequence similarity of the toxin 
(summarised in Table 1). Most prokarytotic TAs encode toxins which inhibit 
translation, these are: MazF, RelE, HigB, Doc, VapC, HipA and HicA. Only a few 
toxins inhibit replication, ParE and CcdB, and one peptidoglycan synthesis, δ (Toxin 
targets will be discussed in detail in Chapter 2).     
Table 1 Summary of prokaryotic Type II TA loci in 964 prokaryotic genomes1 
TA 
family 
Antitoxin DNA – binding 
domain
1,2
 
Protease Toxin Activity Number 
of loci
1
 
Phylogenetic 
distribution
2
 
 
 
CcdAB 
 
CcdA 
 
RHH 
 
Lon 
 
CcdB 
 
Inhibition of 
DNA gyrase 
 
8 
 
Gram
-
 
 
MazEF 
 
MazE 
 
Xre/HTH, RHH,  
XF1863/RHH & 
AbrB  
 
 
ClpAP/Lon 
 
MazF 
 
mRNA 
cleavage 
 
126 
 
Gram
-
 &  
Gram
+
 
 
RelBE 
 
RelB 
 
Xre/HTH, RHH, 
COG1753/RHH, 
AbrB & Phd 
 
Lon 
 
RelE 
 
Ribosome 
dependent 
mRNA 
cleavage 
 
889 
 
Gram
-
,  
Gram
+
 & 
Archaea 
 
ParDE 
 
ParD 
 
RHH & Phd 
 
ND 
 
ParE 
 
Inhibition of 
DNA gyrase 
 
50 
 
Gram
-
  
 
HigBA 
 
HigA 
 
COG5606/HTH & 
RHH 
 
Lon 
 
HigB 
 
Ribosome 
dependent 
mRNA 
cleavage 
 
 
54 
 
Gram
-
 &  
Gram
+
 
 
Phd-Doc 
 
PhD 
 
RHH, Phd 
YhfG 
 
ClpXP 
 
Doc 
(fic) 
 
Associating 
with 30S 
ribosomal 
subunit 
 
92 
 
Gram
-
 &  
Gram
+
 
 
VapBC 
 
VapB 
 
Xre/HTH, 
COG2442/HTH,  
COG2886/HTH, 
MerR/HTH RHH, 
COG2880/AbrB, 
AbrB  & Phd 
 
 
ND 
 
VapC 
(PIN) 
 
Ribonuclease 
 
1316 
 
Gram
-
,  
Gram
+
 & 
Archaea 
 
HipBA 
 
HipB 
 
Xre/HTH 
 
Lon 
 
HipA 
 
Phosphorylation 
of translation 
factor EF-Tu 
 
 
258 
 
Gram
-
,  
Gram
+
 & 
Archaea 
 
HicAB 
 
HicB 
 
HicB 
 
Lon 
 
HicA 
 
mRNA 
cleavage 
 
247 
 
Gram
-
,  
Gram
+
 & 
Archaea 
 
 
ω-ε-δ 
 
ω 
 
RHH 
 
N/A 
 
δ 
 
Phosphorylation 
of 
peptidoglycan 
precursor 
 
 
16 
 
Gram
+
 
The table excludes 117 and 615 loci which could only be assigned to specific superfamilies of 
MazF/CcdB and RelE/ParE, respectively. 1(Makarova et al., 2009) 2(Shao et al., 2011). 
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An early bioinformatic study revealed by high resolution sequence alignments that in 
fact ParE and RelE belong to a super family of toxin proteins, the ParE/RelE super 
family, which share conserved residues forming the core of secondary structural 
elements (Anantharaman and Aravind, 2003). The HigB toxin family is also part of 
the ParE and RelE super family, yielding a larger RelE/ParE/HigB superfamily of 
toxins, as HigB shares low but significant sequence similarities with RelE and is a 
ribosome dependent mRNA interferase (Anantharaman and Aravind, 2003;Pandey 
and Gerdes, 2005). HigBA is, however, easily distinguished from RelBE or ParDE as 
the antitoxin is positioned downstream of the toxin.  Similar observations have been 
made for CcdB and MazF which share a SH3 barrel structural fold and therefore also 
constitutes a superfamily, the CcdB/MazF super family (Loris et al., 1999;Kamada et 
al., 2003;Buts et al., 2005). These observations are intriguing as it seems that RelE 
and ParE or MazF and CcdB have evolved from the same ancestral proteins to target 
both replication and translation. Futhermore, that proteins from two different 
structural superfamilies such CcdB and ParE have evolved independently to acquire 
the same cellular target. The other toxin families have evolved independently and 
constitute their own structural super families including: Doc, VapC, HipA, HicA and 
δ. 
Antitoxins can be classified by their N-terminal DNA domain, but are far less 
conserved compared to toxins. The common classes of DNA-binding domains 
employed by antitoxins are; Helix-Turn-Helix (HTH), Ribbon-Helix-Helix (RHH), 
AbrB and Phd. Interestingly, DNA-binding domains are not restricted to a specific 
TA family and often antitoxins within the same TA family utilises different classes of 
DNA-binding domains (Anantharaman and Aravind, 2003;Pandey and Gerdes, 
2005;Makarova et al., 2009;Leplae et al., 2011) (see Table 1).  
These observations all suggest that TAs undergo rapid evolution and prone to gene 
shuffling events. It has become increasingly clear that TAs belong to a prokaryotic 
„mobileome‟ which refer to genes that rapidly spread via horizontal gene transfer 
(HGT) (Makarova et al., 2009;Leplae et al., 2011). The mobilome also includes 
prophages, restriction modification systems (RMs) and clustered regularly interspaced 
short palindromic repeats (CRISPR) with CRISPR associated systems (CRISPR-Cas), 
which are thought to be anti-phage immunity systems (Barrangou et al., 2007). The 
mobilome has recently been reviewed (Koonin and Wolf, 2008). 
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From Table 1 it is observed that translational inhibitors (including the mRNA 
interferases) have far the greatest representation ~98%, whereas vapBC is the most 
represented TA loci familiy ~ 43%. While mazEF, higBA, cddAB, parDE, phd-doc 
and ω-ε-δ TA loci are more or less restricted to bacteria, hicAB, relBE- and vapBC-
homologues are widely distributed in both bacteria and archaea.  
There is a distinct phyletic pattern of TA loci distribution: bacteria that have 
drastically reduced genomes such as obligate host-associated parasites or symbiotes 
only retain a few loci (Pandey and Gerdes, 2005;Makarova et al., 2009;Leplae et al., 
2011). There are, however, exceptions which include intracellular pathogens of the 
Rickettsia family, but this group only recently evolved and the genomes are still 
undergoing reductive evolution (Ogata et al., 2001). This observation led Gerdes and 
co-workers to suggest that TA loci might be specifically beneficial to free-living 
prokaryotes (Pandey and Gerdes, 2005;Gerdes et al., 2005;Sevin and Barloy-Hubler, 
2007). 
However, there is also a relationship between the genome size and number of TAs 
and the lack of TAs in organisms with small genomes could also be a consequence of 
TA abundance scaling with genome size (Makarova et al., 2009;Leplae et al., 2011). 
Nevertheless, there is enrichment for TAs in organisms belonging to the phyla of 
proteobacteria, cyanobacteria, green sulphur bacteria and actinobacteria often 
characterized by high phenotypic plasticity. These include proteobacteria such as 
Nitrosomonas europaea (~59 TAs) which has a very versatile metabolism and 
Photorhapdus luminescens (~66 TAs), with a versatile life cycle (Leplae et al., 2011). 
Both organisms have high numbers of insertion sequences in their genomes. 
Another example is the human pathogen Mycobacterium tuberculosis which contains 
up to 88 TA loci (Ramage et al., 2009)(Figure 2C). In stark contrast obligate 
intracellular Mycobacterium leprae contains only one predicted TA and several 
pseudo TAs (non-functional TAs) (Pandey and Gerdes, 2005;Leplae et al., 2011). M. 
leprae has evolved from M. tuberculosis by massive reductive evolution and the 
presence of several pseudo genes indicates it is still undergoing decay (Cole et al., 
2001). M. tuberculosis has a persistent growth state, which is highly tolerant to 
antibiotics and has an extracellular and intracellular growth phase (Stewart et al., 
2003). This observation also supports a theory that TAs might be beneficial to M. 
tuberculosis as it needs to be more versatile to confront more varied environments 
than M. leprae. Organisms with high phenotypic plasticity seem to share common 
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traits as many are characterised by very low growth rates and therefore TAs might 
contribute to or be beneficial during slow growth (Pandey and Gerdes, 2005). 
Model organism Escherichia coli K-12 is known to have at least ten TA-systems, 
seemingly scattered throughout its genome, and are primarily of the type which 
A
C
Vibrio cholera
Chr II
Escherichia 
Coli K-12
Mycobacterium
tuberculosis
H37Rv
B
 
Figure 2 Predicted and verified TA loci on selected bacterial chromosomes. A) Escherichia coli 
K-12 (4.6 Mb) with 12 TAs. This prediction does not include recently described yafNO (which is 
homologues to RelBE TA-family (Christensen-Dalsgaard et al., 2010) B) Vibrio cholerae Chr II 
(1.1Mb) with 16 TAs C) Mycobacterium tuberculosis H37Rv (4.4Mb) with 61 TAs. The TAs are 
either classified by TA-family or DNA-binding domain and toxin family. New putative TA 
families include; YhfG–Fic; which is a predicted Fic (Doc-like) toxin with a new YhfG antitoxin 
family. RHH-COG2929; RHH containing antitoxin with COG2929 toxin (distant RelE 
homologue). RHH-GNAT; RHH containing antitoxin with GNAT toxin (Predicted N-
acetyltransferase). COG2442-PIN; COG2442 (Predicted helical RNA/DNA binding protein) 
antitoxin and PIN domain toxin (VapC). ArsR-COG3832; AsrR antitoxin (Predicted HTH 
binding domain) and COG3832 toxin (homologues to eukaryotic stress proteins). Xre-COG5654 
and COG5642-COG5654; Xre and COG5652 antitoxins (HTH DNA binding domains) with 
predicted COG5654 toxin (conserved protein of unknown function). Adapted from (Makarova et 
al., 2009;Shao et al., 2011). 
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inhibit translation by mRNA cleavage (Figure 2A). However, TAs are not in all cases 
randomly scattered as there are chromosomal gene contexts which have higher TA 
frequency than others. These contexts can be highly diverse even between closely 
related species (Pandey and Gerdes, 2005;Makarova et al., 2009).  
An example is the mazEF locus of Escherichia coli K-12, E. coli O157 and E. coli 
EDL933 (Pandey and Gerdes, 2005). In these strains mazEF is positioned just 
downstream of the relA gene. Interestingly, in closely related species such as E. coli 
CFT073 and Shigella flexneri 2A a TA locus in this position is completely absent. 
What is more striking is that in related species as Salmonella Typhimurium LT2, S. 
typhi and S. typhi 2A, mazEF in this position is substituted for a parDE TA locus 
(Pandey and Gerdes, 2005). Variability in TAs between closely related organisms was 
recently analysed using 41 genome sets of closely related prokaryotic organisms 
which drew the same conclusion, as variability was strikingly high (Makarova et al., 
2009).  
It is therefore conceivable that specific places on the chromosome such as the position 
downstream of the relA gene are “hot spots” for TA integration. Another extreme 
example of preferential localization patterns has been observed for Vibrio cholorae 
where all TAs, including those predicted and verified experimentally, reside inside a 
mega integron on chromosome II in close proximity of attC recombination sites 
(Pandey and Gerdes, 2005;Makarova et al., 2009) (Figure 2B). Highly clustered TAs 
are also found in Mycobacterium tuberculosis and Nitrosomonas europaea as the 
majority of TAs seem to reside inside “TA Islands” on the chromosome (Pandey and 
Gerdes, 2005;Makarova et al., 2009) (Figure 2C). 
With increasing numbers of available sequenced genomes, comparative genomics 
approaches have been widely used to identify new TA families. The hicAB locus was 
discovered in a pilus gene cluster of Haemophilus influenza also called hif cluster (H. 
Influenzae fimbrae). Bioinformatic approaches such as comparative genomics 
predicted hicAB to be a new TA family. This was recently verified experimentally 
(Makarova et al., 2006;Jorgensen et al., 2009). Numerous TAs have been identified 
by searching the genetic context of a putative toxin for antitoxin-like or predicted 
DNA-binding proteins (Makarova et al., 2009;Leplae et al., 2011). These putative 
TAs are often restricted to certain phyla or plasmids which complicates their 
identification.   
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Several three-component type II TAs have also been described, which are variations 
on the two component systems. Some of these have been described including: ω-ε-δ 
of broad-range plasmid pSM19035 of Bacillus subtilis , pasABC of pTF-CF2 from 
Thiobacillus ferrooxidans and paaR-paaA-parE of Escherichia coli O157:H7(de la 
Hoz et al., 2000;Smith and Rawlings, 1997;Hallez et al., 2010). These types of TAs 
are commonly found on plasmids and often the antitoxic and DNA-binding activities 
are encoded by two separate proteins rather than one.  
Bioinformatic approaches have also revealed the presence of solitary toxins in 
prokaryotic genomes, which might have evolved alternative functions. A studied 
example is the solitary mazF toxin of Myxococcus xanthus, which has been shown to 
induce programmed cell death as a part of a complex multicellular developmental 
program (Nariya and Inouye, 2008). In about 5% of identified VapC toxins the 
reading frame was found to be without any antitoxin partner, but in these cases the 
VapC toxin was found to fused with a TRAM domain (RNA binding), KH domains 
(RNA binding) and AAA+ ATPase domains, which suggests that the toxin has 
adapted alternative functions (Anantharaman and Aravind, 2003).  
The following chapter, Chapter 2, will outline the structural aspects and the molecular 
target of the toxin of type II TAs and related cytotoxins. 
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Chapter 2: Toxins 
Structure and activity of Toxins 
In recent years the numbers of identified TA and TA-like systems have expanded 
rapidly and this chapter will focus on the structure and activity of different 
characterised toxin families. Escherichia coli K-12 is the major bacterial model 
organism and consequently its TAs have been studied in greatest detail including; 
dinj-yafQ (relBE TA-family), yafNO (relBE TA-family), hicAB (renamed from yncN-
ydcQ), hipBA, relBE, yeeUV (new putative TA-family), yefM-yoeB (relBE TA-
family), mazEF (renamed from chpA), mqsR-mqsA (renamed from ygiU-ygiT), higBA 
(renamed from ygjN-ygjM), prlF-yhaV (relBE TA-family), chpB (chpS-chpB/mazEF 
TA-family) (Figure 2A).  
To date the majority of identified toxin targets have been shown to target the 
translational machinery, which is also the case for TAs of E. coli K-12. The majority 
of all toxins inhibit translation by ribonuclease activity which in most cases is 
dependent on the ribosome. A few other described toxin families have evolved 
different targets inside the translation machinery or in distinct cellular processes 
outside the translation machinery. Toxin expression in general results in bacteriostatic 
growth inhibition from which the cells can be resuscitated by subsequent expression 
of antitoxin. The following section separates the toxin from the antitoxin counterparts 
to define the structural features and cellular activity of toxins. 
Toxin targets outside the translation machinery – CcdB, ParE, Zeta and 
YeeV 
Inhibitors of DNA gyrase – CcdB and ParE  
Both CcdB and ParE target the DNA gyrase, which is an essential type II 
topoisomerase in E. coli (Bernard et al., 1993;Jiang et al., 2002).  
The structure of CcdB revealed a N-terminal five-stranded β sheet, a 13 residue C-
terminal α-helix, and central three small stranded β-sheet containing a loop (Figure 
3A left) (Loris et al., 1999). CcdB forms a dimer and the structure resembles that of 
MazF despite the fact that they only share low sequence similarity (Figure 3A right). 
Enigmatically, MazF is an mRNA interferase, whereas CcdB does not cleave RNA 
and, accordingly, residues involved in RNA hydrolysis are not present (Buts et al., 
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2005). The crystal structure of ParE from Caulobacter crescentus has recently been 
solved (Dalton and Crosson, 2010). The structure revealed a ParE dimer of monomers 
with two N-terminal α-helices connected by a single tryptophan W26 forming an 
antiparallel hairpin structure which packs against a three stranded β-sheet (Figure 3B 
left). Intriguingly, ParE structure resembles that of RelE and YoeB from Escherichia 
coli, which like MazF are mRNA interferases (Figure 3B right). These observations 
suggest a similar evolutionary origin (Buts et al., 2005). 
Instead of cleaving RNA, CcdB and ParE are DNA gyrase inhibitors which have 
evolved from two distinct structural superfamilies. DNA gyrase is a topoisomerase 
that induces negative supercoiling as well as resolves interlinked plasmids, making it 
essential in replication, transcription, DNA repair and recombination (Bernard and 
Couturier, 1992;Nollmann et al., 2007). The gyrase consists of two subunits, GyrA 
containing a catalytic domain and GyrB containing ATP-binding domain, which in 
concert facilitate double-stranded DNA break as well as rejoining activity. The crystal 
structure of CcdB bound to its target has been solved (Dao-Thi et al., 2004;Dao-Thi et 
al., 2005). CcdB binds to a fragment of GyrA by three C-terminal residues W99, 
G100 and I101, causing two distinct effects whether the DNA gyrase is associated 
with DNA or not. If GyrA is in its free state or bound to GyrB in the absence of DNA, 
CcdB forms GyrA-CcdB or GyrA-GyrB-CcdB complexes which are inactive. When 
DNA gyrase is in its catalytically active state with DNA, CcdB blocks the closing of 
GyrA subunits which creates DNA roadblocks that inhibit replication and 
transcription. The W99 residue in CcdB dimer interacts with Arg462 in GyrA dimer, 
 
Figure 3 Structures of CcdB and ParE. A) Left the Structure of CcdB dimer and right E. coli 
MazF dimer structure. α-Helices (yellow) and β-sheets (Red)  B) Left the structure of ParE dimer 
from C. crenscentus with structural features coloured in one monomer and right ParE 
superimposed on E. coli RelE and YoeB. Adapted from (Dao-Thi et al., 2005;Buts et al., 
2005;Dalton and Crosson, 2010). 
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and CcdB resistant DNA gyrases are obtained by a Arg462Cys substitution (Dao-Thi 
et al., 2005).  
ParE also inhibits DNA gyrase, which prevents initation of replication at oriC (Jiang 
et al., 2002). However, ParE seems to act by a distinct mechanism as ParE from 
Vibrio cholera has been shown to bind GyrA but not GyrA fragments as observed for 
CcdB. Furthermore, a strain containing a GyrA Arg462Cys substitution mutation is 
still sensitive to ParE (Yuan et al., 2010). Nevertheless, CcdB and ParE both result in 
DNA strand breaks as DNA is not resolved by DNA gyrase and both efficiently 
inhibit replication and cell division (Couturier et al., 1998) 
Targeting peptidoglycan synthesis and cell division – Zeta and YeeV 
Zeta is the toxin of three component TA system ε-ω-δ which has been described from 
plasmid pSM19035 and pezAT (pneumococcal ω ζ) from the chromosome of 
Streptococcus pneumoniae (Zielenkiewicz and Ceglowski, 2005;Khoo et al., 2007). 
Crystal structures of Zeta and PezT revealed monomeric proteins folding into α/β 
structures  similar to that of phophotransferases with a ATP/GTP-binding pocket 
(Meinhart et al., 2003;Khoo et al., 2007). More recently it has been shown that PezT 
inhibits cell wall synthesis by phosphorylating petidoglycan precursor diphosphate-N-
acetylglucosamine (UNAG) using ATP (Mutschler et al., 2011).  
YeeV is the toxin component of a new putative TA system yeeUV present on the 
chromosome of E. coli K-12 (Brown and Shaw, 2003). It has recently been shown 
that YeeV might constitute a new toxin family, different from CcdB and ParE, which 
inhibits cell division (Tan et al., 2011). YeeV was found not only to inhibit the 
GTPase activity and GTP–dependent polymerisation of FtsZ, an essential tubulin-like 
cell division protein, but also the ATP-dependent polymerisation of MreB, an actin-
like protein involved in cell divison and determination of cell shape. 
Toxin targets inside the translation machinery 
The ribosome and translation 
The main actor of the translation machinery is the ribosome. In bacteria, translation 
involves formation of a 70S ribosomal initiation complex of 50S and 30S ribosomal 
subunits with the aid of mRNA, fMet-tRNA
fMet
 and initation factors (IF1, IF2 and 
IF3) (Figure 4A). Selection of translation initation site is often governed by the 
interaction of a unique mRNA leader sequence, referred to as the Shine & Dalgarno 
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sequence, with the anti-Shine & Dalgarno sequence of 16S rRNAt. However, this 
mechanism is not exclusive as other structural features of the mRNA also increase 
specificity and leaderless translation initation has also been found to occur (Laursen et 
al., 2005;Nakamoto, 2009). Initiator fMet-tRNA
fMet
 contains universally conserved 
structural features as the G-C stem of the anticodon stemloop, which increases its 
selection in 30S ribosomal subunit P-site. This selection is increased in the presence 
of initiation factors (Hartz et al., 1989;Antoun et al., 2006). It has recently been 
shown that multiple copies of tRNA
fMet
 genes in E. coli ensure high cellular levels of  
tRNA
fMet
, which might also be crucial for the fidelity in P-site selection (Kapoor et 
al., 2011). After the formation of 70S translation intiation complexes, cycles of 
translation elongation can occur. Cognate aminoacyl charged tRNA bound to 
Elongation factor-Tu (EF-Tu) with GTP enters in the ribosomal A-site and peptidyl 
transfer occurs (Figure 4B). Peptidyl transfer is followed by translocation stimulated 
by elongation factor G (EF-G) and GTP, which moves the ribosome forward and 
uncharged P-site tRNA is moved to E-site and A-site tRNA with peptide chain to the 
P-site, this leaves the A-site vacant on the next codon for subsequent rounds of 
translation elongation (Shoji et al., 2009). Translation is terminated when ribosomal 
A-site reaches a stop codon (UAG, UAA or UGA), which is recognised by peptide 
chain release factor 1 or 2 (RF1 or RF2) (Loh and Song, 2010). Release factors trigger 
the hydrolysis of the tRNA peptide ester bond and release of the peptide (Figure 4B). 
Subsequently, the GTPase activity of Release factor 3 (RF3) catalyses release of RF1 
and RF2. Post termination complexes are recycled by combined action of Ribosome 
recycling factor RRF and EF-G, mRNA and deacylated tRNA is finally removed by 
IF3, which also has anti-association activity preventing 30S and 50S re-assembly 
(Seshadri and Varshney, 2006;Petry et al., 2008). 
The E. coli ribosome incorporates amino acids into a peptide chain with elongation 
rates ranging from 10-18 amino acids/sec depending on the doubling rate of the cell 
(Dennis and Bremer, 1974). To avoid mistranslation, the ribosome has adapted 
mechanisms which increase translation fidelity..  
Key steps in translation quality control involves correct selection during aminoacyl-
tRNA synthesis (recognition of correct amino acid and tRNA by aminoacyl-tRNA 
synthases), EF-Tu binding, aminoacyl-tRNA selection in the ribosomal A-site and 
post peptide bond formation selection in ribosomal P-site (Reynolds et al., 2010).  
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Figure 4 Overview of translation A) Translation initiation. IF1 (red) and IF3(green) associates with 
30S and keeps 50S and 30S dissociated. fMet-tRNAf
Met (purple) with IF2(blue) and GTP  associates 
with mRNA(yellow) and 30S ribosomal subunit in an 30S preinitation complex. Anticodon 
interaction leads to conformational changes and ejection of IF1 and IF3. 50S ribosomal subunit 
associates with 30S initation complex by IF2-GTP hydrolysis and ejection of IF2-GDP + Pi. B) 
Translation elongation and termination. Ternary complex of EF-Tu-GTP bound aminoacyl-tRNA 
binds in vacant ribosomal A-site. Peptidyl transfer of aminoacyl group of tRNA in P-site to 
aminoacyl-tRNA in ribosomal A-site occurs and translation factor ejection is mediated by hydrolysis 
of GTP. The ribosome moves one codon by hydrolysis of EF-G-GTP which positions P-site 
deacylated tRNA in the E-site and A-site tRNA with peptide in the P-site. Translation is terminated 
when A-site reaches a stop codon and peptide released by the action of release factors. C) The trans-
translation mechanism. Alanine acylated tmRNA (Alanyl group, orange square) bound to SmpB 
(purple square) and EF-Tu-GTP (not shown) enters the ribosomal A-Site of a ribosome stalled on a 
mRNA 3‟-end. tmRNA accepts the peptide chain from P-site tRNA by peptidyl transfer and 
translation resumes on tmRNA reading frame which encodes proteolytic tag. The mRNA (blue) is 
released and degraded by cellular RNases. Translation terminates normally on the protease tag 
reading frame stop codon by Release factor  (Red rectangle) mediated peptide release. The tmRNA 
tagged peptides (green squares) are now targeted for proteolysis by cellular proteases. Adapted from 
(Laursen et al., 2005;Zaher and Green, 2009;Keiler and Ramadoss, 2011). 
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These quality control mechanisms result in low incorporation error rates with an 
average of 3.4 × 10
-4
 per codon, which can vary slightly depending on the tRNA 
abundance of a specific codon (Kramer and Farabaugh, 2007). 
Trans-translation 
If the mRNA is damaged or if ribosomes are deprived from terminating, ribosomes 
will normally stall (Sunohara et al., 2004;Li et al., 2007). Ribosome stalling is also 
induced by depletion of aminoacyl-tRNA either by amino acid starvation or by 
consecutive rare codons (decoded by low abundance aminoacyl-tRNA) in an mRNA 
(Li et al., 2008b;Garza-Sanchez et al., 2008). Ribosome stalling has been observed to 
induce mRNA cleavage in the ribosomal A-site(Hayes and Sauer, 2003;Garza-
Sanchez et al., 2009). This is induced either by an unknown endoribonuclease and/or 
by the action of 3‟-5‟exoribonuclease RNase II by degradation of mRNA which is not 
protected by ribosomes (The possible role of mRNA cleaving toxins in A-site 
cleavage will be discussed).  
This results in a non-stop mRNA (mRNA without a stopcodon) containing a stalled 
ribosome on mRNA 3‟-end and trailing ribosomes, which are deprived of an 
opportunity of terminating translation normally. The ribosome can be released and 
recycled by a process referred to as trans-translation, which simultaneously facilitates 
the degradation of damaged truncated mRNA and translated peptide (figure 4C and 
recently reviewed (Keiler and Ramadoss, 2011)). The central player in trans-
translation is tmRNA which only functions in concert with protein SmpB and EF-Tu-
GTP. The tmRNA is unique as it contains a 5‟- and 3‟-end tRNA-like domain 
resembling a tRNA with an amino acyl acceptor stem a T-arm and a D-loop, as well 
as a short 10 codon mRNA reading frame (Komine et al., 1994;Tu et al., 1995). 
Alanyl tRNA-synthase (alaRS) is required as tRNA-like domain of tmRNA has to be 
charged with an alanyl group before it is recognized by EF-Tu-GTP (Barends et al., 
2001). SmpB is a crucial partner as it not only mimics tRNA anti-codon in the 
ribosome but also facilitates the interaction of tmRNA with alaRS, thus, the 
resumption of translation on tmRNA reading frame (Karzai et al., 1999;Hanawa-
Suetsugu et al., 2002). Trans-translation is independent of normal translation 
initiation and tmRNA contains a GCA codon (resume codon) on which translation 
resumes (Williams et al., 1999). Resuming of translation on tmRNA reading frame 
leads to release of non-stop mRNA, which is degraded primarily by the activity of 
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RNase R, and tagging of truncated peptide for proteolysis by cellular proteases (Lies 
and Maurizi, 2008;Ge et al., 2010). Resumption of translation allows ribosomes to 
terminate normally and to be recycled. The trans-translation mechanism seems to be 
important for translation quality control in E. coli, but might also be an integral part in 
gene regulation as it affects the timing of DNA replication in Caulobacter crescentus 
and affects virulence in Salmonella enterica and Yersina pestis (Julio et al., 
2000;Keiler and Shapiro, 2003;Okan et al., 2010). Recently, two additional proteins 
ArfA (YhgL) and YaeJ have been identified in E. coli, which can perform tmRNA 
independent peptide release and ribosome rescue (Chadani et al., 2010;Chadani et al., 
2011). ArfA was shown to be synthetic lethal with tmRNA in E. coli, which indicates 
the importance of a functional ribosome rescue system.  
The majority of Type II TA toxins have cellular targets inside the translation 
machinery and are all potent inhibitors of translation. These include; RelE, HigB, 
MazF, HicA, MqsR, Doc, HipA and VapC. The term mRNA interferases (mi) has 
been adopted by Inouye and co-workers to describe proteins which inhibit translation 
by mRNA cleavage, and is now generally used to describe: RelE, HigB, MazF, HicA 
and MqsR toxins. 
Ribosome dependent mRNA Interferases – RelE and HigB 
The relBE locus of the E. coli chromosome is one of the best described TA loci. The 
relB gene was first identified in a screen for relaxed (rel) mutants during amino acid 
starvation (Diderichsen et al., 1977). On the onset of amino acid starvation, synthesis 
of ribosomal RNA stalls, which is a result of accumulation of RNA polymerase 
binding alarmone ppGpp, synthesized by RelA in response to a decrease in cellular 
level of charged tRNA (Potrykus and Cashel, 2008) (discussed in Chapter 4). Relaxed 
mutants continue rRNA transcription in response to amino acid starvation. 
It was observed that a mutation in relB resulted in a “delayed relaxed response”, 
which was different from the relaxed phenotype, since rRNA synthesis was delayed 
for about 10 min upon onset of amino acid starvation (Diderichsen et al., 1977;Bech 
et al., 1985). It is now known that relB is the antitoxin component of TA locus relBE, 
and the “delayed relaxed” response is due to hyper-activation of the toxin RelE during 
amino acid starvation in a RelB
101
 mutant with a A39T substitution which renders 
RelB less stable (Gotfredsen and Gerdes, 1998;Christensen and Gerdes, 2004).  
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This phenomenon can be explained by rapid and efficient Lon protease dependent 
activation of RelE in a RelB
101
 mutant during amino acid starvation. RelE toxin 
inhibits global translation which reduces the turnover of charged tRNA pools in the 
cell and results in decreased ppGpp and continued rRNA synthesis, hence the term 
“delayed relaxed” (Christensen and Gerdes, 2004).  
RelE-mediated inhibition of translation is caused by mRNA cleavage between the 
second and third base of an mRNA codon positioned in the ribosomal A-site 
(Christensen and Gerdes, 2003;Pedersen et al., 2003). RelE acts catalytically with 
codon base preferences. Not only Stop codons UAG and UAA are cleaved efficiently 
in vitro with Km/Kcat (s
-1
µM
-1
) values of 17 and 2.7, respectively but also sense 
codons CAG and UCG with Km/Kcat 11 and 22, respectively (Pedersen et al., 2003). 
This codon preference could also be confirmed in vivo (Christensen and Gerdes, 
2003). Interestingly, RF1 (peptide chain release factor 1) can compete with RelE for 
UAG stop codon cleavage, which suggests competition in the ribosomal A-site and 
indeed, RelE does not cleave mRNA in the absence of the ribosome (Pedersen et al., 
2003).  
E. coli RelE is an 11.2 kDa protein (95 amino acids) which consists of a compact, 
four-stranded antiparallel β sheet flanked by three α helices (Figure 10B) that is very 
similar to that of RelE from archaea Pyrococcus horikoshii OT3 (Figure 5A) and 
Methanococcus jannaschii (Takagi et al., 2005;Francuski and Saenger, 
2009;Neubauer et al., 2009;Li et al., 2009). The archaeal RelE homologues are both 
toxic in E. coli and RelE of M. jannaschii has also been shown to cleave inside the 
mRNA reading frame in vivo, which indicates conservation in the mechanism 
cleavage (Christensen and Gerdes, 2003;Shinohara et al., 2010). Mycobacterium 
tuberculosis encodes three relBE homologues (Figure 2C) that are all functional TA 
systems and inhibit growth of Mycobacterium smegmatis (Korch et al., 2009;Yang et 
al., 2010). A RelE homologue from the gram-positive organism Streptococcus 
pneumoniae was also found to be active and to cleave mRNA in the reading frame 
(Christensen and Gerdes, 2003;Nieto et al., 2006).  
Recently, the crystal structures of E. coli RelE in complex with 70S ribosome of 
Thermus themophilus containing mRNA in pre-cleavage (3.3Å) and post-cleavage 
state (3.6Å) were solved (Neubauer et al., 2009). The structures confirmed that RelE 
occupies the ribosomal A- site (Figure 5B) and induces cleavage of mRNA after the 
second base by re-orienting and activating mRNA for 2‟OH dependent hydrolysis 
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(Figure 5C). This mechanism also explains the strict requirement of the ribosome in 
mRNA cleavage and suggests preferences for a pyrimidine in the first codon base and 
purines in the second and third position (Neubauer et al., 2009).   
E. coli K-12 contains at least five other TAs of the relBE and higBA family: 
yefM/yoeB, prlF-yhaV, dinJ-YafQ, yafNO and higBA. The E. coli YoeB crystal 
structure revealed an α/β fold very similar to that of RelE (Figure 5A) (Kamada and 
Hanaoka, 2005). Interestingly, YoeB and RelE seem to share structural similarities to 
RNase T1, barnase and RNase Sa, and active site residues of RNase T1 are also 
 
Figure 5 RelE structure and activity A) RelE (P. horikoshii OT3) and YoeB (E. coli) contains an 
α/β-fold which shares similarity to that of RNase T1(Aspergillus orygae). α-helices (yellow) and β-
sheets (Red) 2‟guanosine monophosphate is shown in green sticks in the activity site of RNase T1. 
B) Thermophilus thermophilus 70S ribosome (50S blue, 30S wheat) containing RelE (A site, blue), 
tRNAfMet (P site, green), a noncognate tRNAfMet (E site, red), and mRNA (magenta) in precleavage 
state. C) Model for RelE activity. RelE (blue) occupies the A site where it pulls the mRNA (purple) 
into its active site (arrows). Here, the second nucleotide („„2‟‟) of the mRNA stacks with Y87 of 
RelE (blue), while the third nucleotide („„3‟‟) stacks with C1054 of 16S RNA (orange). Additional 
relevant basic residues in the active site are shown including water molecule used in the catalysis. 
The red arrow indicates the nucleophilic attack of the 2‟-O-. Adapted from (Buts et al., 
2005;Neubauer et al., 2009). 
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present in YoeB, which could explain non-specific RNase activity observed by YoeB 
in vitro (Figure 5A). YoeB associates with 70S ribosomes and 50S ribosomal subunits 
and cleave translated mRNA preferentially in the second codon of mRNA and in stop 
codons (Christensen-Dalsgaard and Gerdes, 2008;Zhang and Inouye, 2009).   
YhaV and YafQ toxins have been shown to have RNAse activity in vitro, whereas 
YafQ and YafO inhibit translation by mediating ribosome dependent mRNA cleavage 
in vivo (Schmidt et al., 2007;Prysak et al., 2009;Zhang et al., 2009;Christensen-
Dalsgaard et al., 2010).  HigBAs from the Vibrio cholera mega integron and from E. 
coli have recently been characterized and HigB was observed to inhibit translation by 
ribosome-dependent mRNA cleavage, but with a different cleavage pattern to RelE 
(Christensen-Dalsgaard and Gerdes, 2006;Budde et al., 2007;Christensen-Dalsgaard 
et al., 2010).  
In conclusion, generally toxins of the relBE TA family cleave mRNA in the 
ribosomal A-site. Evidently, RelE mediated mRNA cleavage will lead to ribosome 
stalling on the 3‟-end of a non-stop mRNA, which is the substrate for trans-
translation. Indeed it has been observed that a tmRNA deficient mutant is hyper-
sensitive to RelE and that over expression of tmRNA and smpB can counteract RelE 
toxicity (Christensen and Gerdes, 2003). Futhermore, tmRNA seems to be required 
for complete resuscitation of RelE inhibited cells and rapid recovery of translation by 
RelB expression. This suggests that tmRNA counteracts RelE toxicity by rescue of 
stalled ribosomes from damaged mRNAs. A similar observation has been made for 
mRNA interferases MazF and ChpBK (Christensen et al., 2003). These observations 
suggest that that mRNA-cleaving toxins could be integral components of the same 
quality control management program as tmRNA (discussed in Chapter 4). Consistent 
with this interpretation both RelE and MazF have been reported to cleave mRNA 
during amino acid starvation, however their specific roles remain elusive (Christensen 
et al., 2003) 
Ribosome independent mRNA interferases – MazF, HicA, and MqsR 
E. coli K-12 has two chromosomal mazEF TA loci, mazEF (chpA) and chpB (Masuda 
et al., 1993). MazEF from E. coli chromosome and Kis-Kid of ParD from plasmid R1 
are the most extensively described TAs of the mazEF TA family. The crystal structure 
of MazEF revealed that the toxin MazF, a ~12 kD protein (111 AA) forms dimers 
with an α/β-fold very similar to that of CcdB (Figure 3A) (Kamada et al., 2003). 
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Conditional overexpression of MazF and ChpBK (toxin of chpB) inhibits cell growth, 
which can be reversed by cognate antitoxins MazE and ChpBI (Masuda et al., 
1993;Pedersen et al., 2002). In vitro and in vivo studies have shown that MazF and 
ChpBK are ribosome-independent ribonucleases, which cleave primarily single 
stranded RNA at specific sequences that result in inhibition of translation. E. coli 
MazF exclusively cleaves ACA sequences, whereas ChpBK cleaves ACY sites 
(where Y is A, G or U). (Zhang et al., 2003b;Zhang et al., 2005). MazF is thought not 
to cleave rRNA and tRNA (Suzuki et al., 2005). 
Recently, it has been shown that a pentapeptide “quorum sensing” molecule produced 
under certain conditions, greatly increases the endoribonucleolytic activities of both 
MazF and ChpBK (Belitsky et al., 2011) ( discussed in Chapter 4). 
Several MazF homologues have been characterised, including MazFsa from 
Staphylococcus aureus and several MazFmt from Mycobacterium tuberculosis. MazFsa 
cleaves the pentad sequence U*ACAU (*indicates the cleavage site), which is highly 
abundant in several mRNAs including sraP mRNA encoding a protein known to be 
important for adhesion of the pathogen (Zhu et al., 2009). Up to seven MazF 
homologues have been identified on the chromosome of M. tuberculosis and cause 
growth inhibition when expressed in E.coli (Zhu et al., 2006). MazFmt-1 cleaves 
A*UC, MazFmt-3 cleaves UU*CCU/CU*CCU, MazFmt-6 cleaves U-rich regions 
(U/C)U*(A/U)C(U/C) and MazFmt-7 U*CGCU, all single stranded RNA substrates 
(Zhu et al., 2006;Zhu et al., 2008). The Kid toxin of ParD of plasmid R1 cleaves 
AU(A/C/U) in mRNA, but it has recently been shown that Kid cleaves more 
specifically in UUACU sequences which are rare but present in an RNA that 
represses plasmid R1 replication (Pimentel et al., 2005). This suggests that Kid 
activation simultaneously may regulate growth rate and plasmid-copy number, which 
is a mechanism quite different from PSK. The fact that some MazF homologue toxins 
seem to have very specific RNA cleavage sites suggest that MazF might play a role in 
regulating specific mRNAs (discussed in Chapter 4). 
 
The hicAB TA family has recently been discovered (Makarova et al., 2006). E. coli 
HicA, a 6.8 kDa protein (58 AA), was predicted to contain a double stranded RNA 
binding fold and HicB, a16.1 kDa protein (145 AA), a reduced RNase H fold fused to 
a HTH DNA-binding domain. A recent study showed that HicA is the toxin 
component as ectopic expression of HicA led to growth inhibition, which is 
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counteracted by HicB expression (Jorgensen et al., 2009). HicA was found to inhibit 
global translation by mRNA cleavage, which is not dependent on the translation 
machinery, as non-translated mRNAs were cleaved efficiently. In a more recent study 
homologues of hicAB where indentified in Streptococcus pyogenes, where both HicA 
and HigB were found to be toxic in E. coli cells, indicating an alternative function of 
this locus (Leplae et al., 2011). Deletion of hicB antitoxin gene in E. coli does not 
affect growth; however cells are more sensitive to envelope stress (Button et al., 
2007). Interestingly ∆hicB cells show down-regulated extracytoplasmic stress 
response mediated by alternative sigma factor, σE, and curiously σE is no longer 
essential in this strain. This indicates that ∆hicB cells have low level constitutive 
activity of HicA, which acts on a subset of mRNAs involved in extracytoplasmic 
stress. 
Similar to hicAB, mqsR-mqsA (motility quorum sensing R and A renamed from ygiU-
ygiT) is a relatively recent discovery (Gonzalez Barrios et al., 2006). The mqsR gene 
was found to be necessary for efficient biofilm formation, which will be discussed in 
Chapter 4. More recently it has been shown that MqsR is a ribosome-independent 
mRNA interferase, which inhibits translation by cleaving mRNA at GCU sequences 
in vivo and in vitro (Yamaguchi et al., 2009;Christensen-Dalsgaard et al., 2010). In 
both studies MqsA was found to counteract the activity of MqsR, which gives mqsR-
mqsA a similar genetic setup as hicAB and higBA.  
MqsR is a 11.2 kDa protein (98AA) that does not share any sequence homology with 
MazF, but has been shown to contain an α/β-fold structure similar to that of RelE 
(Brown et al., 2009). Interestingly, the HTH DNA-binding domain of MqsA was 
found to reside in the C-terminal domain, whereas interactions with the toxin are 
found to occur through the N-terminus. This is the first example of a structural RelE 
homologue which cleaves mRNA ribosome-independently in vivo.  
Even though ribosome-independent mRNA interferases are site specific, a recent 
study has shown that translation can drastically stimulate mRNA cleavage, probably 
by unfolding structured mRNA, thus making otherwise protected sites available to 
cleavage (Christensen-Dalsgaard and Gerdes, 2008). 
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Targeting the ribosome – Doc and HipA 
The most common activity of toxins is to inhibit translation by ribunuclease activity 
which is often dependent on the translation machinery. However, a small group of 
toxins, including Doc and HipA toxins, have evolved distinct mechanisms. 
 
Association with 30S ribosomal subunit – Doc 
Bacteriophage P1 encodes the phd-doc TA locus (preventing host death, death on 
curing), which has now also been identified on many bacterial chromosomes. The 
phd-doc TA locus has been demonstrated to aid the maintenance of lysogenic P1 
bacteriophage inside E. coli (Lehnherr et al., 1993;Lehnherr and Yarmolinsky, 1995). 
Early studies on phd-doc showed that the molecular target of Doc toxin likely had to 
reside within the translation machinery as toxin activation inhibited global protein 
synthesis (Hazan et al., 2001). The Doc toxin is highly toxic to E. coli cells and has 
now been shown to interact with 30S ribosomal subunits in 70S ribosomes, inhibiting 
elongation of translation, which results in polysome accumulation (Liu et al., 2008). 
Interestingly, Doc toxin, though being significantly larger, seems to mimic the 
activity of aminoglycoside antibiotic hygromycin B, which binds to Helix 44 in 16S 
ribosomal RNA. This observation was further substantiated as a hygromycin B 
resistant mutation in ribosomes also conferred resistance to Doc toxicity (Liu et al., 
2008). A non-toxic Doc
H66Y
 mutant has recently been crystallized with the C-terminus 
of PhD, which revealed a small, strictly α-helical protein (Figure 6A) (Garcia-Pino et 
al., 2008).  
Doc shares structural similarities to bacterial Fic proteins (filamentation induced by 
cAMP) and AvrB, a secreted bacterial toxin, which suggests a similar evolutionary 
origin. Fic proteins have a central conserved HXFX(D/E)(A/G)N(K/G)R motif that is 
also present in Doc (Figure 6A) and are predicted to retain adenosine monophosphate 
transferase activity (Garcia-Pino et al., 2008;Arbing et al., 2010). However, whether 
there is a functional relationship remains elusive. 
 
Phosphorylation of translation elongation factor EF-Tu – HipA 
HipA was first identified in a screen for E. coli mutants showing increased tolerance 
to ampicillin; these mutants where persistent and therefore termed persisters (Moyed 
and Bertrand, 1983). An isolated HipA7 mutant showed high persistence (Hip) 
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frequencies of 10
-2
 compared to wild type E. coli which only produces persisters in 
frequencies of 10
-6
-10
-5
. Much later it was shown that hipA in fact forms a TA locus 
with its antitoxin hipB (Black et al., 1991;Black et al., 1994). The HipA7 mutant 
contains substitutions G22S and D291A, which are both needed to give high 
persistence frequencies, in a ppGpp dependent manner (Korch et al., 2003) (ppGpp is 
described in Chaper 4). HipA inhibits bacterial growth by decreasing protein 
synthesis, whereas HipA7 does so only to a lesser extent (Korch and Hill, 2006). The 
inhibition was observed to be bacteriostaric as the inhibition could be counteracted by 
subsequent HipB expression. HipA encodes a 440 AA residue protein with a 
structural fold similar to that of eukaryotic ATP-binding serine/threonine kinases, 
which bind ATP (Figure 6B) (Schumacher et al., 2009). EF-Tu was observed to 
strongly interact with HipA in the presence of ATP and magnesium. This was 
stimulated by GDP, which leaves EF-Tu in an open form. These data, combined with 
structure of HipA-EF-Tu peptide substrate, shows that HipA might phosphorylate 
Thr382 which blocks aminoacyl-tRNA binding by EF-Tu, as EF-Tu cannot bind GTP 
when phosphorylated (Schumacher et al., 2009). 
 
Figure 6 Structure of Doc and HipA A) Crystal structure of DocH66Y monomer (Teal) with Phd52-73Se 
(Yellow). Doc is an α-helical bundle protein consisting of six α-helices, stacking in three 
consecutive helix-loop-helix elements. Central α3 and α4 have high hydrophobic residue content 
which facilitates stacking of α1 and α2 on one side and α5 and α6 on the other. Residues conserved 
in Fic proteins are shown in red. B) Crystal structure of HipA in ATP bound (blue) and unbound 
(yellow) state, position of ATP is shown in magenta. The N-terminal is a α/β-fold, whereas the C-
terminal is all α-helical. ATP binding results in a small rotation (~4%) in N-terminal and C-terminal 
domains. Adapted from (Garcia-Pino et al., 2008;Schumacher et al., 2009). 
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Prokaryotic PIN domains - VapC  
The vapBC locus (virulence associated protein) was first identified and described 
from a virulence plasmid of Salmonella Dublin and later found in regions flanking 
virulence genes on the chromosome of Dichelobacter nodosus (Pullinger and Lax, 
1992;Bloomfield et al., 1997). Inactivation of vagC (now referred to as vapB) in S. 
dublin led to growth inhibition on selected media and loss of plasmid-associated 
virulence due to impairment of plasmid stability. Similar phenomena were also 
reported for virulence plasmid pMYSH6000 of Shigella flexneri 2a YSH6000 as 
vapBC locus mvpAT (maintenance of virulence plasmid) stabilise plasmids by PSK 
and work in concert with another conventional partitioning system to efficiently 
stabilise pMYSH6000 (Radnedge et al., 1997;Sayeed et al., 2000;Sayeed et al., 
2005). A more recent study on vapBC locus of Leptospira interrogans revealed 
stronger evidence that vapBC are in fact bona fide TA loci as this study not only 
showed that vapBC could stabilise plasmids by PSK, but also that over expression of 
VapC inhibited growth, which could be counteracted by VapB expression (Zhang et 
al., 2004). An early bioinformatic study predicted the vapBC locus to constitute a new 
toxin-antitoxin family as vapB genes contained DNA binding motifs and were 
encoded upstream of vapC, which contained predicted PIN domains (Anantharaman 
and Aravind, 2003).  
PIN domains make up a large structural domain family, which are found in bacteria, 
archaea and eukaryotes. The domain was originally identified in the N-terminus of an 
ATPase involved in biosynthesis of type IV pili in Myxococcus xanthus (pilT N-
terminal domain). However, the functional relationship between the ATPase and the 
PIN domain still remains unclear (Wall and Kaiser, 1999). An early bioinformatic 
study using PSI-BLAST to detect remote sequence homologies, revealed that though 
PIN domains generally share only low sequence similarity, conserved residues could 
still be detected (Clissold and Ponting, 2000). PIN domains were found to contain 
four to five highly conserved acidic amino acid residues (glutamate or aspartate) and a 
single hydroxyl residue (serine and threonine). This pattern of acidic residues are 
often found in proteins which bind divalent metal ions (Mg
2+
 and Mn
2+
) and Clissold 
and Ponting predicted PIN domains to produce a nuclease active site similar to that of 
5‟-nuclease domain families (nuclease domain of taq polymerase, T4 RNase H and 
5‟3‟ FLAP endonucleases). This relationship was confirmed with the crystal structure 
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of the PIN domain of PAE2754 from Pyrobaclolum aerophilum (Arcus et al., 2004). 
PAE2754 was found to form a tetramer in solution by association of two PAE2754 
dimers. The PAE2754 monomer contains α/β/α- fold with seven α-helices and central 
twisted parallel β-sheets (Figure 7A). As predicted by Clissold and Ponting PAE2754 
PIN domain did not share any similarity with T4 RNAse H (Figure 7B), however it 
was observed that active site residues involved in coordinating metal ions could be 
aligned (Figure 7C). In addition, PAE2754 showed weak Mg
2+
-
 
and Mn
2+
-dependent 
nuclease activity on single stranded DNA substrates, suggesting nuclease activity 
(Arcus et al., 2004). To date 11 PIN domain structures are available in the Protein 
Data Bank (PDB), which all share low sequence similarity, but nevertheless show the 
same conserved three-dimensional fold (Arcus et al., 2011). More recently it has been 
shown that VapC most likely is a ribonuclease as VapC-1 (of vapBC-1) from non-
typable Haemophilus influenzae was shown to degrade total RNA in vitro, which was 
inhibited in the presence of VapB-1 (Daines et al., 2007). VapC-1 did not show any 
activity towards double stranded and single stranded DNA. RNase activity of VapC in 
 
Figure 7 Structures of VapC PIN domain proteins A) PAE2754 monomer α-Helices shown in red 
(numbered except α6) and central twisted parallel β-sheets shown in green. B) T4 RNase H (blue) 
superimposed onto PAE2754 (grey). C) Close-up on proposed active site of PAE2754 (grey) with 
active site residues of T4 RNase H (blue). D) FitB (cyan) superimposed onto PAE2754 (blue). E) 
putative active site residues of FitB (cyan) and PAE2754 (blue). Adapted from (Arcus et al., 
2004;Mattison et al., 2006). 
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vitro has now been reported from several independent studies, which are summarised 
in Table 2. These observations all support that VapC toxins are ribosome independent 
ribonucleases. 
PIN domains are present in many Eukaryotic proteins, and are involved in conserved 
processes of rRNA maturation and RNA quality control (recent review on eukaryotic 
endoribonucleases (Tomecki and Dziembowski, 2010)). Yeast Dis3 (also called 
Rrp44) is the catalytic domain of the eukaryotic exosome, which is involved in the 
degradation of rRNA processing by-products and cryptic unstable transcripts (CUTs) 
in the nucleus. Dis3/Rrp44 contains a C-terminal RNase II-like 3‟-5‟exoribonuclease 
domain and an N-terminal PIN domain (Schneider et al., 2009;Schaeffer et al., 2009). 
The PIN domain was found not only to exhibit Mn
2+
-dependent endoribonuclease 
activity on single stranded hairpin-loop RNA, but also to assist the binding of Dis3 to 
Table 2 summary of reported VapC RNase activity 
Name/organism Condition Substrate Metal ion 
dependency 
Counteract 
toxicity 
Reference 
Haemophilus 
influenza 
     
VapC-1 (HI0322) In vitro Total RNA ND VapB-1 
(HI0321) 
(Daines et 
al., 2007) 
Mycobacterium 
tuberculosis 
     
VapBC-5 
(Rv0626-
Rv0627) 
In vitro RNA 
hairpin-loop 
Mg2+ RNase-OUT (Miallau et 
al., 2009) 
 
VapC (Rv0301) In vitro MS2 RNA ND VapB 
(Rv0300) 
(Ramage et 
al., 2009) 
 
VapC (Rv1561) In vitro MS2 RNA ND N/A (Ramage et 
al., 2009) 
 
VapC (Rv0065) In vitro 150nt RNA Mg2+ VapB 
(Rv0065A) 
(Ahidjo et 
al., 2011) 
 
VapC (Rv0617) In vitro 150nt RNA Mg2+ VapB 
(Rv0616A) 
(Ahidjo et 
al., 2011) 
 
Sulfolobus 
solfataricus 
     
VapC-6 
(SSO1493) 
In vitro Total RNA, 
dppB-1 
mRNA, tetR 
mRNA and 
vapB-6 
mRNA 
Mg2+ VapB-6 
(SSO1494) 
(Maezato et 
al., 2011) 
 
Piscirickettsia 
salmonis 
     
VapC (Ps-tox) In vitro Total RNA ND VapB (Ps-
antitox) 
(Gomez et 
al., 2011) 
 
ND (Not Described) 
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the exosome. Interestingly, Dis3/Rrp44 was found to specifically degrade 
hypermodified damaged tRNAi
Met
 (initiator tRNA) in vitro, although recognition did 
not seem to be linked to the N-terminal PIN domain as mutations in RNase II domain 
abolished tRNAi
Met
 binding (Schneider et al., 2007) 
Yeast also harbours a second PIN domain protein Swt1 which is involved in RNA 
surveillance on exported nuclear mRNPs (messenger ribonucleoprotein 
particles)(Skruzny et al., 2009). Swt1 was found to cleave unstructured regions of 
RNA in vitro independently of metal ion addition. Other yeast PIN domains are Nob1 
and Utp24, which are necessary for processing of 18S ribosomal RNA (Bleichert et 
al., 2006;Lamanna and Karbstein, 2009). Utp24 acts in the early steps of rRNA 
maturation, whereas Nob1 only acts on 20S pre-rRNA. Nob1 showed specific 
manganese-dependent endoribonuclease activity on a RNA substrate containing 20S 
pre-rRNA cleavage site (also referred to as D-site) in vitro (Pertschy et al., 2009). A 
fifth PIN domain found in eukaryotes is SMG6 which is involved in nonsense 
mediated messenger decay (NMD). It is governed by an mRNA quality control 
system which degrades mRNAs containing premature termination codons 
(Huntzinger et al., 2008). Human SMG6 showed manganese-dependent ribonuclease 
activity in vitro on single stranded RNA (Glavan et al., 2006). An interesting pattern 
seems to appear as most of the PIN domain proteins are involved in quality control 
where the PIN domain endoribonucleolytic activity initiates RNA degradation by 3‟-
5‟ exoribonucleases. This has some analogy to prokaryotic RNase E and G, that 
initiate RNA maturation or degradation events by RNA cleavage, which is followed 
by exoribonuclease mediated RNA degradation (Recently reviewed (Picard et al., 
2009)). 
 
Despite that our knowledge of Eukaryotic PIN domains has advanced greatly in 
recent years, the targets and specific activities of prokaryotic PIN domains are still not 
clear. 
Previously it has been reported that mutation in ntrR of ntrPR of plant symbiont 
Sinorhizobium meliloti increased the expression of nodulation (nod) and nitrogen 
fixation (nif) genes (Olah et al., 2001). The ntrR gene is a vapC homologue and ntrP 
contains an AbrB-like DNA binding domain. The expression of ntrR was found to 
decrease the growth of E. coli cells by an unknown mechanism (Bodogai et al., 2006). 
A transcriptome analysis of ntrR deletion strain showed that several genes were 
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affected including metabolic genes and not only not and nif symbiotic genes (Puskas 
et al., 2004). This suggests that ntrR might, by an unknown mechanism, interfere with 
general regulatory mechanisms, especially under anaerobic growth. 
Another well described vapBC locus is fitAB from the human pathogen Neisseria 
gonorrhoea. The fitAB (fast intracellular trafficking) locus was identified in a genetic 
screen for mutations which gives a fast trafficking phenotype in a monolayer of 
epithelial cells (Hopper et al., 2000). Mutations in fitAB allowed mutants to transverse 
the epithelial barrier 5-6 times faster than wild type cells and it was suggested that 
fitAB regulates the intracellular growth rate during pathogenesis. The FitAB TA-
complex has been crystallised bound to DNA and revealed a [FitA2-FitB2]2 hetero 
octamer (Mattison et al., 2006). FitA is a RHH DNA-binding protein and FitB a PIN 
domain protein, which perfectly aligns with the structure of PAE2754 including the 
proposed acidic catalytic residues of PAE2754 (Figure 7D & E). It is however still 
unknown how FitB regulates the intracellular growth rate of N. gonorrhoea.       
Transcriptome analysis in the crenarcheon Sulfolubus solfataricus have shown that 
many of the 26 chromosomal vapBC loci are upregulated in response to heat shock 
(Tachdjian and Kelly, 2006;Cooper et al., 2009). It is therefore suggested that VapC 
might be involved in adjusting metabolism in response to heat shock. More recently it 
has been shown that inactivation of vapBC-6 locus results in heat shock sensitivity 
and heat shock dependent reduction in the growth rate of S. solfataricus (Maezato et 
al., 2011). By quantitative PCR a preferential increase in dppB-1 dipeptide transporter 
(~20-fold) and tetR (~5-fold) transcriptional regulator in vapBC-6 deficient strain, 
suggesting that these genes are regulated by vapBC-6. In vitro these transcripts where 
degraded by purified VapC-6 and it was suggested that VapC targets these transcripts 
during heat shock (Maezato et al., 2011). Interestingly, a vapBC-6 deficient strain 
also showed decreased transcripts house keeping sigma factor (rpoD) and eIF2 
gamma domain, of Initation factor 2 during heat shock, which could account for the 
observed sensitivity to heat shock. However, it is still unclear how vapBC-6 assists 
the heat shock response in S. solfataricus. 
It is now known that ectopic expression of several VapCs (including VapC from 
Mycobacterium smegmatis, as well as several Mycobacterium tuberculosis VapCs 
(Rv0301, Rv1561 and Rv1829c) inhibit cell growth by decreasing the global rate of 
translation, without substantial effects to transcription and replication (Robson et al., 
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2009;Ramage et al., 2009).  Despite these observations, the specific molecular target 
of the VapC toxin has evaded exposure.  
Diverse toxin families which target the translational machinery of E. coli  
Similar to ribosome-dependent mRNA interferases, colicin D treatment has been 
shown to induce ribosomal A-site cleavage in response to ribosomal pausing (Garza-
Sanchez et al., 2008). Colicin D belongs to a group of colicins that target the 
translation machinery (recently reviewed (Cascales et al., 2007)). Colicins share many 
similarities with TAs as they are often plasmid resident and encode toxic proteins, 
which are neutralised by host-encoded immunity proteins. Colicins are secreted from 
producer cells and transported to the cytosol of target cells by outermembrane 
receptors and imported to the cytosol by translocation (Kleanthous, 2010). Colicin E3 
cleaves 16S ribosomal RNA between A1493 and G1494 near the 3‟-end, which 
interferes with the decoding center of the ribosomal A-site and abolishes protein 
synthesis (Bowman et al., 1971).  
Colicin E5 and colicin D inhibit protein synthesis by cleaving in the tRNA anticodon 
loop (Ogawa et al., 1999;Tomita et al., 2000). Colicin E5 cleave tRNA
Tyr
, tRNA
His
, 
tRNA
Asn
 and tRNA
Asp
 between position 34 and 35 containing a queuine (a modified 
guanine) at the wobble base and colicin D cleave all tRNA
Arg
 between position 38 and 
39. Treatment of E. coli with colicin D has been shown to induce ribosome stalling on 
arginine codons as the cells are depleted  of amino acylated tRNA
Arg
  (Garza-Sanchez 
et al., 2008). This in turn induces mRNA cleavage in the ribosomal A-site, which is 
dependent on an unknown ribonuclease or could be mediated by mRNA interferases. 
Arginine, tryptophan, histidine and serine starvation has also been shown to induce 
similar A-site cleavage (Li et al., 2008b;Garza-Sanchez et al., 2008). 
Another anticodon nuclease is encoded by the prr locus of clinical E. coli strains  and 
has been shown to be induced upon phage T4 infection and potentially cleave its own 
tRNA
lys 
(Depew and Cozzarelli, 1974;David et al., 1982). The anticodon nuclease 
gene prrC is integrated into the prrABD gene cluster, which encodes EcoprrI: a type I 
restriction modification system (Amitsur et al., 1992). Upon phage T4 infection, 
phage encoded peptide Stp suppresses EcoprrI, which leads to activation of PrrC. 
PrrC cleaves 5‟ to the anticodon of tRNAlys between position 33 and 34 with required 
modified wobble base (David et al., 1982;Amitsur et al., 1987;Jiang et al., 2001). 
PrrC expression does not immediately lead to cell death as T4 phage encode an RNA 
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repair system with a 3‟-phosphotase-polynucleotide kinase which hydrolyses 2‟,3‟-
cyclic phosphate and phosphorylate 5‟-OH, which can be joined by phage-encoded 
RNA ligase restoring intact tRNA
lys
. Therefore, PrrC is only a potential phage 
abortive system as the phage, ingeniously, can repair the RNA damage. 
Similar to PrrC, both colicin E5 and colicin D produces 5‟-cleavage products with 3‟ 
2‟,3‟-cyclic phosphate and 3‟-cleavage products with  5‟-hydroxyl groups, although 
no homology exists between these three nucleases (Ogawa et al., 1999;Tomita et al., 
2000). Archaea (and eukaryotes) hold a number of intron-containing tRNA genes, 
which are cut out by an tRNA splicing endonuclease (Peebles et al., 1983). Cleavage 
generates a 5‟ exon with a 2‟,3‟-cyclic phosphate terminus and a 3‟exon with a 5‟-
hydroxyl group, which is the substrates of 3‟phosphate RNA ligase RtcB, that creates 
the functional tRNA (Englert et al., 2011). E. coli encodes a homologue of 
3‟phosphate ligase, RtcB, which is situated in a putative RNA repair operon (Tanaka 
and Shuman, 2011). E. coli RtcB has been shown to actively ligate cleavage products 
of Kluyveromyces lactis γ-toxin anticodon nuclease, which produces similar cleavage 
products to PrrC, colicin E5 and colicin D. This could indicate an evolutionary and 
functional link between tRNAses and RNA ligase repair systems.  
More recently, a new group of toxin systems have been identified in proteobacteria. 
These systems are thought to be intercellular communication systems, which mediate 
contact-dependent growth inhibition (CDI) (Aoki et al., 2005;Hayes et al., 2010). The 
CDI systems consist of a CdiB/CdiA two-partner secretion system (TPS) and an 
additional immunity protein CdiI. CdiB facilitates the translocation of CdiA “exo 
protein” onto the cell surface and CdiI protects against autoinhibition. If CDI+ 
bacteria get in direct contact with other bacteria, CdiA “exo protein” is taken up by 
concerted action of BamA receptor protein and AcrB membrane transport protein and 
if the cell fails to produce cognate immunity proteins (CDI
-
) it leads to growth 
inhibition.  
It has recently been shown that the C-terminal domain of CdiA protein is responsible 
for growth inhibition, CdiA-CT (Aoki et al., 2010). CdiA-CT3937-2 of plant pathogen 
Dickaya dadantii showed efficient Mg
2+
-dependent DNase activity in vitro, whereas 
CdiA-CT536 from uropathogenic E. coli showed specific tRNAse activity (confirmed 
degradation of tRNA
His
 and tRNA
ala
, without degradation of ribosomal RNA (Aoki et 
al., 2010). In CdiA-CT the nuclease activity was inhibited in the presence of 
immunity proteins.  Interestingly growth inhibited CDI
-
 cells could be recovered by 
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subsequent expression of CdiI in trans from a plasmid, suggesting that the metabolic 
downshift mediated by CdiA is reversible (Aoki et al., 2009). 
It is clear that a multitude of toxin targets exist within the cell. The toxin targets are 
primarily placed within the translation machinery, but all affect growth and cell 
division. The following chapter, Chapter 3, will focus on the activity of the antitoxin 
and the structures of toxin-antitoxin complexes. Furthermore it includes a discussion 
on how antitoxins contribute to DNA binding and neutralisation of the toxin. Chapter 
3 will also outline the transcriptional repression mechanisms by TA complexes and 
how transcription can be activated by protease-dependent degradation of antitoxins 
and more directly by toxin molecules, affecting cooperative binding and repression of 
the TA promoter.   
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Chapter 3: Antitoxins 
Structure and activity of Antitoxins 
The most important role of the antitoxin is to prevent the cognate toxins from 
inhibiting their cellular targets. This is achieved by direct non-covalent protein-
protein interactions, leading to the formation of inactive TA complexes. The 
metabolic stability of antitoxins should be sufficiently low as to allow liberation from 
the toxin. In addition, the antitoxin autoregulates transcription of the TA operon, 
which maintains tight control of toxin and antitoxin levels in the cell. These functions 
are all programmed within these small molecules (~70-150 amino acids) in different 
domains of the protein. Despite the functional relationship between all antitoxins and 
their small size, the sequence and structures are quite diverse. Even cognate antitoxins 
of structurally homologous toxins can be quite different and contain different DNA-
binding domains. This diversity is suggested to have evolved by gene-shuffling events 
(see Chapter 1) (Anantharaman and Aravind, 2003;Makarova et al., 2009). 
Interestingly, degradation of antitoxins by cellular proteases activates TA 
transcription, but it is not an exclusive mechanism. Recently, it has become clear that 
changes in antitoxin/toxin ratio also affect the ability of a TA complex to repress 
transcription: a condition now generally referred to as conditional cooperativity. 
In the following Chapter, structural and functional relationship between antitoxins and 
TA complexes of the best characterised TA systems (i.e. CcdAB, MazEF/Kis-Kid, 
RelBE, Phd-Doc and VapBC) will be described in detail. 
CcdA and the CcdAB TA complexes 
CcdA antitoxin encoded by E. coli F plasmid forms a dimer of two 8.4 kDa 
monomers containing a N-terminal RHH-like DNA binding domain and a highly 
flexible C-terminus. These RHH-like domains are found transcriptional repressor 
proteins like CopG, MetJ and Arc. The CcdA dimer was also found to specifically 
bind three direct repeats in the ccdAB promoter of which the first one overlaps with 
the promoter (Figure 8A) (Madl et al., 2006). Binding of one CcdA dimer to a direct 
repeat (Kd ~149 µM) cooperatively increases the affinity of binding of the second 
dimer (Kd ~71 µM) and subsequently the third dimer (Kd ~59 µM), which could be 
due to unspecific interactions between antitoxin dimers or bending of DNA. These 
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affinities are however low, and affinity and specificity of CcdA for DNA is drastically 
increased in the presence of CcdB (Dao-Thi et al., 2002). This is also consistent with 
the observation that CcdA only represses transcription in vivo in the presence of 
gyrase toxin, CcdB (Tam and Kline, 1989).  
 
Figure 8 Regulation of ccdAB and gyrase rejuvenation A) Structure of CcdA dimer N-terminal 
RHH domain (in red and blue) binding to major grove of B-form DNA (6bp palindrome 5‟-
GTATAC-3‟ shown in green). Arg4, Thr6 and Thr8 from each dimer beta sheet form base-specific 
contracts. B) CcdB dimer (cyan and blue) with two CcdA37-72 bound with high affinity (green) and 
low affinity (red). Both CcdA37-72 bind CcdB dimer with Arg40-Met61 segments, but only one 
(green) binds with Ser64-Trp72 which results the other CcdA37-72 C-terminal (Red dashed line) to 
be unstructured and disordered. C) Hydrophobic binding pockets on CcdB dimer can accommodate 
both Phe65 and Trp72 of CcdA37-72 monomer. The interactions of the hydrophobic binding pocket 
of one CcdB monomer (cyan) with Phe65 (blue) and the other CcdB monomer (yellow) 
interactions with Trp72. D) The complete model of CcdA and CcdB activities. 1) CcdB dimer 
(blue) converts between two conformations. 2) In a conformation with distorted CcdA binding site 
and intact GyrA binding site CcdB binds to gyrase which result in poisoning. 3) Initial binding of 
CcdA65-72 to CcdB dimer changes the conformation of CcdB to a form with distorted GyrA binding 
site. 4) CcdA2-CcdB2 complexes are released from gyrase and it is rejuvenated. 5) In free CcdA2-
CcdB2 complexes, CcdA
37-65 zips in and forms High affinity complexes (H) and with one free 
CcdA C-terminal. 6) The free CcdA C-terminal can bind with low affinity to another High affinity 
complex and chains of CcdA2-CcdB2 complexes, which bind to direct repeats in the promoter 
region will polymerise along the DNA.7) When CcdA levels decrease in response to Lon protease 
dependent degradation it leads to increases in CcdB which resolve repression complexes by CcdA 
titration on high affinity binding sites. 8) This leads to transcriptional derepression and increased de 
novo synthesis of CcdA which in turn allows CcdA2-CcdB2 complexes to be formed which repress 
transcription. 9) When Lon mediated degradation of CcdA out competes the de novo synthesis of 
CcdA, CcdB is freed to act on its target. Adapted from (Madl et al., 2006;De et al., 2009) 
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Upon binding of CcdA C-terminus to CcdB dimer, which can be free or in complex 
with its target GyrA, CcdA becomes becomes structured. CcdA C-terminal residues 
46-73 are shielded by CcdB by binding to hydrophobic pockets on either CcdB 
monomer (Madl et al., 2006;De et al., 2009) (Figure 8B). This leads to an allosteric 
change in CcdB which favours CcdA binding and decreases affinity of CcdB for 
GyrA. 
Recent crystal structures revealed that when CcdA/CcdB ratios are 1:1, CcdA binds to 
two sites in the CcdB dimer, one with high affinity which requires the interaction of 
the complete C-terminus of one CcdA dimer and another with low affinity which only 
requires residues 40-61 of an additional CcdA dimer (Figure 8B and C)(De et al., 
2009). Previously, it has been shown that CcdA and CcdB bind DNA in a 1:1 
complex of [CcdA2-CcdB2]n  protecting a region of ~113 bp from DNase I nuclease 
degradation in vitro and using cell extracts in vivo (Tam and Kline, 1989;Dao-Thi et 
al., 2002). This observation suggests that [CcdA2-CcdB2]n bind to direct repeats in the 
promoter region and that complexes extend from there in both directions as helical 
polymers. In these complexes a free CcdA C-terminus from one CddA2-CcdB2 
tetramer interacts with the low affinity site on CcdB in the neighbouring CcdA2-
CcdB2 hereby increasing the affinity of the next complex for DNA (Figure 8D)  
The unstructured features of CcdA in solution render it vulnerable to proteolytic 
degradation and it is degraded by the ATP-dependent Lon protease in vitro and in 
vivo (van Melderen et al., 1996). In vivo, CcdA has a T½ ~ 30 min and in the presence 
of CcdB it is increased to T½ ~ 60 min. If de novo synthesis of CcdA does not keep up 
with Lon-dependent degradation of CcdA it results in a decreased CcdA:CcdB ratio. 
An early study has shown that a CcdA:CcdB ratio of 1:2 results in formation of 
[CcdA2-CcdB4]n complexes, which have drastically decreased affinity for DNA (Afif 
et al., 2001). This is caused by preferential binding of CcdA to the high affinity site of 
CcdB dimer, and when CcdA levels are low, CcdA bound in the low affinity site will 
be titrated to high affinity sites. The non-toxic CcdA2-CcdB4 complexes are sterically 
hindered in the DNA binding of CcdA and therefore have decreased affinity for DNA 
(Madl et al., 2006;De et al., 2009).The decreased repression of ccdAB promoter, 
allows de novo syntheses of CcdA and the return of a 1:1 ratio of CcdA:CcdB, 
favouring formation of repression competent complexes [CcdA2-CcdB2]n. The 
complete interaction diagram of ccd with rejuvenation of CcdB poised DNA gyrases 
is summarised in Figure 8D.  
 44 
MazEF and Kis-Kid TA complexes 
The mazEF locus of E. coli K-12 is a chromosomal homologue of kis-kid of plasmid 
R1 (Masuda et al., 1993). The Kid toxin is smaller than MazF 12.1/14.8kD, but shares 
25% sequence identity, and Kis antitoxin shares 33 % sequence identity with MazE 
antitoxin. MazE is an intrinsically unstructured protein, which upon interaction with 
DNA or MazF becomes structured and dimerises whereby the N-terminal domain 
forms a barrel-like structure in which both monomers contribute a pair of β-sheets 
connected by a short α-helix (Loris et al., 2003). An identical structure has been 
reported for Kis antitoxin (Kamphuis et al., 2007). The crystal structure of MazEF 
revealed a MazF2-MazE2-MazF2 structure, where two extended C-termini of a MazE 
dimer reach out into each of two MazF dimers (Figure 9A) (Kamada et al., 2003). 
The MazF dimer contains two identical mRNA binding sites which change 
conformation upon binding of one MazE C-terminus, accounting for the inactivation 
of MazF (Li et al., 2006). Residues 48-76 of MazE interact with the MazF dimer with 
four surface regions including one by the N-terminal globular domain and three by the 
C-terminus. NMR structural data on Kis-Kid showed that they most likely resemble 
those of the MazE-MazF complex (Kamphuis et al., 2007).  
Both MazE and MazF, and Kis and Kid, are required for trancriptional autoregulation 
of mazEF and parD, respectively (Ruiz-Echevarria et al., 1991;Marianovsky et al., 
2001). The N-terminal globular domain formed by two MazE dimers resembles the 
N-terminal domain of homodimeric AbrB repressor protein of Bacillus subtilis, which 
contains a looped hinge helix (LHH) fold (Figure 9B) (Bobay et al., 2005). The N-
terminal DNA binding domain binds DNA by interactions from central β-sheets into 
the major groove of DNA (Figure 9C). In the MazF2-MazE2-MazF2 crystal structure, 
a MazE dimer only occupies two of four possible sites in two MazF dimers which 
could allow binding of an additional MazE dimer and formation of [MazE2-MazF2]n 
in which MazF dimers bridges between MazE dimers bound to DNA (Kamada et al., 
2003).  
The mazEF locus is primarily transcribed from a single promoter (P2) which contains 
alternating palindromes with an inverted repeat overlapping with -10 pribnow box 
(5‟-ATTGATATATACTGTATCTACATA-3‟) of P2 and a single repeat 
overlapping with -35 sequence (5‟-TCGTATCTACAAT-3‟) (Marianovsky et al., 
2001). The promoter is only partially repressed in the presence of only MazE and 
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MazF acts as a co-repressor (Marianovsky et al., 2001;Zhang et al., 2003a). Crude 
cell extracts of MazEF expressing cells were found to protect a 47 bp region 
containing the alternating palindromes from DNAse I nuclease activity, consistent 
with MazEF binding. The parD locus contains to inverted repeats one imperfect (-52 
to -70, 5‟-AAGTTATATTTTATTAAACATT-3‟), and one perfect which overlaps 
with -10 sequence and transcriptional start site (-15 to +3, 5‟-
ATGTTATATTTAAATATAACTT-3‟). Heterooctameric species of Kis2-Kid2-Kis2-
Kid2 complexes were identified to protect these two inverted repeats from hydroxyl 
radical treatment indicating that these sites are bound by Kis-Kid (Monti et al., 2007). 
In addition, Kis-Kid complexes were found to bind the perfect inverted repeat with 
higher affinity than the imperfect repeat, suggesting it to be important for 
transcriptional repression. Interestingly, Kis antitoxin alone binds operator DNA with 
low affinity, but showed low unspecific cooperative binding similar to that reported 
for CcdA.   
 
Figure 9 Structure of MazEF TA complex.  A) Crystal structure of MazF2-MazE2-MazF2 complex. 
MazE2 dimer (Red and blue) forms a globular domain with the N-termini. The C-terminal of each 
dimer reaches out into the mRNA binding pocket of MazF2 dimer (grey). This conformations 
leaves two un occupied mRNA binding pockets. B) Structures of N-terminal domain of MazE 
(purple) and N-terminal domain of AbrB (blue with secondary structure labelled). C) Model of N-
terminal domain of AbrB binding to bent DNA. The interaction is predicted to be mediated by 
several Arg (or Lys) residues in AbrB N-terminal. Adapted from (Buts et al., 2005;Bobay et al., 
2005). 
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During steady state growth, the ATP-dependent protease ClpAP degrades MazE 
(T½~30 min) and during amino acid starvation, MazE is degraded by the ATP-
dependent Lon protease (T½~30 min) (Aizenman et al., 1996;Christensen et al., 
2003).  
The antitoxin/toxin ratio decreases when de novo synthesis of antitoxin does not keep 
up with the degradation by proteases. Hence, Lon-dependent degradation of MazE 
during amino acid starvation leads to transcriptional activation of mazEF (Christensen 
et al., 2003). It is known that when the Kis/Kid ratios are low ~ 1:2, a hexameric form 
of Kid2-Kis2-Kid2 complexes are formed which have decreased affinity for DNA as 
80% of the complexes present were not associated with DNA (Monti et al., 2007). 
Whether the hexameric Kis-Kid complexes observed are similar to the first published 
hexameric structure of MazEF is not known (Figure 9A). It could indicate that MazEF 
also forms hexameric complexes, when toxin is in excess, which would result in low 
DNA affinity due steric clashes between toxin-complexed dimers as suggested for 
Kis-Kid (Monti et al., 2007). 
The mazEF locus has additional interesting features as it is positioned downstream of 
the relA gene encoding ppGpp synthase and has been proposed to have a concerted 
function in response to ppGpp (Aizenman et al., 1996) (discussed in Chapter 4). 
Furthermore, a FIS binding site was identified immediately upstream of the third 
repeat in the promoter region and was shown to bind FIS protein in vivo and in vitro 
(Marianovsky et al., 2001). FIS is a nucleoid associated protein, which regulates 
various processes including transcription, recombination and replication (reviewed 
(Browning et al., 2010) and was shown to increase the transcription of mazEF 1.6-
fold. FIS levels are high in exponentially growing cells in which mazEF is tightly 
repressed. The specific role of FIS in mazEF transcriptional regulation is however 
unknown (Marianovsky et al., 2001). 
RelBE TA complexes 
The relBE locus of E. coli K-12 is resident inside Qin prophage and is transcribed 
from a single promoter, which in addition to relB and relE also contains hokD (or 
relF), a type I TA locus (Pedersen and Gerdes, 1999). However, hokD is suggested to 
be inactive as upstream regulatory elements are lacking.  
E. coli RelB is a 9.35 kDa protein (79 AA), which contains an N-terminal RHH-like 
DNA binding domain that in solution dimerises and forms multimers in the absence 
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of RelE (Cherny et al., 2007;Li et al., 2008a). By DNase I protection and hydroxyl 
radical footprinting it was shown that two RelB dimers bind an inverted DNA repeat 
of 26 bp (5‟-CTTGTAATGACATTTGTAATTACAAG-3‟) in the promoter region 
between the -10 sequence (pribnow box) and the ribosome binding site (also referred 
to as relO) (Overgaard et al., 2008;Li et al., 2008a). Each 12 bp half-site of the 
inverted repeat can be subdivided into two small 6 bp imperfect inverted repeat which  
is bound by a single RelB dimer (Figure 10A). RelB has relatively low affinity for 
relO DNA (Kd ~ 12.5 µM), which is drastically increased in the presence of RelE (Kd 
~ 3.4 nM). Inrestingly, RelB
1-50
 (lacking C-terminus) had even lower affinity (Kd ~ 
197µM) than full length RelB in the absence of RelE suggesting that RelB, through 
its C-terminus, can itself mediate unspecific weak cooperative binding to relO 
(Overgaard et al., 2008;Li et al., 2008a). RelE does not bind DNA, but mediates 
strong cooperative binding of RelB to DNA, which acts to repress transcription of the 
relBE promoter (Gotfredsen and Gerdes, 1998;Overgaard et al., 2008). Mutations in 
residues of the RelB RHH-like DNA binding domain (e.g Arg7) lead to decreased 
DNA binding and de-repression of relBE promoter (Li et al., 2008a;Overgaard et al., 
2009). The C-terminus of RelB interacts with RelE to neutralise its activity in vivo 
and in vitro (Cherny et al., 2007;Li et al., 2009). The recent NMR structure of the 
RelB C-terminus bound to low toxic RelE
R81A/R83A
 revealed that RelB induces a 
 
Figure 10 Interactions in the RelBE TA complex A) Structure of RelB N-terminal RHH domain 
residues 1-41 modelled onto 12bp 5‟-TTGTAATTACAA-3‟ halfsite inverted repeat. RelB 
monomers are Green and blue, respectively and important residues interacting with DNA are 
shown. B) NMR structure of unbound RelE monomer. C) NMR structure of RelE with bound RelB 
C-terminal. Secondary structure is indicated including interaction sites I and II. D) Structure of 
RelE active site residues in presence and absence of RelB. E) Structure of YoeB active site in the 
presence and absence of YefM. Adapted from (Li et al., 2008;Li et al., 2009). 
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catalytic-incompetent structure of RelE
R81A/R83A
 which involves displacement of α-
helix 4 of RelE
R81A/R83A
 (Figure 10B & C). RelB interacts with RelE
R81A/R83A
 in two 
sites. Site 1 interaction involves an α-helix of the RelB C-terminus (αH3*) with the 
surface of β-sheet core of RelER81A/R83A which perturbs the active site (see Chapter 2) 
by displacing Tyr87 and neutralisation of charged Arg61, Lys52, Lys54 and Arg81 
(The position of Arg81 is predicted as it was substituted for an alanine) (Figure 10D). 
Site 2 anchors the RelB C-terminus to the surface of RelE
R81A/R83A
 in a hydrophobic 
patch formed by β-sheet 1 and α-helix hairpin of H1 and H2. Similar active site 
perturbation is induced by YefM upon binding to the RelE homologue YoeB (Figure 
10 E) (Kamada and Hanaoka, 2005). This change renders RelE or YoeB catalytically 
inactive, either by directly interfering with toxin activity and/or by restricting the 
access of the toxin to the ribosomal A-site. 
RelB is degraded by the ATP-dependent Lon protease in vitro and in vivo (T½< 15 
min) (Christensen et al., 2001;Overgaard et al., 2009). A decrease in rate-of 
translation induced by amino acid starvation or treatment with chloramphenicol leads 
to a decrease in de novo synthesis of RelB and increased turnover leads to a decrease 
in RelB/RelE ratio and transcriptional de-repression which is independent of stringent 
alarmone ppGpp (Christensen et al., 2001). However, transcription was observed to 
increase more rapidly than Lon-mediated RelB decrease, which suggests an additional 
mechanism activating transcription (Overgaard et al., 2008). Consistent with this 
observation, overexpression of non-toxic RelE
C6
 (Deleted for six C-teminal AA) 
induced relBE transcription while the protein levels of RelB did not decrease 
(Overgaard et al., 2008). By gel shift assays and SPR (Surface Plasmon Resonance) it 
was observed that at a RelB/RelE ratio of 2:1, the TA complex had highest affinity for 
DNA, suggesting a DNA-binding complex of RelB2-RelE. Interestingly, when the 
RelB/RelE ratio is shifted towards 1:1, the affinity for DNA drastically decreases 
suggesting the presence of RelB2-RelE2 complexes, which have low affinity for DNA. 
The decrease in affinity for DNA is dependent on the presence of both inverted 
repeats of relO, which suggests that the cooperative binding of two RelB-RelE 
complexes is crucial for this mechanism. This phenomenon was therefore termed 
conditional cooperativity (Overgaard et al., 2008). It was suggested that the strong 
cooperativity of RelB2-RelE complexes could be mediated by RelE bridging between 
a RelB2 dimer such that RelB could interact with RelE in two distinct sites with 
different affinity (similar to CcdAB): The C-terminus of one RelB protomer binding 
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to a high affinity site in RelE and another RelB C-terminus binding to a low affinity 
site. Excess of free RelE with unoccupied high affinity binding sites would titrate low 
affinity bound RelB C-termini and lead to decreased cooperativity and consequently 
affinity for DNA (Overgaard et al., 2008). The presence of high and low affinity RelB 
binding sites has not yet been confirmed and the exact mechanism still remains 
elusive. The phenomenon of conditional cooperativity has more recently been 
reported for three different relBE homologues of Mycobacterium tuberculosis (Yang 
et al., 2010). For two of the three RelBE complexes it was observed that RelB:RelE 
ratios of 1:1 or lower greatly decreased the affinity of complex for promoter DNA, 
which could suggest a mechanism very similar to E. coli RelBE. The crystal structure 
of the YefM-YoeB complex revealed a YefM2-YoeB complex, which makes it 
plausible that RelB-RelE forms a complex with similar stoichiometry (Kamada and 
Hanaoka, 2005). This is, however, in contrast to Archaeal RelB-RelE complexes from 
Pyrococcus horikoshii OT3 and Methanococcus Jannaschii, which both make RelB2-
RelE2 complexes that are significantly different from each other and may therefore 
regulate transcription by different mechanisms (Takagi et al., 2005;Francuski and 
Saenger, 2009). 
Phd-Doc TA complexes 
The phd-doc locus of bacteriophage P1 is autoregulated by Phd antitoxin in vivo 
leading to ~ 9-10 fold repression in the absence of Doc and ~ 40-100 fold repression 
in the presence of Doc, hence Doc acts as a co-repressor (Magnuson et al., 
1996;Magnuson and Yarmolinsky, 1998). The Phd antitoxin is an 8 kDa protein (73 
aa), which, in the absence of Doc or DNA, shows intrinsic disorder as it exists in 
different forms (Garcia-Pino et al., 2010). In the folded conformation Phd forms a 
dimer with a globular N-terminal domain that has a central six-stranded β-sheet 
sandwiched between four α-helices. This overall resembles the fold of antitoxin YefM 
(Kamada and Hanaoka, 2005). By DNase I footprinting Phd has previously been 
shown to protect an inverted repeat (5‟- 
ATTGTGTACACATAACGAGTACACGAG- 3‟) in the promoter region between 
the -10 sequence and the Shine & Dalgarno sequence, consistent with an operator site 
for Phd (OR1/2) (Magnuson et al., 1996). Each half site of the inverted repeat has been 
shown to be occupied by a Phd2  dimer which binds with Kd ~ 3 µM and Doc 
increases the affinity 10-fold by forming a Phd2-Doc
H66Y
 complex as interaction of the 
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Phd C-terminus with Doc
H66Y
 promotes allosteric folding of the Phd N-terminal 
domain and dimerisation (Garcia-Pino et al., 2010). The Doc-induced folding of Phd 
is aided through an α-helix, which connects the C-terminus with the N-terminal DNA-
binding domain.  
Doc
H66Y 
has previously been crystallised with Phd
52-73Se
 C-terminal donor, which 
revealed that the PhD C-terminus forms a kinked α-helix, which in one part makes 
hydrophobic interactions (residues 54-62)  with Doc
H66Y 
and in another makes charge 
complementation (residues 64-72) with positive charges on the Doc
H66Y
 surface 
(Figure 6A) (Garcia-Pino et al., 2008). The Doc toxin contains a reduced Fic-fold 
(discussed in Chapter 2) in which a missing α-helix that is present in Fic, is provided 
by the C-terminal α-helix of Phd. This suggests fold complementation and that Doc 
and Fic share an evolutionary origin. Phd does not directly interfere with putative 
conserved active site residues of Doc and Phd most likely either inhibits access to the 
ribosome or induces a conformational change in Doc (Figure 6A) (Garcia-Pino et al., 
2008).  
In its free state, Phd is an intrinsically unstructured protein, which makes it 
susceptible to proteases and it has been shown that Phd is degraded by the ATP-
dependent protease ClpXP in vivo (T½ ~ 120 min) (Lehnherr and Yarmolinsky, 1995).  
A recent crystal structure of Phd-Doc revealed a Phd2-Doc-Phd2 complex in which 
Doc toxin bridges two Phd2 dimers (Figure 11A) (Garcia-Pino et al., 2010). The C-
terminus of one Phd2 dimer interacts with Doc by high affinity interactions as 
described above, the C-terminus of the other Phd2 dimer however only makes low 
affinity hydrophobic interactions (residues 52-62) with Doc, which occurs at a distinct 
binding site (Figure 11B). This particular configuration explains the observed 
increased cooperative binding of Phd to phd-doc operator in the presence of Doc 
(Garcia-Pino et al., 2010).  Gel shift assays with phd-doc operator at different 
Doc:Phd ratios revealed that Phd-Doc can form complexes with different 
stoichiometry, which also bind DNA with high affinity. At Doc:Phd ratios from 0.25 
to 0.75 Phd-Doc form complexes which are consistent with; Phd2-Doc-Phd2, Doc-
Phd2-Doc-Phd2 and Doc-Phd2-Doc-Phd2-Doc complexes. However at a Doc:Phd ratio 
of 1 and above only smaller complexes with a low affinity for DNA are observed, 
which are consistent with Doc-Phd2-Doc complexes. This can be explained as the low 
affinity bound Phd2 C-termini are titrated on to high affinity binding sites on free Doc 
at a Doc:Phd ratio of 1. The Doc-Phd2-Doc complexes formed are deficient in 
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mediating cooperative binding of Phd2 to operator DNA, which leads to 
transcriptional de-repression that allows Phd de novo synthesis and restoration of a 
Doc:Phd ratio ˂1 that allows transcriptional repression. The complete model for phd-
doc regulation summarised in Figure 11C. 
FitAB and other VapBC complexes  
FitA protein (8.4 kDa) is the antitoxin component of the fitAB TA locus of N. 
gonorrhoea which is homologous to the vapBC TA family and contains a RHH-like 
DNA binding domain, similar to CcdA and RelB (Wilbur et al., 2005). FitA has been 
shown to protect a 62 bp region in proximity to the fitAB promoter, containing -10 
and Shine & Dalgarno sequences, from DNase I nuclease activity. The protected 
region was found to contain an 8 bp inverted repeat which acts as the Fit operator ( 5‟-
AGATTGCTATCATTTTTTTTATTTTGATAGCATTTG-3‟, IR36).    
 
Figure 11 Structure and interactions in the Phd-Doc TA complex. A) Crystal structure of Phd2-
Doc-Phd2 complex. Each Phd dimer (orange and red) interacts with Doc monomer (blue) with the 
C-terminal. B) Mapping of Phd interaction sites on Doc. High affinity interaction site (Site H) is 
coloured in blue and low affinity interaction site (Site L) is coloured green. C) Model for the 
regulation of phd-doc operon. Doc monomer is shown in blue with high (H) and low (L) affinity 
binding sites binds to a Phd2 dimer in red and orange. One Doc monomer can stimulate cooperative 
binding of two phd2 dimers by binding of phd2 to low affinity and high affinity binding sites. 
Increased amounts of Doc can stimulate cooperativity as low affinity bound phd is not titrated. At 
high levels of Doc Low affinity bound Phd2 is titrated to high affinity site in Doc which leads to 
destruction of cooperativity and de-repression of the TA promoter. Adapted from (Garcia-Pino et 
al., 2010). 
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FitA binds to fitAB operator relatively strong in the absence of FitB (Kd ~ 176 nM), 
but the affinity is increased about 38-fold in presence of FitB (Kd ~ 4.5 nM) (Wilbur 
et al., 2005). The crystal structure of FitA-FitB bond to IR36 has been solved (Figure 
12A) (Mattison et al., 2006). The structure revealed that FitA, similarly to CcdA and 
RelB, interacts with DNA through a two-stranded antiparallel β-sheet formed by 
dimerisation of two FitA monomers. The C-terminus of a FitA monomer makes 
intimate contacts with α-Helix (α) 1, 2 and 4 of a FitB monomer (Figure 12B). In the 
DNA bound complex FitB forms a homodimer, which bridges between FitA dimers 
bound to binding sites in the DNA (Figure 12A). The dimerisation of FitB is mediated 
by extensive contacts between α3 of one FitB monomer with α5 of the other. Phe78 in 
the α4-α5 loop is a key residue in this dimerisation, as are several hydrophobic 
residues in α3 (Ala41, Leu45 and Ala48) and α5 (Tyr86, Ala87 and Ser91) and a 
single salt bridge (formed between Arg44 (α3) and Glu80 (α5)). This configurat ion of 
FitA and FitB dimers forms a closed circular unit of two heterotetramers [FitA2-
FitB2]2. This allows the FitB dimer to act as a bridge between the FitA dimer bound to 
each half-site of the DNA inverted repeat, which mediates strong cooperative binding 
of FitA to operator DNA. The interactions of the two FitA2 dimers with operator 
DNA in the crystal structure was mapped to each of the half sites in the inverted 
repeat, which is consistent with the DNase I footprint of FitA (Figure 12E). 
Interestingly, the α3 of the FitA C-terminus wraps around the FitB monomer and 
positions a positive Arg68 residue in the otherwise negative FitB active site composed 
of Asp5, Glu42, Asp104 and Asp122 (Figure 12C). The position of Arg68 is thought 
to expel any divalent metal ions bound to the active site and inactivate the enzyme 
(Mattison et al., 2006). A similar mechanism has more recently been proposed for 
neutralisation of VapBC-6 of M. tuberculosis. VapB-6 positions Arg75 in the vicinity 
of the active site of VapC-6, which is suggested to affect metal ion acquisition (Figure 
12D) (Miallau et al., 2009).   
Autoregulation has also been described for vapBC from M. smegmatis and the vapBC 
homologue ntrPR of S. meliloti (Bodogai et al., 2006;Robson et al., 2009). NtrP 
antitoxin contains an N-terminal AbrB-like DNA binding domain similar to MazE. 
The ntrPR locus is transcribed from a single promoter and a 34 bp stretch in the 
promoter region is protected by E. coli extracts containing NtrP and NtrR in DNase I 
footprinting assays. The protected region contains a direct repeat, which acts as ntrPR 
operator site (5‟-TTCGGCATATACATTTAGGCATATACAAGG-3‟). In the 
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absence of NtrR, NtrP failed to significantly bind the ntrPR operator in vivo, which 
suggests that NtrR acts as a corepressor and is needed for efficient repression of 
transcription (Bodogai et al., 2006).  Gel shifts using a probe lacking one of the direct 
repeats abolished NtrP-NtrR binding, suggesting that NtrR mediates cooperative 
binding of NtrP to the operator sites. This mechanism is consistent with FitA-FitB 
mediated operator binding and though operator sites have different architecture, could 
represent a general mechanism for transcriptional autoregulation for vapBC TA loci.  
No data is available on the stability of VapB/FitA. However, FitA has a secondary 
structure similar to RelB, which suggest a short half-life, especially in its unbound 
state. Although transcriptional regulation of different TA families has been 
extensively studied over the years, the regulation of vapBC TA family still remains 
unclear. 
 
Figure 12 Interactions in the VapBC TA complex. A) [FitA2-FitB2]2 octamer of four heterodimers 
bound to DNA containing  fitAB operator site (IR36). The fitA and FitB proteins are coloured in 
magenta and cyan, respectively. B) FitA and FitB heterodimer secondary structure is labelled and 
position of N and C-termini. C) Interactions of Arg68 of FitA C-terminal with the active site of 
FitB. D) Interactions of Arg75 of VapB-5 C-terminal (Green) with the active site of VapC-5 
(Magenta, Residues in yellow sticks ). E) Interactions made by FitA dimer N-terminal residues with 
DNA operator sites (indicated by black inverted arrows). Blue arrows are side chain DNA hydrogen 
bonds, Green arrows are amide-DNA hydrogen bonds and Yellow arrows are Van der Waals 
contacts. Adapted from (Mattison et al., 2006;Miallau et al., 2009).    
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New regulatory interactions with TAs 
It is clear that TAs have evolved conserved strategies to maintain the toxin and 
antitoxin levels in equilibrium in the cell, which is dependent on the antitoxin/toxin 
ratio. 
Several of the chromosome encoded Type I TAs (e.g. symRE, tisAB) of E. coli are 
induced by the SOS response (Gerdes and Wagner, 2007). The SOS response refers to 
genes that are up-regulated upon DNA damage, and LexA repressor protein plays a 
central role in transcriptional repression under non-damage conditions  (Reviewed in 
(Butala et al., 2009)). SOS induced genes include; dinB, recA, ruvA and ruvB, which 
are required for stress-induced mutagenesis. Recently, LexA binding boxes have been 
identified in promoter regions of two E. coli type II TAs dinJ-yafQ and yafNO, 
whereas both genes were up-regulated in response to DNA damage (Prysak et al., 
2009;Singletary et al., 2009;Christensen-Dalsgaard et al., 2010). LexA was shown to 
specifically bind the LexA box in dinJ-yafQ promoter region in vitro, consistent with 
repression. The majority of yafNO up regulation in response to SOS was, however, 
found to result from co-transcription from the upstream dinB SOS gene (Singletary et 
al., 2009).  The function of these TAs in the SOS response are still unclear and TA 
deletion mutants did not show any effect on viability in response to DNA damage 
(Prysak et al., 2009;Singletary et al., 2009).  
TA transcription can also be regulated by transcriptional activators. γ-proteobacteria 
Haemophilus influenza and Vibrio cholera are naturally competent and encode genes 
involved in DNA uptake and processing (Redfield et al., 2005). Competence related 
genes are transcriptionally activated by Sxy protein in concert with cyclic AMP 
receptor proteins (CRP). E. coli is not naturally competent but contains sxy gene and 
CRP-S binding sites, which are also found to be present in promoter regions of prlF-
yhaV, hicAB, higBA and chpB TAs (Sinha et al., 2009). Interestingly, microarray 
analysis of sxy overexpression led to increased transcription of these TAs, suggesting 
that Sxy and cAMP-CRP could stimulate activity of TAs. Whether this regulation is 
genuine and whether TAs are involved in competence is still unknown.     
Utilisation of host transcription factors is, however, not the only way TAs can be 
incorporated into general stress response pathways. Very recently, a SecB-like 
chaperone (Rv1957) has been identified in M. tuberculosis, which specifically 
prevents aggregation and degradation of HigA of the higBA TA locus (Bordes et al., 
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2011). In bacteria, the SecB chaperone binds and presents preproteins targeted for 
secretion to the SecA motor component of the sec translocon (Reviewed (Driessen 
and Nouwen, 2008)). SecB has general chaperone properties and can, to some extent, 
complement the activities of DnaK and Trigger factor (Ullers et al., 2004). Rv1957 
ORF overlaps with the stop codon of higA ORF, which suggest that Rv1957 is part of 
a TAC system (toxin antitoxin chaperone). The TAC system has the potential to 
respond to export stress as the chaperone can be titrated by other proteins. This in turn 
inhibits the activity of HigA and activates HigB toxin (Bordes et al., 2011). 
Observations like this suggest that there might be a cohort of undiscovered 
mechanisms by which TAs can be adapted into regulatory pathways.  
The following Chapter will concern the different models of proposed biological 
functions of TAs.  
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Chapter 4: Models 
Models for the biological function(s) of chromosomal TAs 
At present the toxin-antitoxin research field is rapidly expanding and several research 
groups have presented models for the biological function of chromosome encoded 
TAs.  
The simplest biological model is that chromosomal TAs perform similar tasks to their 
plasmid encoded counterparts. It has recently been shown that TAs might stabilise 
mobile genetic elements such as superintegrons or integrative and conjugative 
elements (ICE). SXT is an ICE found in clinical isolates of Vibrio cholerae often 
carrying antibiotic resistance genes (Wozniak and Waldor, 2009). For SXT to 
undergo conjugation, it is exercised from the chromosome and circulated and under 
this condition SXT stability is maintained by a TA locus, mosAT. Similar 
observations have been made for the superintegron of Vibrio vulfinificus in which 
TAs have been suggested to stabilise flanking DNA regions, preventing loss during 
recombination events (Szekeres et al., 2007).  
In addition to the function of TAs in stabilising DNA, the opposite has also been 
proposed (Saavedra De et al., 2008). Chromosomal TAs are suggested to be able to 
stimulate loss of DNA containing homologous TAs by counteracting toxin activation, 
which results in anti-addiction. Whether the biological function is to promote stability 
or anti-addiction or just a unspecific consequence of the antitoxin and toxin properties 
is still unclear and few examples have been reported.   
In recent years it has become apparent that the activities of toxins induce 
bacteriostatic growth inhibition, which suggests that TAs are involved in growth rate 
regulation rather than cell killing (Gerdes et al., 2005). The fact that type II TAs are 
prevalent in free-living organisms and can be activated by proteolysis of an unstable 
antitoxin makes TAs capable of responding to changes in the rate of translation and 
increased protease activity. In the following section the more commonly applied 
models for TA function will be outlined. 
Implications of TAs in bacterial stress response and pathogenesis 
Free-living bacteria have evolved elaborate strategies to survive and adapt to changes 
in their environment such as changes in osmotic potential, temperature and nutrient 
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avaliability. Bacteria sense environmental changes and respond through changes in 
the global gene expression profile, which shuts down or turns on expression of genes 
that assist the cell in restoring homeostasis and environmental tolerance. This is 
mainly governed by two-component systems and alternative dissociable sigma factors 
of RNA polymerase (Krell et al., 2010;Osterberg et al., 2011). In the utilization of 
alternative sigma factors, ppGpp has a central function, whereas it affects the 
efficiency of alternative σ factors in competition with σ70 housekeeping sigma factor 
for core RNA polymerase. σ70 has the highest affinity for core RNA polymerase and 
therefore the majority of RNA polymerases are occupied with σ70 during steady state 
growth: approximately 70% are employed in transcribing rRNA operons (Raffaelle et 
al., 2005). However, when the level and activity of alternative sigma factors increase 
e.g. during stress or when entering stationary phase, alternative sigma factors compete 
with σ70 for core RNA polymerase directing transcription to other genes. Stationary 
phase/stress induced molecules as ppGpp and Rsd (anti-sigma factor) increase the 
ability of alternative sigma factors to compete for core polymerase (Bernardo et al., 
2006;Jishage et al., 2002;Jishage and Ishihama, 1998). Gram-negative bacteria uses 
two different pathways to produce (p)ppGpp (guanosine 3‟-diphosphate 5‟ 
triphosphate, which is subsequently hydrolyzed to ppGpp): a RelA- and a SpoT-
dependent pathway. RelA associates with the ribosome and synthesizes (p)ppGpp in 
response to deacylated tRNA in the ribosomal A-site and therefore responds to amino 
acid limitations (Wendrich et al., 2002). This is also referred to as the stringent 
response. SpoT is a bifunctional (p)ppGpp synthetase that also has hydrolase activity 
and regulates the (p)ppGpp levels in response to most conditions other than amino 
acid starvation. However, mechanisms for SpoT activation are still unclear (Gentry 
and Cashel, 1996;Potrykus and Cashel, 2008). The alarmone, ppGpp, binds RNA 
polymerase and exerts both direct negative and positive effects on transcription 
depending on the promoter (Kvint et al., 2000). Generally, σ70-dependent promoters 
involved in growth and proliferation are negatively regulated, while σ70-dependent 
promoters involved in maintenance and stress defence are positively regulated during 
stringent response (Chang et al., 2002). The mechanism for how ppGpp directly 
exerts this dualistic function depending on the type of promoter is still unclear and 
different models have been suggested (Magnusson et al., 2005). These include effects 
on RNA polymerase open complex formation and stability, thereby affecting mostly 
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promoters with intrinsically unstable open complexes (e.g. rRNA promoters), but also 
promoter clearance has been proposed.  
The direct effects of ppGpp is enhanced by DksA, a protein that has structural 
resemblance to transcriptional elongation factor GreA, and binds the RNA 
polymerase (Perederina et al., 2004;Paul et al., 2005). Both ppGpp and alternative 
general stress response sigma factor σS (encoded by rpoS) have been found to be 
important not only for stress but also virulence (Dalebroux et al., 2010;Dong and 
Schellhorn, 2010).  
Early studies have shown that protein degradation increases during conditions of 
amino acid starvation and is important for adaptation. This is primarily due to the 
activity of ATP-dependent proteases (e.g Lon , Clp and FtsH) (Sussman and Gilvarg, 
1969;Maurizi, 1992). More recently it has been shown that activity of Lon protease 
changes in response to accumulating levels of polyphosphate, which is a consequence 
of ppGpp mediated inhibition of PPX (exopolyphosphatase) activity (Kuroda et al., 
1997;Kuroda et al., 2001). Polyphosphate binds to Lon and stimulates degradation of 
idling ribosomal proteins and could thus establish a link between protein turnover and 
stringent response creating an endogenous source of amino acids (Kuroda, 2006). 
Increased protease activity is not only observed under nutrient deprivation, but also 
under conditions of heat shock where proteases help to regulate alternative sigma 
factors and chaperones as well as degrading misfolded proteins (Meyer and Baker, 
2011).  
In general, TAs are up-regulated in response to translation inhibition induced either 
by amino acid starvation or treatment with antibiotics, which depends on activities of 
cellular proteases (Christensen et al., 2001;Christensen et al., 2003;Jorgensen et al., 
2009;Christensen-Dalsgaard et al., 2010). This is in agreement with the turnover of 
labile antitoxins when de novo synthesis is decreased, which in turn liberates the toxin 
to act on its target and reduce the growth rate. 
Induction of TAs in response to antibiotics has also been reported in organisms as 
diverse as Streptococcus pneumoniae and Mycobacterium tuberculosis (Singh et al., 
2010;Nieto et al., 2010). In M. tuberculosis several TAs were also found to be up-
regulated during anoxic growth and in infected human macrophages (Korch et al., 
2009;Ramage et al., 2009). Interestingly, some TAs were up-regulated specifically 
under anoxic growth, whilst others were only up-regulated during macrophage 
infection. This indicates that these TAs might respond to virulence and different 
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environmental cues. In addition to these observations, mutants of vapBC homologue 
fitAB of Neisseria gonorrhoea were shown to increase replication during intracellular 
growth in epithelial cells (Hopper et al., 2000). This did not affect host-independent 
growth, which suggests that fitAB can affect the growth rate during infection. 
Similarly, mutants of another vapBC homologue, ntrPR of Sinorhizobium meliloti, 
allow the bacterium to form root nodules with leguminous plants more efficiently, and 
fix more nitrogen than wild-type, consistent with mutants having higher transcription 
and translation capacity (Olah et al., 2001;Puskas et al., 2004). It appears that these 
TAs limit bacterial growth upon encountering eukaryotic host cells.   
Recently it has been observed that TAs in archaea also respond to stress as several 
vapBC loci of Solfolubus solfataricus are up-regulated in response to heat shock 
(Tachdjian and Kelly, 2006;Cooper et al., 2009). Interestingly, disruption of a single 
vapBC locus (out of ~26 TA loci) resulted in significant loss of viability after heat 
shock, which suggest that this specific vapBC locus is involved in heat shock survival. 
Ectopic expression of Lon protease in E. coli, which inhibits translation, has been 
shown to induce strong cleavage in the ribosomal A-site dependent on the yefM/yoeB 
TA-system (Christensen et al., 2004). A-site cleavage is observed in response to 
amino acid starvation and ectopic expression of mRNA interferases such as RelE and 
MazF (see Chapter 2). Interestingly, A-site cleavage has also recently been observed 
by ectopic expression of Doc toxin in E. coli, which is a result of trans-activation of 
mRNA interferases from the E. coli chromosome. Doc inhibits translation and was 
found to activate RelE-dependent A-site cleavage (Garcia-Pino et al., 2008). This 
observation also suggests that the mechanism by which translation is inhibited can 
activate specific TAs to cleave mRNA (see Chapter 2). Ribosomal A-site cleavage 
and trans-translation activity in response to amino acid starvation is also observed in a 
strain deleted for five chromosomal TAs (∆5: relBE,yefM/yoeB,dinj/yafQ,mazF,chpB) 
(Li et al., 2008b). This suggests that these five systems are not required for A-site 
cleavage, but does not exclude that other mRNA interferases, which are present in E. 
coli, may contribute to trans-translation and mRNA quality control. Activation of 
toxins that cleavage mRNA during amino acid starvation are therefore suggested to 
rapidly contribute to adjustment of rates of nutrient and energy consumption to a 
lower level (Gerdes et al., 2005). The toxin-mediated reduction in the global rate of 
translation results in a lower drain on charged tRNA pools which would produce a 
lower level of translational errors (Sorensen et al., 1994;Sorensen, 2001;Dittmar et 
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al., 2005) Stalled ribosome complexes can be recycled by toxin-dependent or -
independent A-site cleavage and subsequent trans-translation.  
An alternative model predicts specific environmental cues as activators of TAs to 
degrade specific mRNAs, which redirects translation to those which are not cleaved 
(Ramage et al., 2009;Wang and Wood, 2011). Proteome remodelling has been 
proposed to be important for heat shock in S. solfataricus in which VapC mediates 
degradation of specific mRNAs, resulting in increased survival during heat shock 
(Maezato et al., 2011). Similar models have been proposed for MazFsa of 
Staphylococcus aureus and MazFmt-3 and MazFmt-7 of M. tuberculosis as the toxins 
have very rare cleavage sites (Zhu et al., 2008;Zhu et al., 2009) (summarised in 
Figure 13). 
An interesting new interaction with the general stress response has recently been 
discovered, mediated by the mqsR-mqsA TA locus of E. coli (recently reviewed in 
(Wang and Wood, 2011)). The mqsR-mqsA TA locus is up-regulated in E. coli 
biofilms and its deletion significantly reduces biofilm formation (Ren et al., 
2004;Gonzalez Barrios et al., 2006;Kasari et al., 2010). MqsA antitoxin has recently 
been shown not only to autoregulate mqsR-mqsA transcription, but also directly 
 
Figure 13 The stress response model for TAs. Environmental stress or starvation leads to 
proteolysis of the antitoxin and activation of the toxin. The toxin inhibits translation by mRNA 
cleavage, which results in growth inhibition and adjustments in the translation machinery. This 
may help stress adaptation as stalled ribosomes are recycled by trans-translation and redirected to 
translate certain mRNAs or reduces translation with increased fidelity. Stress adaptation results in 
antitoxin production and toxin neutralisation, which in turn recovers translation and growth. 
Adapted from (Hayes and Low, 2009). 
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represses transcription of DNA replication inhibitor cspD and alternative stress sigma 
factor σS by binding to mqsR-mqsA-like inverted repeats in the promoter region (Kim 
et al., 2010;Wang et al., 2011). Lon protease degrades MqsA and is necessary for the 
activity of mqsR-mqsA, which makes it a protease-sensitive switch. Degradation of 
MqsA is suggested to increase transcription of rpoS as well as to liberate MqsR toxin 
to cleave mRNA and redirect translation. MqsR is a GCU-specific RNase and 
fourteen GCU-deficient mRNAs exist in E. coli, of which six are up-regulated in 
biofilms, which suggest a possible link (Yamaguchi et al., 2009). 
Other TAs have also been suggested to be involved in biofilm formation as a strain 
deleted for five TAs (mazEF, relBE, chpB, yefM-yoeB, dinj-yafQ) as well as single 
deletions showed decreased production of biofilm (Kim et al., 2009;Kolodkin-Gal et 
al., 2009).  
Multicellular communities of biofilms are highly tolerant to antibiotics in which the 
organisms often adopt a dormant growth state resembling that of persisters (Shah et 
al., 2006). It has been suggested that MqsR and toxins in general can contribute to 
such a quasi-dormant growth state (Wang and Wood, 2011). 
TAs in Persistence – tolerance to antibiotics 
Persisters are dormant non-dividing variants of normal cells that form stochastically 
in a microbial population, particularly in biofilms, which serve as a protective habitat 
for persisters. Recently reviewed (Lewis, 2010). When cells are treated with 
antibiotics, most bacterial cells die but persisters survive; if survivors are re-
inoculated with antibiotics the same biphasic pattern is observed. Hence, these cells 
are tolerant rather than resistant. Persisters have been implicated in the recalcitrance 
of chronic infectious disease to antibiotic treatment.  
Several independent studies have implicated TAs in persistence. Persistence was 
initially linked to TAs by isolation of E. coli mutants of hipA which induced high 
level of persisters (see Chapter 2) (Moyed and Bertrand, 1983). Recently,  
key insights to hipBA-mediated increase in persisters have been made, which 
describes a threshold based model that determines persistence depending on the level 
of HipA in the cell (Rotem et al., 2010). Overexpression of toxins leads to a quasi-
dormant growth state very similar to persisters, which are both highly tolerant to 
antibiotics (Vazquez-Laslop et al., 2006). 
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Consistent with TAs being involved with persister cell formation, several TAs 
(mazEF, dinj-yafQ, relBE, yefM-yoeB, mqsR-mqsA) were up regulated in isolated 
persisters (Shah et al., 2006). The deletion of mqsR-mqsA or only mqsR in both cases 
decreases the number of persisters, which could be reverted by MqsR-MqsA 
production suggesting that the toxin is involved in facilitating dormancy (Kim and 
Wood, 2010). In addition to type II TAs, Type I TA tisAB has been shown to increase 
persistence in response to DNA damage induced by ciprofloxacin treatment (Dorr et 
al., 2010).  
Very recently it was shown that successive deletions of ten mRNA interferase toxins 
in E. coli were shown to decrease the persister frequency 100- to 200-fold after 
treatment with ciprofloxacin or ampicllin (Maisonneuve et al., 2011). This indicates 
strong redundancy between mRNA interferases as the strongest effect on persister 
frequency was observed after successive deletion of five TAs. The decrease in persister 
frequency was dependent on Lon protease, which is consistent with Lon-dependent 
stochastic degradation of the antitoxin in a subpopulation of growing cells. 
Programmed Cell Death and phage abortive system 
Biofilm formation often involves cell-to-cell signals such as quorum sensing 
molecules (Davies et al., 1998). The mqsR-mqsA TA locus has previously been linked 
to the autoinducer-2- quorum sensing system which stimulates biofilm formation in 
response to autoinducer-2 (AI-2) (Gonzalez Barrios et al., 2006).  
An early study by Engelberg-Kulka and co-workers showed that mazEF expression is 
inhibited by increased levels of ppGpp (Aizenman et al., 1996). This is proposed to 
decrease transcription of mazEF and to stimulate MazE degradation and MazF 
activation. This in turn kills a subpopulation of cells by an altruistic suicide 
mechanism beneficial to the surrounding population and is also referred to as 
programmed cell death (PCD). Similarly, mutants lacking mazEF were also shown to 
be significantly more resistant to a variety of stress conditions including different 
antibiotics, thymine-/amino acid starvation, high temperatures and oxidative stress 
(Sat et al., 2001;Sat et al., 2003;Kolodkin-Gal and Engelberg-Kulka, 2006;Hazan et 
al., 2004). Analogous to biofilm autoinducers, mazEF has recently been shown to be 
activated in response to a small pentapeptide quorum sensing molecule, referred to as 
extracellular death factor (EDF) (Kolodkin-Gal et al., 2007). The EDF molecule 
(Asn-Asn-Trp-Asn-Asn) is secreted in response to high culture density and increases 
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MazF mediated cell killing. Very recently it has been shown that EDF most likely acts 
by amplifying the endoribonucleolytic activity of MazF and the MazF homologue 
ChpBK (Belitsky et al., 2011).  
A role for MazF-mediated PCD in preventing spreading of phage P1 infections has 
also been proposed (Hazan and Engelberg-Kulka, 2004). Interestingly, this 
observation requires cross-talk between two different TA-loci namely, phd-doc from 
P1 phage and the mazEF locus of the E. coli chromosome. A similar role has also 
been proposed for a new putative TA locus rnlAB (RNase LS) as it was shown to 
efficiently inhibit reproduction of T4 Phage (Koga et al., 2011).  
Whether mazEF mediated PCD is a universal or a strain specific observation is not 
clear, as this phenomenon has not yet been observed by other groups (Gerdes et al., 
2005;van Melderen, 2010). It is obvious that many models exists, which describe the 
possible benefits by having TAs on the chromosome. Nevertheless it is still far from 
clear and will undoubtedly be the subject of many future studies. 
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Results Section I: The Molecular and Cellular target of Enteric 
VapC toxins 
Introduction to the experimental work 
The subject of this thesis concerns the characterization of prokaryotic vapBC loci. 
Since the discovery of the first vapBC locus in 1992, vapBC TA loci have been the 
topic of many studies and, though VapC homologues are now identified as PIN 
domain proteins with proposed nucleolytic activity, the cellular target and 
physiological function of vapBC and PIN domains in general are still unknown. The 
vast number of vapBC loci identified in both Bacteria and especially Archaea makes 
vapBC a very interesting TA locus. In addition, interesting observations have been 
made regarding its possible involvement in pathogenesis and growth under stress 
conditions. 
The experimental work presented in Results Section I focuses on the identification of 
the cellular target of VapC. E. coli K-12 is used as a model organism in all in vivo 
studies presented here.  
The bioinformatics study by Pandey and Gerdes showed that Escherichia coli K-12 
does not contain chromosomally encoded vapBC loci (Pandey and Gerdes, 2005). 
However recent protein-protein BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) 
searches for VapC-like proteins revealed the presence of homologues in several 
recently sequenced isolates of pathogenic E. coli including strain: EIEC 53638, EHEC 
MS146-1, EHEC H120 and EHEC M863. Enteroinvasive (EIEC) E. coli share 
similarities with S. flexneri and Salmonella Typhimurium as they invade and 
proliferate inside epithelial cells (Tsolis et al., 2008). VapC has previously been 
phenotypically linked to intracellular growth of human pathogen of Neisseria 
gonorrhoea which makes these VapCs an interesting subject of study (Hopper et al., 
2000).   
The vapBC locus of the human pathogen Salmonella enterica serovar Typhimurium 
LT2 was selected as the model system for this study. The vapBC locus of S. enterica 
LT2 chromosome (STM3034, STM3033) has been predicted to have the same genetic 
organization as E. coli K-12 relBE (Pandey and Gerdes, 2005). Furthermore, vapBC 
homologue, mvpAT from Shigella flexneri 2a YSH6000 virulence plasmid 
pMYSH6000, which have been shown to be active in E.coli K-12 derivatives (Sayeed 
 65 
et al., 2000), is also investigated in this study. An alignment of S. enterica LT2, 
STM3033 (referred to as VapCLT2), S. flexneri 2a pMYSH6000 MvpT (referred to as 
VapC) with previously characterised VapCs  show that, despite the overall low 
sequence similarity between the different PIN domain proteins, the putative active site 
residues of the PIN domain are conserved (Figure 14). The primary objective of this 
section is to identify the molecular and cellular target of enteric VapC toxins.  
VapC toxin expression leads to bacteriostatic inhibition of translation  
To test the activity of VapCLT2 of S. enterica LT2 and VapC from S. flexneri YSH600 
virulense plasmid pMYSH6000 in E. coli K-12, VapCLT2 and VapC were cloned onto 
low copy plasmids in front of an arabinose inducible promoter. In addition, 
corresponding antitoxins, VapBLT2 and VapB were cloned onto low copy R1 plasmids 
in front of an IPTG inducible promoter. The activity of toxin and antitoxin was 
assayed by counting the colony forming units (CFU) of cells expressing toxin with 
and without subsequent antitoxin expression (Figure 15). It is observed that VapCLT2 
and VapC are potent toxins in E. coli K-12 cells, which reduce CFU ~10
4
-fold 30 min 
after addition of arabinose. Furthermore, it is observed that if cells are plated onto 
agar plates containing IPTG, which allows transcription of antitoxin, cells regain 
almost full viability (compared with vector control). Efficient resuscitation can be 
 
Figure 14 Alignment of experimentally analysed Prokaryotic VapC PIN-domain proteins. The 
quartet of highly conserved negatively charged amino acid residues that form the catalytic site and 
bind Mg2+ are shown as blue columns. The D to A change in VapCLT2 is indicated with an arrow. 
PIN domains were initially suggested to have RNase activity due to structural features shared with 
RNAse H and Flap endonucleases that have a quartet of conserved acidic residues stabilising an 
Mg2+ in its catalytic centre. This was later confirmed by crystal structures  (Clissold and Ponting, 
2000;Arcus et al., 2004).VapCH.infl from Haemophilus influenzae has non-specific ribonuclease 
activity in HEPES buffer containing 15 mM NaCl  (Daines et al., 2007); VapC from the archaon 
Pyrobaculum aerophilum has a Mg2+ dependent exonuclease activity in 20 mM NaCl + 10 mM 
MgCl2  (Arcus et al., 2004).The vapBC (fitAB) locus of Neisseria gonorrhoeae delays intercellular 
trafficking of the bacterium in an in vitro infection model  (Mattison et al., 2006); VapC5 of M. 
tuberculosis has Mg2+ dependent, non-specific RNase activity  (Miallau et al., 2009).  
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obtained even after extended periods of toxin expression (180 min), which clearly 
shows that the toxin is bacteriostatic rather than being bacteriocidal. 
To identify the molecular target of VapCLT2 and VapC, rates of DNA, RNA and 
protein synthesis were measured after toxin induction. E. coli K-12 strains containing 
VapCLT2 and VapC were grown in AB minimal medium (antitoxins were included in 
these strains to decrease toxicity of toxin in uninduced cells) and samples collected 
before and after toxin induction were pulsed for 1 min with methyl-
3
H-thymidine 
(DNA synthesis), 
3
H-uridine (RNA synthesis) or 
35
S-methionine (protein synthesis). 
From Figure 16 A and B it is observed that ectopic expression of VapCLT2 and VapC 
does not reduce the global level of replication and transcription after 60 min which is 
comparable to RelE induction. The rate of replication and transcription seems to 
slightly increase after toxin induction, however decreases to the pre-induction level 
after 30 min. The rates of transcription and replication seem to follow similar trends 
after toxin induction and do not indicate any decrease. The rate of translation on the 
other hand decreases rapidly upon vapCLT2 and vapC induction (Figure 16C) to <10% 
of pre-induction levels which is comparable to the levels generated by expression of 
mRNA interferase RelE. This indicates that VapCLT2 and VapC, similar to mRNA 
interferases (such as RelE), target the translation machinery.  
 
Figure 15 The vapBC locus from S. typhimurium LT2 and vapBC from S. flexneri pMYSH6000 are 
bona fide TA-loci.  E. coli K-12 MG1655 carrying the following plasmids; pBAD33 and 
pNDM220 (vector) (), pKW52 (pBAD::SDopt:vapCLT2) and pKW51 (pA1/04/03::SDopt::vapBLT2) 
( -IPTG and  +IPTG ), pKW82 (pBAD::vapC) and  pKW81 (pA1/04/03::vapB) ( -IPTG and  
+IPTG ) were grown exponentially in LB medium containing Cm (25 g/mL) and Amp (30 
g/mL). Transcription was induced at time zero by adding 0.2% arabinose. Samples were taken out 
at time points indicated, diluted and plated on plates containing Cm 25 g/mL, Amp 30 g/mL, 
0,2% glucose and with or without 2 mM IPTG. 
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VapC expression activates endogenous YoeB mRNA interferase to 
cleave mRNA at stop codons 
VapCLT2 and VapC mediated inhibition of translation is consistent with the proposed 
nuclease activity of the PIN domain (see Introduction Chapter 2). In addition, the 
majority of the characterised mRNA interferases cleave mRNA and it is therefore 
plausible that VapCLT2 and VapC inhibit translation by mRNA cleavage. The tmRNA 
transcript was selected as a model RNA as it is translated, small, highly abundant and 
constitutively expressed during steady-state growth. The stability of the tmRNA 
transcript was monitored by Northern blot analysis before and after vapCLT2 and vapC 
induction. From Figure 17A (lanes 1-4 and 5-8) VapCLT2 and VapC expression 
slightly reduces the levels of matured full-length tmRNA indicating degradation. 
Interestingly, as the levels of tmRNA decrease (between 30 min and 60 min of 
induction) an RNA fragment of smaller size appears proportional to the decrease of 
full-length, which indicates specific cleavage. It is also observed that RelE expression 
decreases the level of full-length tmRNA (lanes 9-12), which is consistent with 
previous observations (Christensen and Gerdes, 2003). Furthermore, inhibition of 
translation by chloramphenicol does not affect the stability of tmRNA which suggests 
a specific effect of toxin induction (lanes 13-16). 
To identify the location of the VapCLT2 dependent cleavage(s) observed in tmRNA, 
primer extension analysis was performed on RNA samples isolated in Figure 17A 
(Figure 17B). The specific cleavage is found to occur in the stop codon of the small 
reading frame inside tmRNA, which suggests that the cleavage is ribosome dependent 
 
Figure 16 VapC toxins inhibit global translation. E. coli K-12 MG1655 carrying one of the 
following plasmids; pKP3035 (pBAD::relE) (▲), pKW52 (pBAD::SDopt::vapCLT2)/ pKW51 
(pA1/03/04::SDopt::vapBLT2) () or pKW82 (pBAD:: vapC)/ pKW81 (pA1/03/04:: vapB) () were 
gown exponentially in AB-minimal medium with 0.5% glycerol as carbon source and transcription 
of the toxins was induced by addition of arabinose (0.2%) at time zero. The rates-of A) replication, 
B) transcription and C) translation were determined at time points indicated and the pre-induction 
rates were set to 100%. Results in A) and B) are shown as a mean ± SE (n=4) and mean ± SE 
(n=4), respectively. 
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(lanes 1-3). As VapC is found to inhibit global translation, it potentially also activates 
endogenous mRNA interferases present on the E. coli K-12 chromosome. This has 
previously been observed for Doc toxin expression (Garcia-Pino et al., 2008). To 
confirm that this is not the case, primer extension was also performed on RNA 
purified from different mRNA interferase single deletion strains (∆chpA, ∆chpB, 
∆relBE, ∆yefM/yoeB and ∆dinJ/yafQ), as well as a strain deleted for the five mRNA 
interferases Figure 17B lanes 4-21). A Lon protease deficient strain is also 
investigated as Lon is the major protease responsible for antitoxin degradation (lanes 
 
Figure 17 Expression of VapC toxins leads to activation of YoeB dependent cleavage in tmRNA. 
A) Northern blot analysis on tmRNA. E. coli K-12 MG1655 containing either; pKW52 
(pBAD::SDopt::vapCLT2), pKW82 (pBAD::vapC), pKP3035 (pBAD::relE) were grown 
exponentially in LB medium at 37ºC. At time zero 0.2% arabinose was added to induce 
transcription. Cm (50 g/mL) was added at time zero to MG1655 to inhibit translation and was 
used as a control. Total RNA was purified from the samples taken out at time points indicated 
(min) and fractionated by PAGE. B) Expression of VapCLT2 induces Lon-dependent YoeB 
cleavage in tmRNA. E.coli K-12 MG1655,  MG1655ΔchpAK (mazF), MG1655ΔchpB, 
MG1655ΔrelBE, MG1655ΔyefM/yoeB, MG1655Δdinj/yafQ, MG1655Δ5 (lacks all five TA-loci) 
and MG1655Δlon carrying pKW52 (pBAD::SDopt::vapCLT2) were grown exponentially in LB 
medium at 37ºC. At time zero 0.2% arabinose was added to induce expression of VapCLT2. 
Bacterial samples were taken at time points indicated (min), RNA was isolated and primer 
extension analysis performed using primer 10SA-2. 
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22-24). It is observed that cleavage occurs in all strains except strains lacking yefM-
yoeB TA-locus and the Lon protease. YefM is a well known substrate for Lon 
protease (Christensen et al., 2004). Surprisingly, this suggests that VapCLT2 and VapC 
mediated inhibition of global translation might trans-activate endogenous YoeB to 
cleave mRNA in the stop codon of RNA reading frames. Similar observation has been 
reported to occur as a result of global translation inhibition by Lon protease over-
expression (Christensen et al., 2004). Hence, ectopic expression of VapCLT2 and 
VapC does not directly affect the stability of tmRNA, but indirectly as inhibition of 
global translation activates YoeB mRNA interferase.           
Ribosome dependent YoeB cleavage reveals possible ectopic initiation 
of translation at elongator codons, which depends on Shine & Dalgarno 
sequence 
YoeB toxin is a ribosome dependent mRNA interferase in vivo, which cleaves 
between the 2
nd
 and 3
rd
 base in the A-site, but also degrades mRNA ribosome-
independently in vitro (Christensen et al., 2004;Kamada and Hanaoka, 
2005;Christensen-Dalsgaard and Gerdes, 2008). To investigate whether VapC-
induced YoeB activation leads to ribosome dependent cleavage as observed in the 
stop codon of tmRNA, primer extension analysis was performed on dksA mRNA after 
vapCLT2 induction. This was done by analysing different variants of dksA mRNA; one 
of which contains a premature termination codon and two which contains out of frame 
stop codons (Figure 18A). Using this setup it is predicted that if YoeB is ribosome 
dependent, YoeB will only cleave in genuine stop codons and will not recognise out 
of frame stop codons. As observed in Figure 18B after 30 min VapCLT2 triggered 
YoeB mRNA cleavage which only occurs in stop codons (lanes 1-3, 6-8, 11-13 and 
16-18) and out of frame stop codons are not cleaved by YoeB (lanes 11-13 and 16-
18). These observations suggest that cleavage is dependent on the translation 
machinery. Translation inhibition by chloramphenicol does not trans-activate YoeB 
cleavage hence the cleavage is induced specifically by VapC and not translation 
inhibition by chloramphenicol (lanes 4-5, 9-10, 14-15 and 19-20). 
It is observed that YoeB is a ribosome dependent RNAse and can therefore be used as 
a sensitive method to map position of ribosomes on mRNA during vapCLT2 and vapC 
expression. YoeB is a RelE homologue and RelE has previously successfully been 
used to map ribosome position with high resolution (Temperley et al., 2010). To 
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investigate if VapCLT2 and VapC affect translation of dksA, three variants of dksA 
mRNA were constructed in which the Shine & Dalgarno (SD) sequence, the start 
codon or both were changed (Figure 19A). Primer extension analysis was then 
performed on RNA isolated before and 60 min after vapCLT2 and vapC induction. 
Consistent with previous results, vapCLT2 and vapC induction resulted in ribosome-
dependent YoeB cleavage within the stop codon of wild-type dksA mRNA (denoted 
 
Figure 18 VapCLT2 activated YoeB stop codon cleavage is ribosome dependent. A) Presentation of 
wt and mutated version of dksA mRNA used to analyse the ribosome dependent cleavage in B). The 
dksA gene has been inserted in pKW254T creating pKW25420T (dksA mRNA). Plasmid 
pKW25423T (dksAmut1 mRNA) contains dksA were bases 448-450 GCT (codon 150) in the reading 
frame have been changed to TAA creating an in-frame premature stop codon. Plasmids 
pKW25424T (dksAmut2 mRNA) and pKW25425T (dksAmut3 mRNA) contains dksA were bases 447-
449 GGC and 446-448 TGG have been changed to TAA, respectively. The TAA bases have been 
inserted out-of-frame and translation terminates at wild-type stop codon. YoeB cleavage is 
indicated by an arrow B) Primer extension analysis on VapCLT2 dependent stopcodon cleavage in 
dksA mutant. Strains MG1655ΔdksA /pKW25420T (wt dksA), MG1655Δ dksA /pKW25423T 
(dksA3, GCT448-450 changed to TAA), MG1655Δ dksA /pKW25424T (dksA 4, GGC 447-449 
changed to TAA) and MG1655Δ dksA /pKW25425T (dksA 5, TGG446-448 changed to TAA) were 
co-transformed with pKW52 (pBAD::SDopt::vapCLT2) and grown exponentially in LB medium at 
37ºC. At time zero 0.2% arabinose was added to induce transcription. Cm 50g/mL was added to 
strains without toxins and used as a control for translation inhibition. Total RNA was purified from 
samples taken out at time points indicated (min) and primer extension was performed using primer 
pKW71D-3#PE. Arrows indicate the position of YoeB cleavage. 
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SDwt AUG mRNA in Figure 19A) (Figure 19B, left panel, lanes 1, 2 & 5). This 
cleavage disappeared if the yefM yoeB TA locus was deleted from the chromosome 
(lanes 4 & 7) showing that the cleavage depended on activation of YoeB. 
Consistently, induction of yoeB encoded by a plasmid led to efficient cleavage of the 
wild type dksA mRNA (lane 8). Mutational change of the SD-sequence abolished stop 
codon cleavage in all three cases, showing that YoeB cleavage required that the 
mRNA was translated (lanes 3, 6 and 9). Next, a similar series of experiments was 
performed on mRNAs in which the AUG start-codon had been changed to an 
 
Figure 19 Ectopic production of VapCLT2 and VapC affects initiation of translation. (A) Drawing 
showing the four mRNAs analysed in (B). The top wavy lines symbolise wild type dksA mRNA 
with SD, AUG start-codon and UAA stop codon. SDmut indicates that the SD sequence of dksA 
AGGAG, was changed to UCCUC. In the two bottom mRNAs, an AAG lysine codon replaces the 
AUG start codon. Arrows pointing at the UAA codons indicate possible YoeB cleavage in the stop 
codon of dksA.  (B) Primer extension analysis of VapC-mediated ribosome-dependent YoeB 
cleavage. MG1655 or MG1655∆(yefM-yoeB) containing either pKW25420T (SDwt AUG), 
pKW25421T (SDwt AAG), pKW25427T (SDmut AUG) or pKW25428T (SDmut AAG) together with 
pKW3352HC (pBAD33::vapCLT2-H6), pKW3382HC (pBAD33::vapC-H6) or pRB100 
(pBAD33::yoeB) were grown exponentially in LB medium at 37ºC. At time zero, 0.2% arabinose 
was added to induce transcription. Samples were taken before and 60 min after vapC induction. 
yefM-yoeB refers to experiments done in deletion strain, whereas SD indicates presence or absence 
of Shine&dalgarno sequence. VapCLT2, VapC or YoeB refers to toxin induction. 
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elongator codon, AAG (Figure 19B, right panel). Induction of yoeB did not lead to 
cleavage of the SDwt AAG mRNA, showing that the reading-frame starting with AAG 
was normally not translated (lanes 15, 16). In contrast, the SDwt AAG mRNA was 
cleaved after vapC induction (lanes 11 and 13). VapC-induced cleavage of the SDwt 
AAG mRNA was abolished by mutational change of the SD sequence (lanes 12 and 
14). This observation is surprising and raises the possibility that VapCLT2 and VapC 
affect translation initiation as translation is initiated at the AAG codon of dksA mRNA 
if the codon is positioned correctly relative to an SD sequence leaving the reading 
frame intact.  
VapC expression does not decrease stability of model mRNAs in vivo in 
the absence of YoeB activation but inhibits translation 
In order to confirm that the observed decrease in mRNA stability is only due to the 
trans-activation of YoeB and not directly by the activity VapCLT2 and VapC mRNA 
interferase, northern blot analysis was performed on several model RNAs, ompA, 
dksA and lpp mRNA in the absence of yefM-yoeB TA-locus (Figure 20A). It is 
observed that neither vapCLT2 nor vapC induction significantly affect the stability of 
these mRNAs as full length mRNA is detected even 60 min after addition of 
arabinose. In all cases induction of mRNA interferase relE leads to efficient cleavage 
of model mRNAs. Translation inhibition by chloramphenicol also does not decrease 
the stability of these mRNA. This observation suggests that YoeB mRNA interferase 
is responsible for the majority of the observed mRNA cleavage. Weak degradation is 
observed in dksA mRNA in the absence of yefM-yoeB, but cannot account for the 
˂10% inhibition of global translation (Figure 16C), which suggests that additional 
mRNA interferases might be active. To ensure that the observed activation of 
endogenous YoeB is not due to indirect effects such as VapCLT2 and VapC titrating 
YefM antitoxin and to confirm that VapCLT2 and VapC in fact inhibit translation, a 
second pulse-chase experiment was performed in a lon protease deficient strain 
(Figure 20B). It is observed that in the absence of YoeB activation (and the majority 
of mRNA interferases) both vapCLT2 and vapC induction leads to efficient inhibition 
of translation. This shows that both VapCLT2 and VapC are active and it is most likely 
the decrease in rates of translation by VapCLT2 and VapC which triggers the Lon-
dependent activation of YoeB. 
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VapC toxins decrease polysomes, but does not specifically associate 
with the ribosome or ribosomal subunits 
Previous studies showed that mRNases, such as RelE, associate with the ribosome and 
cleave the mRNA at A-site codons (Pedersen et al., 2003;Neubauer et al., 2009). 
 
Figure 20 VapCLT2 and VapC do not cleave mRNA in the absence of YoeB activation but inhibits 
translation. A) Northern blot analysis on ompA, dksA and lpp mRNA. E. coli K-12 MG1655 ∆5 
(ΔchpAK, ΔchpB, ΔrelBE, ΔyefM/yoeB and Δdinj/yafQ) carrying pKW52 
(pBAD::SDopt::vapCLT2), pKW82 (pBAD::vapC) or pKP3035 (pBAD::relE) were grown 
exponentially in LB medium at 37ºC. At time zero 0.2% arabinose was added to induce 
transcription. Cm (50g/mL) was added at time zero to MG1655 ∆5 to inhibit translation and was 
used as a control. Total RNA was purified from the samples taken out at time points indicated 
(min). B) VapC toxins inhibit global translation in the absence of YoeB activation. E. coli K-12 
MG1655 ∆lon carrying pKW52 (pBAD::SDopt::vapCLT2) /pKW51(pA1/03/04::SDopt::vapBLT2) () 
or pKW82 (pBAD:: vapC)/ pKW81 (pA1/03/04:: vapB) () were gown exponentially in AB-
minimal medium with 0.5% glycerol as carbon source and transcription of the toxins was induced 
by addition of arabinose (0.2%) at time zero. The rate-of translation was measured by pulse-chase. 
Pre-induction levels were set to 100%. 
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Cleavage of mRNA by mRNA interferases leads to a decrease in the abundance of 
polysomes (e.g. chains of translating ribosomes on single mRNAs) as the mRNA is 
cleaved and ribosomes released by mechanisms such as trans-translation. Ribosome 
associating toxins such as Doc do not decrease polysomes, but rather stabilises 
polysomes (Liu et al., 2008). As VapCLT2 and VapC are observed to inhibit global 
translation without cleaving model mRNAs, it was interesting to see how these toxins 
affect polysomes. This was done by analysing fractions of an extract from cells 
expressing vapCLT2, separated by sucrose gradient ultracentrifugation. As observed in 
Figure 21A ectopic expression VapCLT2 leads to a significant decrease in polysomes 
and corresponding increase in free 30S and 50S subunits. Co-expression of antitoxin 
VapBLT2 allows translation which is also observed as higher abundance of polysomes 
can be detected. The VapCLT2 induced decrease in polysome abundance is consistent 
with the observed inhibition of translation, however not with lack of degradation of 
mRNA. This indicates that VapCLT2 and VapC inhibit translation by a different 
mechanism compared to RelE and Doc. 
Therefore it was investigated whether VapCLT2 and VapC would associate with 
ribosomes. Extracts of E. coli K-12 expressing VapC or VapCLT2 were separated on 
5-40% sucrose gradients by ultracentrifugation and VapC detected by Western blot 
analysis. As seen, VapC and VapCLT2 were found in highest concentrations in the 
fractions that contained 5S ribosomal and tRNA (Figure 21B left and right). However, 
VapCLT2 was also detected in fractions containing ribosomal subunits and 70S. To 
investigate the specificity of the interaction observed with ribosomal subunit and 70S, 
total ribosomal RNA was separated into subunits under conditions of low 
concentration of magnesium ions. This condition also removes free 5S and tRNA 
(Figure 21C left and right). The Western blot revealed that VapC did not associate 
with ribosomal subunits. However, VapCLT2 was present in fractions containing 
ribosomal RNA but did not localise in a subunit-dependent manner as observed for 
other toxins.  It is possible that this association is an artefact caused by VapCLT2 over 
expression as it might partly aggregate. It is also observed that gradients from 
VapCLT2 (Figure 21B) extracts appear to have less polysomes compared to extracts 
prepared from cells expressing VapC, which is most-likely caused by different 
contrast settings between the two experimens and the manual fractionation of the 
gradients. In all experiments performed, both VapCLT2 and VapC extracts contained 
less polysomes compared to non-induced extracts (data not shown). 
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In conclusion, the ribosome analysis showed that the majority of VapCLT2 and VapC 
was present in fractions containing tRNA and did not specifically associate with the 
ribosome or ribosomal subunits. This suggests that the target of VapCLT2 and VapC is 
not the ribosome directly. The toxins, nevertheless, somehow inhibit global 
translation as well as decrease polysome abundance without significantly affecting 
stability of mRNA.   
 
Figure 21 Ribosome profiles in response to VapCLT2 and VapC A) Ribosome profiles after vapCLT2 
induction. E. coli K-12, MG1655 ∆lon pKW3352HC (pBAD33::vapCLT2-H6)/pKW51 
(pA1/03/04::SDopt::vapBLT2)  were grown exponentially in LB medium and were collected after 20 
min of vapCLT2 or vapCLT2and vapBLT2 induction. Samples were separated in a 5-40% sucrose 
gradient at 35.000rpm at 4ºC for 3h 30 min and fractions were visualised by agarose gel 
electrophoresis and EtBr staining. B) MG1655 ∆lon carrying pKW3352HC (pBAD33::vapCLT2-H6) 
or pKW3382HC (pBAD33::vapC-H6) were grown exponentially in LB medium and samples were 
collected after 15 min of toxin induction. The top panels show ribosome profiles of cells expressing 
VapCLT2-H6 (left) or VapC-H6 (Right) while the lower panels shows His6-tag detected by Western 
blotting using anti-his-tag antibodies. The numbers corresponds to fractions in the upper panels. In 
(B), 10 mM Mg2+ was present in the gradients to keep the ribosomal subunits assembled in 70S 
particles. C) Similar to B) but the ribosomal subunits disengaged due to conditions of low 
magnesium ions (1 mM Mg2+). Ribosomal RNA was visualized by agarose gel electrophoresis and 
EtBr staining.  
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Purified VapC inhibits translation 
To reduce the number of possible factors involved in the observed VapC activity in 
inhibiting translation, it was informative to reproduce the observed inhibition of 
translation in vitro. Translation was investigated using a cell free in vitro translation 
extract with purified VapC. Addition of purified, native VapC (4.5 pmol) to an in 
vitro translation reaction abolished translation even after 1 h of incubation with MS2 
mRNA (~0.7 pmol) (Figure 22A, lanes 1 and 2). Pre-incubation with VapB antitoxin 
neutralized VapC activity, showing that VapCs inhibition of translation was specific 
(lane 3). Thus, the preparation of VapC was active in vitro and its activity could be 
counteracted by VapB. For reasons unknown, VapCLT2 was not active in in vitro 
assays and subsequent in vitro work was performed using VapC. 
It is possible that VapC degrades the MS2 mRNA in the in vitro extract and causes 
inhibition of translation. To test this, MS2 mRNA (~0.7 pmol) was incubated with 
VapC (2.5 – 10 pmol) in the presence of divalent metal ions Mg2+ and/ or Mn2+ 
 
Figure 22 VapC inhibits translation in vitro. A) Native VapC inhibits translation in vitro and can 
be neutralized by VapB. Each reaction contained the following: 6 μL Premix, 4.5 μL S30 Extract, 
1.5 μL amino acid mix without methionine, 0.5 μL 35S-methionine and 4.5 pmol VapC with and 
without pre-incubation with 30 pmol VapB. The reaction was incubated for 5 min at 37ºC before 
addition of 1 μL MS2 RNA (~0.7 pmol) (Roche). The reactions were incubated for 1 h at 37ºC 
before termination of the reaction by acetone precipitation. The protein products were visualized by 
SDS-PAGE and phosphorimaging. B) VapC degrades MS2 RNA in the presence of Mn2+, which 
can be reversed by Mg2+. 2.5, 5.0 or 10 pmol of VapC was incubated with 0.7 pmol of MS2 RNA 
in 10 mM HEPES pH 7.5 and 15 mM KCl in the presence of either 3 mM Mg2+ and/or 3 mM Mn2+ 
for 1 h at 37ºC. RNA was visualized with EtBr staining. The right-most lane shows that addition of 
Mg2+ to the VapC reaction containing Mn2+ inhibited the non-specific activity of VapC. The 
stability of MS2 RNA did not change in the presence of only Mg2+ and Mn2+ during the cause of 
the assay (Left-most lane). Neither Mg2+ nor Mn2+ activated VapCLT2 on any RNA substrate that 
we tested in vitro. 
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(Figure 22B). After 1 h of incubation, efficient degradation is only observed in the 
presence of Mn
2+
. This shows that VapC is an RNase that can degrade MS2 RNA in 
the presence of Mn
2+
. However, addition of equal amounts of Mg
2+
 and Mn
2+
 to the 
same reaction significantly decreases the degradation of MS2 RNA. The decreased 
RNase activity in the presence Mg
2+
, could indicate that Mg
2+
 can displace Mn
2+
 from 
the  PIN domain active site and might be the preferred metal ion.. 
As the cellular concentration of Mg
2+
 is significantly higher than Mn
2+
 might indicate 
that the observed Mn
2+
 dependent RNase activity is not physiological. In that case 
VapC could target something else than MS2 RNA in the extract.  Incubation of MS2 
RNA with Mg
2+
 and Mn
2+  
without VapC did not significantly change the RNA 
stability in the cleavage assay. 
VapC specifically cleaves tRNAfMet in vitro and in vivo without affecting 
stability of other tRNAs 
Another possible target of VapC is tRNA, which would be consistent with all the 
previous observations. In addition, a plausible tRNA target would be tRNA
fMet
 
considering the observed effects on translation initiation in response to VapCLT2 and 
VapC production. To test this idea purified VapC (5 pmol) was incubated with 2 pmol 
of tRNA
fMet
, tRNA
Val
 and tRNA
Phe
 in the presence of Mg
2+
 (Figure 23A). VapC 
completely degraded purified E. coli tRNA
fMet
 in a 15 min reaction. In contrast, 
tRNA
Val
 and tRNA
Phe
 were not degraded, which shows specificity of VapC towards 
tRNA
fMet
. Cleavage of tRNA
fMet
 was counteracted by the prior addition of VapB to 
VapC, which shows that it is the activity of VapC that is responsible for observed 
degradation. EDTA also inhibited the reaction, revealing that VapC activity required 
divalent cations or, more specifically, Mg
2+
. The tRNA cleavage assay was not 
performed in the presence of Mn
2+
. 
To confirm this observation in vivo, vapCLT2 and vapC were induced in E. coli K-12 
and stability of tRNA followed by northern blot analysis (Figure 23B). It is observed 
that both vapCLT2 and vapC induction leads to rapid decrease in the stability of full-
length tRNA
fMet
 with the co-occurrence of a smaller cleavage product.  
Consistent with this observation neither inhibition of translation by chloramphenicol 
nor expression of mRNA interferase RelE significantly affected the stability of this 
tRNA.  
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Figure 23 VapC cleaves tRNAfMet. A) Cleavage of tRNAfMet in vitro. VapC (2.5 pmol or 5 pmol) 
was incubated with 2 pmol tRNAfMet, tRNAVal or tRNAPhe for 15 min. Controls: VapC (5 pmol) 
was pre-incubated with either VapB (30 pmol) or 12.5 mM EDTA before the addition of tRNA fMet. 
tRNA was separated on an agarose gel and visualised by EtBr staining. B) Cleavage of tRNAfMet in 
vivo. MG1655Δlon containing pKW3352HC (pBAD33::vapCLT2-H6), pKW3382HC 
(pBAD33::vapC-H6) or pKP3035 (pBAD33::relE) were grown exponentially in LB medium at 
37ºC. At time zero, arabinose (0.2%) was added to induce transcription. Samples were taken at 
time points indicated (min). Chloramphenicol (50 μg/mL), Cm, was added to MG1655Δlon as a 
control. tRNAs (tRNAfMet, tRNAMet , tRNAArg2, tRNAHis, tRNAPhe, tRNAThr1, tRNATyr, tRNAVal and 
tRNALeu1) were analysed by northern blot analysis. The use of a Δlon strain prevented fortuitous 
induction of mRNases by VapC over expression. C) Cleavage of tRNAfMet in S. enterica LT2. 
KP1001 S. enterica LT2 containing pKW3352HC (pBAD33::vapCLT2-H6) were grown and induced 
as in B). Samples were taken at time points indicated (min). CL indicates cleavage fragments 
detected. 
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Interestingly, however, VapC seems to be more active than VapCLT2 as full-length 
tRNA
fMet
 cannot be detected after 10 min of vapC induction. In the case of vapCLT2 
induction, full-length RNA can still be detected after 30 min. The stability of several 
elongator tRNAs including tRNA
Met
 , tRNA
Arg2
, tRNA
His
, tRNA
Phe
, tRNA
Thr1
, 
tRNA
Tyr
, tRNA
Val
 and tRNA
Leu1
 was also not affected, which indicates the specificity 
of VapCLT2 and VapC towards tRNA
fMet
. Weak tRNA
fMet
 cleavage is observed in the 
pre-induced samples (-2) which is most likely caused by low leakiness of the pBAD 
promoter. 
It should be noted that tRNA
fMet
 are identical in both E.coli K-12, S. enterica LT2 and 
S. flexneri 2a and could therefore constitute a possible target,. Accordingly, vapCLT2 
induction in S. enterica LT2 was also observed to induce tRNA
fMet
 cleavage (Figure 
23C). 
It was observed that VapCLT2 and VapC are bacteriostatic and inhibited cells can be 
resuscitated after 180 min of induction (Figure 15). As VapCLT2 and VapC most likely 
inhibit global translation by tRNA
fMet
 cleavage, the relation between growth rate and 
tRNA
fMet
 stability can be investigated by subsequent antitoxin induction in toxin 
inhibited cells. As observed in Figure 24A, both vapCLT2 and vapC induction 
efficiently inhibits growth which is resumed after a short delay upon vapBLT2 or vapB 
induction. Consistent with the growth inhibition, a decrease in full-length tRNA
fMet
 is 
observed (Figure 24B, left and middle panel). Furthermore, a transcriptional induction 
of vapBLT2 and vapB resulted in accumulation of full-length tRNA
fMet
 and resumption 
of growth is observed. Interestingly, the delay in resuming the growth is related to the 
accumulation of full-length tRNA
fMet
 and VapC, which produces a more efficient 
depletion, has a longer delay before growth resumption (~ 90 min for vapB induction 
compared to ~ 30 min for vapBLT2 induction).   
As previously mentioned, the catalytic centers of PIN-domain proteins consist of 
quartets of conserved acidic residues (Figure 14). It is predicted that the aspartate in 
position +7 and +98 of VapCLT2 and VapC are required for the catalytic activity. To 
test this possibility, aspartates in these positions were changed to an alanine in 
VapCLT2 and tested for toxicity (Figure 24C). As observed, both VapCLT2
D7A
 and 
VapCLT2
D98A
 expression is less toxic compared to wild type VapCLT2. It is observed 
that VapCLT2
D98A
 expression decreases colony size, which suggests that this mutant 
still retains partial activity. To confirm the inactivity of VapCLT2
D7A
 the activity was 
tested in a growth experiment.   
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As observed in Figure 24A vapCLT2
D7A
 does not inhibit growth upon induction and is 
reflected in the levels of tRNA
fMet
, which were not affected (Figure 24B right). This 
shows that D7A substitution renders VapC catalytically inactive and that the predicted 
active site is necessary for the observed RNase activity.       
 
Figure 24 Regulation of the growth rate by tRNAfMet cleavage. (A) Bacterial growth after VapC 
expression and subsequent VapB expression. Strains MG1655Δlon / pKW3352HC 
(pBAD33::vapCLT2-H6) / pKW51 
(R1::pA1/O4/O3::vapBLT2) (♦), MG1655Δlon / pKW3382HC (pBAD33::vapC-H6) / pKW81 
(pA1/O4/O3::vapB) (■) or MG1655Δlon / pKW3353 (pBAD33::vapCLT2-H6 
D7A) (▲) were grown 
exponentially in LB medium at 37ºC. At 100 min, vapC transcription was induced by the addition 
of 0.2% arabinose. In the case of strains carrying vapC and vapCLT2, vapC expression was 
terminated at 130 min by the addition of 0.4% glucose and transcription of vapB and vapBLT2 was 
induced by addition of 2 mM IPTG. (B) Northern blotting analysis on tRNAfMet of cell samples 
from (A) VapCLT2 (Left Panel), VapC (Middle Panel) and VapCLT2 D7A (Right Panel). C) Toxicity 
of VapCLT2D7A and VapCLT2D98A. MG1655Δlon containing either pKW3352HC 
(pBAD33::vapCLT2-H6), pKW3353 (pBAD33::vapCLT2-H6 
D7A) or pKW3354HC 
(pBAD33::vapCLT2-H6 
D98A) were streaked onto NA plates with or without 0.2% arabinose.  
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tRNAfMet is most-likely the sole target of VapC 
VapCLT2 and VapC cleave tRNA
fMet
, but it is not clear whether this tRNA is the sole 
target in the cell. Investigations to shed more light on this were done with an in vitro 
and in vivo approach. The in vitro approach was to reactivate a VapC-inhibited 
translation extract by addition of fresh charged fMet-tRNA
fMet 
(Figure 25A). 
Consistent with previous results, incubation of VapC with the extract inhibits 
translation (lane 1 and 2). Addition of VapB to the reaction does not affect the activity 
of the extract (lane 4); however subsequent addition of fresh fMet-tRNA
fMet
 to the 
extract reactivates translation (lane 3). This is a clear indication that tRNA
fMet
 is the 
only tRNA being targeted in the extract. To confirm this in vivo, E. coli cells are 
pulsed with VapCLT2 or VapC in the presence or absence of additional tRNA
fMet
 
supplied from an inducible promoter on the chromosome (Figure 25B left and right). 
Due to the difference in toxicity, vapCLT2 is induced for 2 min and vapC for 1 min. As 
it can be observed for both toxins, cells which have excess of tRNA
fMet
 recover 
 
Figure 25 tRNAfMet is the sole target of VapC and VapCLT2. A) Inhibition of translation in vitro by 
VapC can be reversed by fMet-tRNAfMet. VapC (9 pmol) (lanes 2, 3 and 4) or buffer (lane 1) were 
added to an E. coli S30 extract and incubated for 5 min before VapB (60 pmol) (lane 3 and 4) or 
buffer (lane 1 and 2) was added at +5 min and incubation was continued; at +10 min, fMet-
tRNAfMet (lane 3) or buffer (lane 1, 2 and 4) was added together with 35S-met and MS2 RNA. The 
reaction was terminated after incubation for an additional 10 min. B) Ectopic overexpression of 
tRNAfMet counteracts VapC-mediated growth inhibition. C41 (DE3)/pKW3221 (pT7::tRNAfMet) / 
pKW3352HC (pBAD33::vapCLT2-H6) or C41 (DE3)/pKW3221 (pT7::tRNA
fMet) / pKW3382HC 
(pBAD33::vapC-H6) were grown exponentially to OD450  0.5 in LB medium at 37ºC. The cultures 
were diluted to OD450  0.05 in medium with or without 2 mM IPTG to induce production of T7 
RNA polymerase and ultimately tRNAfMet. The cells were grown exponentially to an OD450  0.4. 
A vapC transcription pulse was generated by the addition of arabinose (0.2%) for 2 min (vapCLT2 ) 
or 1 min (vapC) which was terminated by the addition of 0.4% glucose. The cultures were diluted 
to OD450  0.01 in preheated medium with and without 2 mM IPTG and cell density was measured 
at the time points indicated. Right panel: vapC; left panel: vapCLT2. Squares and diamonds indicate 
growth with and without IPTG, respectively. 
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growth more rapidly compared to cells with lower levels of tRNA
fMet
. It is also 
observed that VapCLT2 is less toxic than VapC as growth resumes faster, which is 
consistent with previous results. It should be noted that expression of tRNA
fMet
 by 
itself does not affect the growth rate. This indicates that tRNA
fMet
 is probably the sole 
target of VapCLT2 or VapC in vivo, because if otherwise the toxins would have 
targeted additional tRNAs, tRNA
fMet
 production would not make a significant 
advantage for growth resumption. These observations also support that the observed 
Mn
2+
 dependent RNase activity on mRNA in vitro is unspecific. 
VapC cleavage occurs at the anticodon stem-loop of tRNAfMet 
The tRNAse activity observed by VapCLT2 and VapC produce tRNA
fMet
 fragments 
consistent with specific cleavage in the tRNA. To analyse this in detail, tRNA
fMet
 was 
radiolabelled in the 5‟- and 3‟-end and subsequently treated with increasing 
concentration of VapC (Figure 26 A), B) and C)). Incubation of tRNA
fMet
 with VapC 
produces one specific cleavage product, which is mapped to occur between position 
+38 and +39 in the anticodon loop, adjacent to the universally conserved GC stem 
(Figure 26D). 
The cleavage site could also be mapped in vivo by analysing tRNA
fMet
 fragments 
isolated from E. coli K-12 cells expressing VapCLT2 and VapC. Cleavage fragments 
were isolated using a biotinylated primer specific for tRNA
fMet
 and subsequently 
radiolabelled. Using a tRNA
fMet
 specific probe, a cleavage fragment is isolated with 
the same size as 5‟-labelled in vitro cleaved tRNAfMet (Figure 27A). Interestingly, 
smaller fragments are also isolated which could be products of subsequent 
ribonuclease activity by other ribonucleases in the cell as the cleavage products might 
become unstable. Consistent with the Northern blots (Figure 23B) no cleavage 
products are isolated in cells expressing RelE or those treated with chloramphenicol, 
and only full-length tRNA
fMet
 can be recovered. As the VapC cleavage site is in the 
middle of tRNA
fMet
 sequence, the observed cleavage product could correspond to 
unspecific hybridisation to the 3‟-end cleavage product as it would have similar size 
to the 5‟-end cleavage product. In order to clarify this, two new biotinylated primers 
were designed, specific for either 5‟-end or 3‟-end cleavage fragment (Figure 27B and 
C). It can be observed that only weak cleavage fragment can be observed with the 5‟-
end specific primer, whereas the smaller ribonuclease degradation products are clearly 
visible. Conversely, with the 3‟-end primer, only a specific cleavage fragment is 
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isolated. This could indicate that the GC stem prevents the 3‟-end cleavage product 
from being degraded by other ribonucleases and 5‟-end is more prone to degradation 
as it is unprotected (Figure 27D). A similar observation has been made for colicin D, 
which cleaves between position +38 and +39 of tRNA
Arg
, which in vivo is 
subsequently degraded to +34 by other ribonucleases (Tomita et al., 2000). This 
degradation can also be a result of the tRNA purification process as cellular 
ribonucleases are released upon lysis of the cells. In conclusion, VapCLT2 and VapC 
 
Figure 26 VapC cleaves tRNAfMet in the anticodon stem-loop in vitro. A) and B) In vitro cleavage 
of 5‟-labeled tRNAfMet. C) In vitro cleavage of 3‟-labeled tRNAfMet. One pmol tRNAfMet was 
treated with increasing concentrations (0.01, 0.025 and 0.05 pmol) or 0.05 pmol alone of VapC for 
15 min. M: untreated tRNA
fMet
; OH-: hydroxyl ladder of tRNA
fMet
; T1: RNase T1 digestion of 
tRNAfMet RNase A: RNase A digestion of tRNAfMet. D) Primary and Secondary structures of E. coli 
fMet-tRNAfMet. The arrow indicates the mapped cleavage site. 
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act by endoribonucleolytic cleavage at a specific site in the anticodon stem-loop of 
tRNA
fMet
. The anticodon stem is not conserved in the elongator tRNA
Met
, which could 
explains why this tRNA is not cleaved (Figure 23B). 
An abrupt decrease in the rate of translation induces VapC cleavage of 
tRNAfMet from plasmid resident vapBC locus 
Endoribonucleolytic cleavage of tRNA
fMet
 by VapC seems to be highly specific. 
Therefore Northern blot analysis of tRNA
fMet
 is a highly sensitive assay to analyse the 
activity of VapC. Previously it has been shown that when the de novo synthesis of 
antitoxin decreases, for example by treatment with choramphenicol, transcription 
from the promoter increases (Described for vapBC in Results Part II) (Christensen et 
al., 2001). It is therefore now possible to test the activity of VapC activated from the 
vapBC operon, when the synthesis of antitoxin and toxin is blocked. The vapBC or 
vapBC
D7A
 (Asp 7 to Ala substitution which is non-toxic) operon under the control of 
the native promoter were therefore cloned onto low-copy number plasmids and 
transformed into E. coli K-12. Translation was blocked by addition of 
chloramphenicol and the stability of tRNA
fMet
 followed by northern blot analysis. As 
 
Figure 27 Analysis of the tRNAfMet cleavage product in vivo. tRNAfMet was isolated from total 
tRNA samples taken in Figure 23B) at 10 min by hybridization to a biotinylated probe 
complementary to the cleavage products of tRNA
fMet
 (Fmet-bio). The RNA/DNA hybrid was 
subsequently purified using Streptavidin sepharose and labelled with 32P in its 5‟-end. M is 
untreated tRNAfMet and lane C is in vitro cleavage of tRNAfMet by VapC (0.01 and/or 0.05 pmol of 
VapC). FL: Full-length tRNAfMet; CL: Cleavage product of tRNAfMet. A) tRNAfMet specific probe 
(Fmet-bio) B) 5‟-specific tRNAfMet probe (FMET-BIO-N) C) 3‟-specific tRNAfMet probe (FMET-
BIO-3). D) Primary and Secondary structures of E. coli fMet-tRNAfMet. The arrow indicates the 
mapped cleavage site. Circled shaded bases in the anticodon loop are subsequently removed by 
cellular ribonucleases either in the cell or in the tRNA purification process.    
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seen in Figure 28, blocking translation in cells carrying vapBC induces detectable 
cleavage. No such cleavage is detected in cells carrying non-toxic vapBC
D7A
. This 
clearly shows that VapC can be activated by abrupt translation inhibition consistent 
with degradation of VapB during such conditions. Interestingly however, only weak 
cleavage is detected which can reflect either low intrinsic activity of VapC in this 
setup or that VapC is activated only in a sub population of cells.    
Depletion of tRNAfMet by VapC results in ectopic initiation of translation 
at elongator codons 
As it is now clear that VapCLT2 and VapC depletes the cells for tRNA
fMet
 this might 
explain the observed ectopic initiation on AAG lysine codons when they are 
positioned in optimal distance to the Shine & Dalgarno sequence (Figure 19B). 
Depletion of tRNA
fMet
 might promote the use of elongator tRNAs inserted in the 
ribosomal P-site during translation initation. To investigate this conjecture in a 
simpler and more general context, a dual luciferase assay was performed to measure 
the fidelity of translation initiation (Kimura and Suzuki, 2010). Firefly luciferase gene 
(lucF) had its AUG start-codon changed to either AAA or AAG lysine codons; renilla 
luciferase (lucR) was included to normalize LucF activity (Figure 29). The 
LucF/LucR ratios were very low for the AAA and AAG constructs before induction 
of vapCLT2, consistent with the absence of initiation of translation from AAA and 
AAG elongator codons. Strikingly, induction of vapCLT2 resulted in 20-fold (AAA) 
and 4-fold (AAG) increases in the LucF/LucR ratios. No increase was observed 
 
Figure 28 Cleavage of tRNAfMet by VapC activated from vapBC operon during translation 
inhibition. E. coli K-12 MG1655/pKW254812 (vapBC) and MG1655/pKW254813 (vapBCD7A) 
were grown exponentially in LB medium at 37 ºC. At time zero, 50 µg/mL of chloramphenicol was 
added. Samples were taken at time points indicated (min). The lane marked C shows tRNAfMet 
cleaved by VapC (10 min sample from Figure 23B). CL denotes the VapC cleavage product(s) of 
tRNAfMet. 
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when translation was inhibited with chloramphenicol or yoeB induction. These results 
confirm that vapC induction activated ectopic translation initiation at elongator 
codons positioned correctly in respect to a Shine & Dalgarno sequence. This 
observation also indirectly indicates that VapCLT2 and VapC only affect tRNA
fMet
 as 
the rest of the translation machinery is left intact. 
 
Figure 29 Measurement of relative translational initiation frequencies at elongator codons (AAA 
and AAG) by a dual luciferase assay. E. coli K-12 MG1655∆lon containing plasmids pQE-AAA or 
pQE-AAG and pKW3352HC (pBAD33::vapCLT2-H6) or pRB100 (pBAD33::yoeB) were grown 
exponentially in LB medium at 37ºC. Samples were taken before and 30 min after induction of 
vapC. Cm, Cell samples treated with chloramphenicol (50 μg/ml) were included as additional 
controls. F/R: Firefly/Renilla activity ratio. 
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Discussion Section I 
Extensive bioinformatic analysis of toxins, based on sequence similarity, led to the 
identification of at least ten different TA families (Anantharaman and Aravind, 
2003;Pandey and Gerdes, 2005;Makarova et al., 2009;Leplae et al., 2011). Five of 
these toxin families have been shown to inhibit translation primarily by mRNA 
cleavage e.g RelE, MazF, HigB, HicA, HipA Doc. Two toxin families, CcdB and 
ParE, are known to inhibit replication by inhibiting DNA gyrase activity and one Zeta 
(δ) has been identified to target cell wall synthesis. VapC is known to inhibit 
translation but the molecular target was so far unknown.  
VapC is the largest family of toxins and in a recently published TA database with 
collected data from  964 prokaryotic genomes, 1316 loci were classified as vapBC, 
making this TA locus family the most abundant, representing approximately 43% of 
all identified TA loci (Shao et al., 2011). In order to understand and elucidate the 
biological function of vapBC loci and TA loci in general, it is therefore of 
considerable interest to identify the cellular target of VapC.   
 
It is shown here that expression of VapC homologue STM3033 (here referred to as 
VapCLT2) from S. enterica LT2 and VapC homologue MvpT (here referred to as 
VapC) of S. flexneri 2a. YSH6000 virulence plasmid pMYSH6000 inhibits growth of 
E. coli K-12 cells and reduces viability (Figure 15). In addition, it has previously been 
shown that mvpAT locus efficiently stabilizes plasmids and that MvpA co-expression 
leads to loss of plasmid suggesting plasmid stabilization by the mechanism of PSK 
(Radnedge et al., 1997;Sayeed et al., 2000). This phenotype is a consequence of a 
difference in stability of the antitoxin (MvpA)  compared to the toxin (MvpT) (Gerdes 
et al., 2005). Daughter cells that lose the plasmid containing mvpAT experience rapid 
decay of the antitoxin by cellular proteases (Lon and/or Clp). Due to lack of continued 
antitoxin synthesis, the toxin is liberated from its inactive state in the complex and 
inhibits growth.  
Here it was shown that VapCLT2 and VapC inhibited cells can be rescued to almost 
100% viability after three hours by subsequent expression of antitoxins (Figure 15). 
This indicates that these toxins do not kill the cells, but rather are bacteriostatic and 
restrict cell growth when expressed. This is consistent with previous observations for 
other TA loci e.g. relBE and mazEF and suggests that the plasmid stabilization 
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observed by mvpAT is an indirect effect of toxin and antitoxin component properties 
(Pedersen et al., 2002).  
In this study evidence is also presented that VapCLT2 and VapC inhibit growth by 
reducing the rate of global translation (Figure 16 and 20B). Concomitantly, by 
Northern blotting and primer extension analysis it was observed that tmRNA and 
dksA mRNA is cleaved between the 2
nd
 and 3
rd
 base of the UAA stop codon (Figure 
17A,  17B and 18B). Subsequent studies, however, carried out in strains lacking 
yefM/yoeB TA locus and the Lon protease, showed that the observed cleavage was 
mediated by endogenous YoeB and dependent on the activity of Lon protease and not 
directly by VapC (Figure 17B). Lon overproduction inhibits translation and has 
previously been shown to specifically activate YoeB mRNA interferase to cleave at 
mRNA stop codon, most-likely by Lon mediated degradation of YefM (Christensen et 
al., 2004). Therefore, this observation suggests that VapC dependent inhibition of 
translation activates Lon protease, either directly or indirectly, to degrade YefM and 
in turn liberate endogenous YoeB to cleave mRNA..In addition to this, mutations in 
the dksA reading frame also revealed that the VapCLT2 and VapC activated YoeB 
cleavage was completely dependent on the ribosome which is consistent with 
previous observations (Christensen et al., 2004;Christensen-Dalsgaard and Gerdes, 
2008) 
These results are interesting as there are other  TA-systems present in E. coli K-12. 
The antitoxins of relBE and mazEF  are also Lon protease substrates (e.g RelB and 
MazE) (Christensen et al., 2001;Christensen and Gerdes, 2003). Accordingly, RelE- 
and MazF- mediated mRNA cleavage would also be expected to occur upon 
translation inhibition by VapC, however this is not observed. 
The Doc toxin from phd/doc of phage P1 has been shown to inhibit translation 
elongation, which indirectly activates endogenous MazF and RelE to cleave mRNA 
(Hazan et al., 2001;Garcia-Pino et al., 2008). In addition, amino acid starvation (by 
addition of Serine hydroxymate which induces serine starvation) or by starving cells 
for specific amino acids leads to A-site cleavage in a amino acid codon specific 
manner, which could depenent on mRNA Interferases (Li et al., 2008b;Garza-
Sanchez et al., 2008). In this respect RelE and MazF toxin have also directly been 
linked to A-site cleavage during amino acid starvation (Christensen et al., 2003). In 
conclusion, amino acid starvation and Lon overproduction both inhibit translation but 
activate different TA loci to cleave mRNA. This supports the idea that inhibition of 
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transcription and/or translation is the key activator of TA systems and can generate 
unbalanced amounts of toxin and antitoxin, as it has previously been shown for relBE 
and mazEF (Aizenman et al., 1996;Christensen et al., 2001). Thus, as shown here, the 
fact that VapC-induced inhibition of translation specifically activates YoeB, is 
consistent with the observation that the mechanism of translation inhibition might 
activate specific TA loci. In relation to this, it has previously been suggested that the 
mode of translation inhibition might leave the ribosomes in a state more or less 
accessible for specific toxins (Christensen et al., 2004). This could also be the 
explanation why mRNA cleavage by other toxins is not observed after VapC 
induction and why cleavage is not observed in cells where translation is inhibited by 
chloramphenicol. Chloramphenicol inhibits peptidyl transfer activity and in such case, 
the ribosomal A-site may not be accessible for ribosome dependent mRNA 
interferases.  
Nevertheless, in the absence of Lon protease, which is responsible for trans-activation 
of the majority of TAs, VapCLT2 and VapC still inhibit translation efficiently to a 
level similar to that caused by RelE expression (Figure 20C and 16C). Furthermore, in 
the absence of yefM-yoeB several mRNAs including ompA, dksA and lpp were found 
to be stable when vapCLT2 or vapC is induced (Figure 20A). This observation suggests 
that VapCLT2 and VapC inhibit translation by a mechanism different from RelE as 
RelE efficiently cleaved all the tested mRNAs.  
Interestingly, VapCLT2 and VapC decreased polysomes, consistent with the inhibition 
of translation, but did not specifically associate to either the ribosome or ribosomal 
subunits (Figure 21A and 21B). This observation confirms that the activity is distinct 
from ribosome dependent mRNAses such as RelE or YoeB, as these toxins both 
associate with ribosomes and ribosomal subunits (Pedersen et al., 2003;Zhang and 
Inouye, 2009). In addition, the mechanism of transltion inhibition by VapC is most 
likely also distinct to the Doc toxin, which activity has been found to stabilise 
polysomes (Liu et al., 2008).  
However, the observation that the highest quantities of VapCLT2 and VapC are 
detected in sucrose gradient fractions containing 5S ribosomal subunits and tRNA, 
suggested that the target might be found there (Figure 21B). Previously performed 
primer extension analysis on 5S ribosomal RNA (rrfD) after VapCLT2 and VapC 
expression did not detect any difference in degradation compared with RelE 
expression or chloramphenicol treatment (data not shown here) (Winther and Gerdes, 
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2009). Futhermore, by analysing the quality of RNA extraction no significant 
difference in purified 5S was detected, suggesting that the target most-likely is not 5S 
and therefore could be a tRNA (data not shown). An interesting observation in 
relation to that was the observed VapC trans-activated YoeB dependent stop codon 
cleavage when the AUG start codon was changed to an AAG lysine codon which 
normally silences the reading frame (Figure 19B). Stop codon cleavage was 
dependent on a Shine & Dalgarno sequence positioned correctly in respect to the start 
codon, but occured independently of a canonical initation codon, which suggested that 
translation initiation was affected by VapCLT2 and VapC expression. As the observed 
YoeB cleavage occured in the stop codon, the data suggested that translation 
elongation was not affected, as ribosomes reached the stop codon even in the absence 
of an AUG start codon (Figure 19B).  
What could then be the target of VapC and the activity of its PIN domain? It has 
previously been proposed that PIN domains retain ribonuclease activity and share 
similarity with 5‟- nuclease domain families (Clissold and Ponting, 2000). In addition, 
conserved acidic residues were identified and suggested to bind divalent cations 
similar to that observed by other metal-ion dependent nucleases. In a following study 
it was shown that the conserved putative active site residues from an Archeal PIN 
domain could be aligned with the active site residues of T4 RNase H facilitating Mg
2+
 
binding. In addition, weak nuclease activity could be confirmed in vitro (Arcus et al., 
2004). In more recent studies using purified VapC from non-typable Hemophilus 
influenzae, Mycobacterium tuberculosis, Sulfolobus solfataricus and Piscirickettsia 
salmonis, it has been shown that VapC indeed posseses RNase activity in vitro, which 
in most cases can be inhibited by the presence of VapB antitoxin (Daines et al., 
2007;Ramage et al., 2009;Maezato et al., 2011;Gomez et al., 2011) (see Table 2). 
These observations suggest that VapC is a ribonuclease.. 
In an attempt to simplify the system, native VapC was purified, and shown to inhibit 
translation in an in vitro translation extract. This inhibition could be counteracted by 
VapB (Figure 22A). VapC was observed to degrade MS2 RNA in the presence of 
Mn
2+ 
(Figure 22B). However, Mn
2+
 dependent RNase activity could be counteracted 
by addition of Mg
2+
,
 
which might suggest that in the presence of Mg
2+
 VapC does not 
degrade MS2 RNA and that Mg
2+
 could be the preferred ion of the active site.. Taking 
into account the higher cellular levels of Mg
2+
 the results possibly indicate that VapC 
does not specifically degrade mRNA and that the inhibition of translaton does not 
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occur by mRNA cleavage. This idea is also consistent with the observation that ompA, 
dksA and lpp mRNAs and tmRNA are not cleaved by VapC in vivo (Figure 20A).  
As it was observed that VapCLT2 and VapC expression might affect translation 
initiation a plausible target would be initiator tRNA. The presence of VapC in 
fractions containing 5S ribosomal RNA and tRNA also supported this idea. 
In fact, it was observed that VapCLT2 and VapC are highly specific tRNA
fMet
 tRNases 
both in vitro in the presence of Mg
2+
 and in vivo (Figure 23A and 23B). Several tRNA 
species were investigated but only tRNA
fMet 
was cleaved under conditions tested. That 
tRNA
fMet
 most-likely is the sole target of VapCLT2 and VapC was further substantiated 
by the ability of additional tRNA
fMet
 to reactivate inhibited in vitro translation extract 
and counteract toxicity in vivo in growing cells (Figure 25A and 25B). The cleavage 
of tRNA
fMet
 could be correlated with the cellular growth and confirmed the results of 
the viable count assays, which showed that the tRNAse activity was bacteriostatic 
(Figure 24A, Figure 24B left and middle and Figure 15). In addition, it was also 
observed that a conserved acidic residue predicted to be in the active site involved in 
configuring the metal ion is important for for PIN domain activity as a mutation of 
Asp7 renders VapCLT2
D7A
 inactive (Figure 24A and 24B Right).  
Several other site-specific tRNases are known, which includes colicin D, colicin E 
and PrrC, but VapC is so far the only tRNase known that cleaves initiator tRNA. 
Colicin D cleaves four isoaccepting arginine tRNAs between positions +38 and +39 
(Tomita et al., 2000), while colicin E5 cleaves in the anticodon loop of 4 different 
elongator tRNAs, between +34 and +35 (Ogawa et al., 1999). The tRNA cleaving 
colicins are considered to be bacteriocidal, and are in contrast to VapC, transported 
out of the producer cells to kill non-producing competitor cells. Colicin-producing 
cells produce immunity proteins that are analogous in function to antitoxins. PrrC, 
which cleaves lysine tRNA in the anticodon loop between +34 and +35, is activated 
by bacteriophage T4 infection (Amitsur et al., 1987).  
The VapCLT2 and VapC dependent cleavage was mapped to occur between position 
+38 and +39 in vivo and in vitro, though in vivo cleaved fragments were subsequently 
degraded, most-likely by cellular ribonucleases (Figure 26 and 27). A similar 
observation has been reported for colicin D (Tomita et al., 2000). Interestingly, the 
anticodon loop including position +38 and +39 is also conserved in elongator 
tRNA
Met
 but is not cleaved (Figure 23B). A recent crystal structure of the tRNA
fMet
 
anticodon stem-loop revealed unique conformational differences to elongator tRNA, 
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which in particular involves interaction between A38 and 2mC32 and C39 and A37 
(Barraud et al., 2008). This could indicate that either the GC stem, which is only 
present in tRNA
fMet
, or these unique structural features of the anticodon loop might be 
the discriminator for VapC recognition. This however still remains to be tested. 
Furthermore, in this study it was shown that VapC can be activated from the vapBC 
operon during abrupt translation inhibition (Figure 28). Surprisingly, only weak 
cleavage of tRNA
fMet
 was detected. This could either caused by intrinsic low activity 
of VapC which might be due to the genetic context, as it is plasmid resident, which 
might affect the regulation. But it could also reflect activation of VapC in a 
subpopulation of cells.  It has recently been shown that TAs might contribute to 
stochastic generation of a subpopulation of cells which are persistent to antibiotic 
treatment (Maisonneuve et al., 2011). In relation to that the weak cleavage observed 
by VapC might reflect high cleavage in just a subpopulation of cells and indicating 
stochastic activation. This however remains to be tested.  
However a very interesting occurrence was observed as depletion of tRNA
fMet
 by 
VapC cleavage activated initiation of translation at elongator codons positioned 
correctly relative to a ribosome binding site. This was observed indirectly by trans-
activated ribosome YoeB cleavage and more directly in the dual luciferase system 
(Figure 19 and 29).   
VapC was therefore found to inhibit global initiation of translation and 
simultaneously activating translation of reading frames that are normally silent. 
Whether this latter effect has physiological consequences (i.e. when endogenous 
VapC is activated in the wild type context) remains to be determined. However, 
Varshney and colleagues recently observed that a reduction of the cellular level of 
tRNA
fMet
 by mutations in the metZWV promoter relaxed the stringency of initiator 
tRNA selection at the ribosomal P-site (Kapoor et al., 2011). This result supports the 
idea that the reduced level of tRNA
fMet
 observed after vapCLT2 or vapC induction 
allows loading of elongator tRNAs in the P-site and thereby stimulates ectopic 
initiation of translation. The requirement for an SD sequence for ectopic initiation is 
in agreement with this interpretation. Another observation which favours this idea was 
the higher initiation of translation observed at AAA codons compared to AAG codons 
(Figure 29). There is a clear correlation between codon usage and cognate tRNA 
abundance (Dong et al., 1996). In E. coli K-12, 73% of lysine codons are represented 
by AAA codons which suggest higher abundance of the cognate tRNA and could 
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explain the observed increased preference in initiation of translation from this codon 
compared to AAG lysine codon.   
Like other components of the translational apparatus, production of tRNA
fMet
 is 
controlled by the stringent response (Nagase et al., 1988). Moreover, the charging 
level of tRNA
fMet
 decreases in response to leucine starvation (Dittmar et al., 2005). 
Thus, bacterial cells regulate the level of tRNA
fMet
 in response to environmental 
changes. This makes physiological sense, since a reduced rate of translation reduces 
both nutrient consumption and the translational error rate (Sorensen et al., 1994) 
which, in turn, may increase cellular fitness. It is shown here that VapC can be 
activated by abrupt reduction of the growth rate (Figure 28). Thus vapBC may reduce 
the translational error rate during conditions of slow growth simply by reducing the 
drain on charged tRNA. In addition, it cannot be excluded that vapBC induces major 
changes in the proteome of slowly growing or starved cells. A possibility would be 
start codon selection shift from AUG and towards reading frames with alternative 
start codons (e. g. GUG and UUG) or maybe even to different reading frames, 
although this remains to be tested. 
 
I propose that enteric VapCs represent a novel class of tRNases that could be 
beneficial during environmental stresses including virulence (Figure 30).  
The Major human pathogen Mycobacterium tuberculosis has an expanded number of 
genes encoding VapC homologues on its chromosome, and 45 vapBC loci have been 
identified so far (Pandey and Gerdes, 2005;Ramage et al., 2009). The majority of 
toxins induce a quasi-dormant growth state, which makes M. tuberculosis an 
interesting organism of study as it has the ability to arrest growth during intracellular 
phases of its lifecycle (Gerdes et al., 2005). Interestingly, it has recently been shown 
that TAs, including loci of the vapBC family, are up-regulated during anoxic growth 
and during growth inside macrophages (Ramage et al., 2009;Korch et al., 2009). The 
vapBC locus has also previously been shown to affect the intracellular growth-rate of 
the human pathogen Neisseria gonorrhoea, which is consistent with a possible role in 
growth rate regulation during virulence (Hopper et al., 2000).   
Both Shigella flexneri 2a and Salmonella enterica serovar Typhimurium, which are 
the host organisms of the vapBC loci investigated in this study, show intracellular 
growth strategies during pathogenesis, which involve states of slow growth and 
vapBC might play a role (Tsolis et al., 2008). It can not be excluded that vapBC loci 
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also play other roles as they a present in non-pathogens and are highly abundant in 
Archaea (Olah et al., 2001;Cooper et al., 2009). In addition, a single vapBC locus has 
recently been linked to heat shock survival of Sulfolubus solfataricus (Maezato et al., 
2011).  
These observations support that vapBC could contribute to growth rate regulation and 
benefit the cell during stress conditions. However, it does not exclude that vapBC TA 
loci may play additional roles in enterics or in other organisms.  
The work presented here has opened the path to identify the cellular targets of VapC 
PIN-domain proteins from other organisms, including M. tuberculosis. 
 
Figure 30 Model for VapC activation and activity. Environmental stress such as nutrient 
deprivation decrease de novo synthesis of antitoxin VapB (salmon) and increase protease activity 
which in turn liberates more stable VapC (cyan), either by degradation of antitoxin in free form or 
in complex. VapC is activated and cleaves initiator tRNA, which inhibits translation at the step of 
initiation. This may have several consequences; (1) VapC inhibits formation of 70S initiation 
complexes which decreases the growth rate and drain on charged pools of tRNA that in turn results 
in higher translational fidelity, (2) Removal of initiator tRNA allows alternative tRNA to compete 
for P-site occupation, which leads to translation initiation events and changes in the proteome.    
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Future Perspectives for Results Section I 
From the data presented Results Section I, it is clear the VapCLT2 and VapC are 
tRNases that specifically cleave tRNA
fMet
. An obvious question that arises is how 
VapCLT2 and VapC distinguish this particular tRNA from 60 different species. It 
would be very interesting to investigate the substrate specificity VapC biochemically 
by introducing mutations in tRNA
fMet
 or the anticodon stem-loop which abolishes or 
enhances the activity of VapC. In general tRNAs are highly modified and it would 
also be interesting to investigate the importance of these modifications for tRNA 
cleavage. Alternatively, the unique structure of tRNA
fMet
 might also be important for 
substrate recognition and can be tested biochemically. In this case a crystal structure 
of VapC bound to its substrate would give crucial information about substrate 
recognition and the mechanism of cleavage.  
Interestingly, it is observed that vapB induction in VapC inhibited cells, which are 
almost devoid of full-length tRNA
fMet
, leads to relatively rapid accumulation of full 
length tRNA
fMet
 and resumption of growth. This suggests that additional mechanisms 
might be present which aids resuscitation. One possibility is that a small pool of 
tRNA
fMet
 is protected from VapC either by binding to aminoacyl tRNA synthetases or 
initation factor 2. An alternative possibility is that some of the cleaved tRNA
fMet
 can 
be repaired by RNA ligases. Recently, a putative RNA repair operon has been 
identified in E. coli K-12 named rtcBA (Chakravarty and Shuman, 2011;Tanaka and 
Shuman, 2011). RtcB is an ATP-dependent 3‟-5‟-RNA ligase and RtcA is a 
3‟terminal RNA cyclase. RtcA has also been observed to have polynucleotide 5‟-
adenylation activity, which raises interesting questions for its biological activity. 
Interestingly Shuman an co-workers showed that tRNAses such as Kleuveromyces 
lactis γ-toxin produces substrates that can be ligated by RtcB, which suggests that 
RtcB has a function in tRNA repair (Tanaka and Shuman, 2011).       
I have also obtained indirect evidence that VapC might produce substrates for RNA 
ligases such as RtcB, with a 3‟ terminus phosphate in the 5‟-cleavage product and a 
5‟-OH in the 3‟ cleavage product. The 3‟-terminus of the 5‟-product of tRNAfMet 
could not be ligated to pCp with T4 RNA ligase, consistent with a 2‟,3‟-cyclic 
phosphate. The 5‟-terminus of the 3‟-product could be phosphorylated without prior 
dephosphorylation, indicating a 5‟-hydroxyl group. This is analogous to other known 
tRNAses such as colicin D or colicin E5 (Ogawa et al., 1999;Tomita et al., 2000). 
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Furthermore, an rtcB deficient strain has been observed to show greater sensitivity to 
VapC than wild type as growth recovery in the mutant is delayed after a VapC pulse. 
This could indicate that RtcB alone or with RtcA could aid resuscitation. It would be 
very interesting to investigate this further to find out if this putative RNA repair 
operon is involved in tRNA
fMet
 repair. 
A second interesting aspect would be the possible role in pathogenesis. In an early 
attempt, I created a vapBCLT2 deletion strain of pathogenic S. enterica SL1344, which 
is very similar to S. enterica LT2. Wild type and mutant were then tested in a 
virulence assay on mammalian epithelial cells (Collaboration with Paul Dean, 
Newcastle University). However, no significant differences were observed comparing 
wild type to vapBCLT2 deletion strain. This suggests that vapBCLT2 is not involved in 
invasion, but does not exclude that vapBCLT2 might be involved in regulating growth 
inside cells as has been observed for fitAB of N. gonorrhoea (Hopper et al., 2000). An 
interesting experiment would be to measure the growth rate of S. enterica SL1344 
ΔvapBCLT2 during vacuolar growth or growth inside macrophages. This can be 
performed using a gentamycin protection assay as bacterial cells are protected from 
gentamycin whilst inside a host cell (Elsinghorst, 1994). Recently it has been shown 
that TAs may contribute to increased frequencies of persisters, e.g. a sub population 
of cells which show high tolerance to antibiotic treatment (Maisonneuve et al., 2011). 
It would be interesting to test whether a plasmid resident vapBC can complement or 
partially complement the decreased persister frequency phenotype of an E. coli K-12 
strain lacking ten TAs.    
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Results Section II: Transcriptional regulation of vapBCLT2 
Introduction to experimental work 
Type II Toxin-antitoxin (TA) loci are abundant on plasmids and chromosomes of 
free-living prokaryotes and generally make up a single transcriptional unit (Gerdes et 
al., 2005). Transcription from the TA promoter is auto-regulated by the antitoxin, 
which contains an N-terminal DNA binding domain thus DNA-binding is enhanced 
by forming a stable, high affinity complex with the toxin via the antitoxin C-terminus. 
The antitoxin is unstable and is rapidly degraded by cellular proteases under 
conditions of stress or treatment with antibiotics, which in turn activates transcription 
from the TA promoter (Christensen et al., 2001;Hazan et al., 2004). Toxins of TAs 
have been divided into at least ten families of which vapBC is by far the most 
abundant in both bacteria and archaea (Pandey and Gerdes, 2005;Jorgensen et al., 
2009;Makarova et al., 2009). In Results Section I, it was reported that VapC toxins 
from enterics are RNases that inhibit global translation by cleavage of tRNA
fMet
 in the 
anticodon stem-loop. The subject of Results Section II is the regulation of the vapBC 
operon.  
It is now clear that VapBC, analogous to other toxin-antitoxin families, auto-regulates 
transcription by binding to inverted repeats in the promoter region (Wilbur et al., 
2005;Bodogai et al., 2006;Robson et al., 2009). The best studied example to date is 
FitAB (fast intracellular trafficking) from Neisseria gonorrhoeae which binds to a 
36bp promoter DNA inverted repeat as (FitA2-FitB2)2, an octamer of four FitA-FitB 
heterodimers, and illustrates how a FitB toxin dimer bridge enhance FitA antitoxin 
DNA-binding (Mattison et al., 2006).  
Several recent studies have shown that the toxin might not only enhance affinity of 
antitoxin for DNA binding, but also under certain conditions decrease affinity; this 
phenomenon has been observed for Kis-Kid, CcdAB, RelBE and PhD-Doc TA-
systems (Monti et al., 2007;Afif et al., 2001;Overgaard et al., 2008;Garcia-Pino et al., 
2010). This phenomenon is also referred to as conditional cooperativety.  
In recent studies of RelBE and PhD-Doc it was observed that toxin in excess 
abolishes cooperativity in the DNA binding. In the reported examples conditional 
cooperativity is based on the presence of a high affinity and a low affinity binding site 
in the toxin. When the toxin and antitoxin levels are balanced both binding sites in the 
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toxin are occupied by antitoxin C-termini. When the toxin and antitoxin levels are 
unbalanced and the toxin is in excess of antitoxin, the high affinity binding sites on 
free toxins will compete for low affinity site bound antitoxin C-terminus, which will 
lead to decreased cooperativity and decreased affinity for DNA. This is by means an 
additional mechanism by which the TA locus can regulate and balance the expression 
of antitoxin and toxin in the cell. A dual role of the toxin in regulating DNA binding 
has not yet been reported for VapBC toxin antitoxin family. 
VapBLT2 is the antitoxin and has been predicted to contain a N-terminal DNA binding 
domain belonging to the family of AbrB transcriptional repressors (predicted by 
Interpro, http://www.ebi.ac.uk/interpro/ ) (Figure 31). The MazE antitoxin of the 
mazEF TA-locus also belongs to this family (Kamada et al., 2003). In this results 
section, Results Section II, the transcriptional regulation of vapBC from Salmonella 
enterica serovar Typhimurium LT2 is analysed (here referred to as VapBCLT2). 
Strict translational coupling between vapBLT2 and vapCLT2 ensures 
excess levels of VapBLT2 during steady state growth 
Translation coupling has previously been described for parD (encoding kis-kid TA-
locus) of plasmid R1, but has not been shown for vapBC TAs (Ruiz-Echevarria et al., 
1995). 
The vapBLT2 and vapCLT2 reading frames overlap by one base such as the last A in 
vapBLT2 UGA stop codon is the first A in vapBLT2 AUG start codon, which indicates 
translational coupling. This possibility was analysed by making a series of mutations 
in the vapBLT2 gene of a translational vapBCLT2
D7A
-lacZ fusion under the control of a 
constitutive Ptac promoter. The ptac promoter here mimics a de-repressed vapBC 
promoter and the D7A substitution in vapCLT2 avoids potential toxicity (Figure 32A). 
It is observed that a start codon mutation in vapBLT2 abolishes all translation of lacZ, 
which indicates strict translational coupling (Figure 32B). It is also observed that a 
 
Figure 31 Sequence alignment of AbrB proteins. Alignment contains MazE, AbrB N-terminal 
domain and VapBLT2. Secondary structure of MazE observed from crystal structure is shown in 
Magenta  (Kamada et al., 2003) and predicted secondary structure 
(http://bioinf.cs.ucl.ac.uk/psipred/) of VapBLT2 shown in black. (Arrows = β-sheets, Boxes = α-
Helices).  
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premature stop codon in vapBLT2 (UAA stop codon at codon 61 instead of 77) and a 
frame-shift mutation which forces the ribosomes to terminate translation inside 
vapCLT2 (UGA stop codon at codon 82 instead of 77) also abolishes translation of 
lacZ. These observations confirm strict translational coupling between termination of 
translation in vapBLT2 to initiation of translation in vapCLT2. A direct translational 
vapBLT2-lacZ fusion results in an approximate ~4-fold higher β-galactosidase activity 
compared to a translational vapBCLT2-lacZ fusion. This indicates a ~4-fold lower 
translation level of vapCLT2 compared to vapBLT2 resulting from the non-optimal 
coupling efficiency. This observation is confirmed in vitro using purified vapBCLT2 
 
Figure 32 Translation of vapBCLT2 transcript from a constitutive promoter results in translation of 
VapBLT2 with strict translational coupling to VapCLT2. A) Expected reading frames of different 
translational lacZ fusions; wildtype (WT), start codon substitution AUG → AAG in vapB, 
premature termination codon (PTC) in vapBLT2, frameshift mutation in vapBLT2 and a direct fusion 
to vapBLT2. Transcribed mRNA is shown in white and translated in grey. B) Analysis of 
translational coupling between vapBLT2 and vapCLT2 in vivo. TB28 (MG1655 ∆lacZIYA) containing 
either pKW253-1 (ptac::vapBCLT2
D7A::lacZYA), pKW253-2 (ptac::vapBCLT2
D7A::lacZYA with vapBLT2 
ATG→AAG), pKW253-3 (ptac::vapBCLT2
D7A::lacZYA with PTC in vapBLT2), pKW253-4 
(ptac::vapBCLT2
D7A::lacZYA with frameshift mutation in vapBLT2) or pKW253-5 
(ptac::vapBLT2::lacZYA) were grown exponentially in LB medium at OD600 = 0.5 samples were 
collected and the activity of β-galactosidase measured (Units). C) Analysis of translational 
coupling in vitro. Purified vapBCLT2 mRNA (1 pmol) without and with premature termination 
codon in vapBLT2 or vapBLT2 start codon mutation was added to a S30 in vitro translation extract 
containing 35S-methionine and incubated at 37ºC for 25 min. In vitro protein products resolved by 
SDS-PAGE and visualised by phosphor imaging. 
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mRNAs in a cell free in vitro translation system (Figure 32C). VapCLT2 is only 
produced with WT mRNA and not with mRNA containing either the premature 
termination codon or vapBLT2 start codon mutation. Only small amounts of VapCLT2 
are detected, which might be caused by the uncoupling of transcription and translation 
in the in vitro assay. These in vivo and in vitro observations indicate that during 
steady state, VapBLT2 will always be produced in excess of VapCLT2, thus is 
consistent with its role as an antitoxin. 
Lon protease is responsible for VapBLT2 degradation which activates 
vapBCLT2 transcription during nutritional stress and by chloramphenicol  
To locate the vapBCLT2 promoter, the transcriptional start site was identified by primer 
extension analysis. This was performed on RNA samples prepared from S. enterica 
LT2 and E. coli MG1655 containing pKW512 (pRBJ200::vapBCLT2::lacZ). The 
primer used is complementary to a region inside vapBLT2 mRNA, making it possible 
to map the region upstream of vapBLT2 start codon and detect transcriptional start sites 
upstream of vapBLT2. A specific band consistent with a transcriptional start site was 
detected upstream of vapBLT2, which includes a short leader containing the Shine & 
Dalgarno sequence of vapBLT2 (Figure 33A). Inspection of the region upstream of the 
mapped transcriptional start site (+1) revealed putative -10 and -35 sequences (Figure 
33D). Furthermore, two inverted repeats were observed in the promoter region, one 
perfect repeat overlapping with -10 sequences and another imperfect repeat 
overlapping the -35 sequence. These inverted repeats are likely to represent the 
binding sites of VapBLT2.  
Previously, it has been shown that transcription of E. coli toxin-antitoxin loci relBE 
and mazEF increases when cells are exposed to antibiotics and nutritional stress e.g. 
amino acid starvation (Aizenman et al., 1996;Christensen et al., 2001;Christensen et 
al., 2003). To investigate whether vapBCLT2 responds in a similar manner, cells of S. 
enterica LT2 and E. coli MG1655 containing pKW512 (pRBJ200::vapBCLT2::lacZ) 
were grown exponentially,  and at time zero exposed to serine hydroximate (SHT). 
SHT induces serine starvation by a competitive inhibition of seryl tRNA synthetase 
which prevents charging of serine tRNA (Tosa and Pizer, 1971). By semi-quantitative 
primer extension, promoter activity was analyzed (Figure 33A). It is observed that 
transcription of vapBCLT2 increases significantly upon SHT induced amino acid 
starvation. It is also observed that transcription increase by translational inhibition by 
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chloramphenicol, which can be linked to the predicted intrinsic instability of VapBLT2 
(Figure 33B lanes 1-6). This indicates that vapBCLT2 expressed from plasmid 
(pKW512 or pKW71512) or chromosome (S. enterica LT2) have properties similar to 
that observed for other TA loci like  relBE and mazEF. 
 To identify the protease responsible for regulating VapBLT2 stability and vapBCLT2 
transcription, semi-quantitative primer extension was performed on vapBCLT2 mRNA 
 
Figure 33 Lon protease regulates vapBCLT2 transcription by the stability of VapBLT2. A) Cells of 
KP1001 (S enterica LT2) and MG1655/pKW512 (pRBJ200::vapBCLT2::lacZ) were grown 
exponentially in LB medium at 37ºC. At time zero SHT ( 1mg/mL) was added. Primer extension 
analysis was performed using primer vapB-5#PE on total RNA purified at the time points indicated 
(min). B) Primer extension on vapBCLT2 5‟-end. MG1655 (E. coli K-12), KW10 (MG1655 ∆lon) or 
KW11 (MG1655 ∆clpP) containing pKW71512 (pNDM71::vapBCLT2) and KP1001 (S. enterica 
LT2) were grown exponentially in LB medium at time zero chloramphenicol (50 µg/mL) was 
added and samples were taken at time points indicated (min). Total RNA was extracted and reverse 
transcription was performed using primer vapB-5#PE. C) Western blot analysis of VapBLT2 
stability. MG1655 (E. coli K-12), KW10 (MG1655 ∆lon) or KW11 (MG1655 ∆clpP) containing 
pKW51 (pA1/03/04::SDopt::vapBLT2) were grown exponentially in LB. 10 min before addition of 
chloramphenicol (50 µg/mL) at time zero 1 mM IPTG was added to induce VapBLT2 production. 
Samples were taken at time points indicated (min) and VapBLT2 stability measured using VapBLT2 
specific polyclonal antibodies. D) DNA sequence of vapBCLT2 promoter region in including RNA 
polymerase binding sites, -10 and -35 sequences, and putative VapBCLT2 complex binding sites 
indicated by two inverted repeats. 
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in protease deficient E. coli strains during translation inhibition. As observed in 
Figure 33B, vapBCLT2 transcription increases after 10 min both from chromosomal 
encoded vapBCLT2 of S. enterica LT2 and from plasmid resident vapBCLT2 in E. coli 
K-12 MG1655. Transcription also increased in MG1655 ∆clpP (lanes 10-12), but not 
in MG1655 ∆lon (lanes 7-9). This indicates that Lon protease is responsible for 
VapBLT2 degradation. This was also confirmed by Western blot analysis using 
VapBLT2 specific polyclonal antibodies in similar strains expressing VapBLT2 (Figure 
33C). Consistent with the primer extension, it is observed, that after 10 min the 
stability of VapB rapidly decreases in MG1655 and MG1655 ∆clp, however not in the 
MG1655 ∆lon strain. This suggests that ATP-dependent Lon protease is responsible 
for VapBLT2 degradation and transcriptional activation during translation inhibition. 
VapBLT2 specifically binds its own promoter DNA and VapCLT2 increase 
the affinity of VapBLT2 for DNA 
Two inverted repeats which represent putative vapBLT2 binding sites were identified 
in the promoter region. To test this hypothesis, native VapBLT2 and VapCLT2 were 
purified, incubated with a DNA fragment containing promoter region, and analysed 
by electrophoretic mobility shift assays (EMSA) (Figure 34A). It is observed that 
VapBLT2, which contains an AbrB-like DNA-binding domain, has affinity for DNA; 
however only at very high concentrations more significant DNA-VapBLT2 complexes 
are observed (lanes 3-7). This indicates that VapBLT2 by itself only has very low 
affinity for DNA. It is also observed that VapCLT2 toxin does not have affinity for 
DNA itself (lane 8). All EMSA reactions contain an excess of salmon sperm DNA to 
avoid unspecific DNA binding.  
However, incubation of low concentrations of VapBLT2 with increasing concentrations 
of VapCLT2 gives a dramatic increase in affinity for DNA (lanes 9-13). This indicates 
that VapCLT2 greatly increases the affinity of VapBLT2 for DNA. It is also observed 
that the VapBLT2 DNA-binding is highly specific for promoter DNA as no binding to 
unspecific DNA (P) occurs. Formation of two DNA-protein complexes, C1 and C2, 
are observed, which could indicate binding to both inverted repeats in the promoter 
region (Figure 33C). To elucidate this in greater detail, a DNase I protection assay 
was performed on DNA bound complexes (Figure 34B). Promoter DNA was 
incubated with VapBLT2 and increasing concentrations of VapCLT2 (lanes 1-4) and 
analysed for DNase I protection. Two protected areas are observed, which overlap 
 103 
with the two inverted repeats. This is consistent with VapBLT2 binding to and 
protecting both these sites, and could suggest that C1 and C2 complexes formed in 
Figure 34A correspond to one and two complexes of VapBLT2 and VapCLT2 bound to 
promoter DNA. On the basis of these data, I rename inverted repeat overlapping with 
-10 sequence to vapO1 (vap Operator) and inverted repeat overlapping with -35 to 
vapO2.  
Two inverted repeats represent four putative VapBLT2 dimer binding sites. However 
only two complexes are observed at high VapBLT2 concentrations, which could 
indicate low cooperative binding within each inverted repeat, similar to that shown by 
CcdA, Kis and RelB (Madl et al., 2006;Monti et al., 2007;Cherny et al., 2007). 
However, the DNA-protein complexes (C1 and C2) observed in the absence of 
VapCLT2 (lanes 3-7) have similar sizes to those which occur in the presence of 
VapCLT2, which could indicate that the VapBLT2 purification might be contaminated 
 
Figure 34 VapBLT2 binds to two inverted repeats in promoter region and VapCLT2 increases the 
affinity of VapBLT2 for DNA. A) Electrophoretic mobility shift assay on VapBLT2 binding to DNA. 
Purified VapBLT2 and VapCLT2 was added to a radio labelled DNA probe containing the vapBCLT2 
promoter region (-179bp and +122bp of transcriptional start site) in concentrations shown (µM) 
(lane 1-14). Bound complexes were separated on a 5% native PAGE gel and visualized by 
phosphor imaging. U is the unbound probe and C1 and C2 are the complexes formed when probe is 
bound. P is a ~200bp DNA fragment from pUC vector and used as control for unspecific binding. 
B) DNase I protection assay on vapBCLT2 promoter region. Purified VapBLT2 and VapCLT2 was 
added to a DNA probe as in A) and subsequently incubated with DNase I (lane 1-4). Digested 
DNA was then separated in an 8% Urea PAGE gel and analysed by phosphor imaging. The 
protected areas are enclosed by boxes and the position of the promoter and the two inverted repeats 
are marked with arrows. 
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by small amounts of VapCLT2. VapBLT2 is purified from protein complex with 
VapCLT2, which makes this explanation plausible. 
Nevertheless, with increasing VapCLT2/VapBLT2 ratio an increased affinity for DNA is 
observed. Interestingly, it can be observed from Figure 34A lane 14, that at a certain 
VapBLT2/VapCLT2 ratio (~1:8), affinity for DNA is observed to decrease slightly as 
decreased amount of C2 complexes and increased amount of C1 are detected. This 
suggests that, at high concentrations, VapCLT2 might play an additional role in 
inhibiting DNA binding.  
VapCLT2 in excess decreases the affinity of VapBLT2 for DNA which is 
reversible 
To investigate this phenomenon in detail, additional EMSAs were performed with a 
greater excess of VapCLT2 compared to VapBLT2 (Figure 35A). It is observed that with 
increasing concentrations of VapCLT2, VapCLT2 initially promotes binding of VapBLT2 
to vapBCLT2 promoter DNA (lanes 2 and 3), but then drastically decreases the affinity 
of the complex for DNA (lanes 4-8). In lane 8 almost no C1 complex is observed. 
This suggests that at a certain VapBLT2/VapCLT2 ratio of above ~1:8, VapCLT2 
gradually decreases the affinity of VapBLT2 for vapBCLT2 promoter DNA. 
To verify that this is in fact a direct effect of VapCLT2, the VapBLT2/VapCLT2 ratio was 
shifted by increasing the concentration of VapBLT2 (lanes 9-11). It is observed that 
addition of VapBLT2 to the reaction results in increased affinity for DNA, consistent 
with a direct reversible effect of VapCLT2. This phenomenon is also confirmed by 
DNase I footprinting (Figure 35B). With increased concentrations of VapCLT2, a 
decreased protection of both vapO1 and vapO2 is observed (lanes 1-7). Furthermore, 
it is observed that protection is decreased at lower VapCLT2 concentrations in vapO2 
that contains an imperfect inverted repeat (compare lane 2 and 3) than in vapO1 
(compare lanes 2-7), which suggests that the complex might have higher affinity for 
vapO1. As observed in the gel shift in figure 35A, when the VapBLT2/VapCLT2 ratio is 
increased protection is regained (lanes 8 and 9). Again it is observed that vapO1 is 
protected before vapO2, consistent with higher affinity of the complex for this site. 
 105 
VapBLT2 binds independently to two inverted repeats in the promoter 
region with different affinity in vitro and in vivo 
To investigate the importance of the two inverted repeats in the conditional repression 
when VapCLT2 is in excess, mutations were introduced in the half site of inverted 
repeat vapO1 and one in the half site of inverted repeat vapO2. The sites mutated 
 
Figure 35 VapCLT2 in excess decreases the affinity of VapBLT2 for DNA. A) Electrophoretic 
mobility shift assay on VapBLT2 binding to promoter DNA. Purified VapBLT2 and VapCLT2 was 
added to radio labelled probe DNA containing the vapBCLT2 promoter region (-179bp and +122 of 
+1) in amounts shown (nM) (lane 1-11). Protein-DNA complexes were separated by 5% native 
PAGE. U is unbound DNA probe and C1 and C2 is complexes to one or two binding site, 
respectively. B) DNase I protection assay on vapBCLT2 promoter region in the presence of excess 
VapCLT2. VapBLT2 and VapCLT2 was incubated with promoter DNA as in A) in amounts shown 
(nM) and subsequently incubated with DNase I (lane 1-9). The DNA digest was separated in an 8% 
Urea PAGE gel and analysed by phosphor imaging. A DNA sequencing ladder was generated using 
5‟-end labelled vapBC_EMSA_down primer. For simplicity the position of inverted repeats (vapO1 
and vapO2) and promoter are indicated by arrows and DNAse I protected areas enclosed by boxes. 
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were selected from the DNA sequence not to affect the binding of RNA polymerase 
(Figure 36A). Subsequently, EMSAs were performed using DNA probes containing 
mutations from Figure 36A. As observed previously, when a DNA probe containing 
wild type promoter is incubated with VapCLT2 and VapBLT2, two complexes are 
observed (C1 and C2). The complexes decrease in intensity with increased 
concentration of VapCLT2, consistent with a decrease of VapBLT2 in affinity for DNA 
(Figure 36B). However, this is also the case when using vapO1mut and vapO2mut 
scrambled probes, which shows that both operator sites are not needed to decrease the 
affinity of VapBLT2 for DNA. Primarily complex C1 is observed in both mutants, 
consistent with only one operator site being occupied and that C1 formed in both 
cases is of similar size.. 
 
Figure 36 VapCLT2 mediated decrease in affinity of VapBLT2 for DNA acts on both inverted repeats 
independently. A) DNA sequences of vapBCLT2 promoter region showing positions of base 
substitutions in binding site (vapO) 1 and 2. The position of promoter and inverted repeats are 
indicated by arrows. B) Electrophoretic mobility shift assay of VapBLT2 binding to promoter DNA 
with binding site (vapO) mutations. VapBLT2 and VapCLT2 were incubated with promoter DNA 
containing base substitution mutations which scrambles binding site 1 and 2 in amounts shown 
(nM). Protein-DNA complexes were separated in a 5% native PAGE gel and analysed by phosphor 
imaging. U indicates unbound DNA probe C1 and C2 is promoter DNA bound by either one or two 
protein-DNA complexes, respectively. C) The vapBCLT2 promoter activity in binding site mutants. 
TB28 containing either pKW512TFZD7A (pwt::vapBCLT2
D7A::lacZYA), pKW512TFZD7A-1 
(pVapOmut1::vapBCLT2
D7A::lacZYA), pKW512TFZD7A-2 (pVapOmut2::vapBCLT2
D7A::lacZYA) or 
pKW512TFZD7A-1-2 (pVapOmut1+2::vapBCLT2
D7A::lacZYA) were grown exponentially in LB medium 
at 37ºC. At OD600 ~ 0.5 samples were collected out and the activity of β-galactosidase measured 
(Units). 
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Interestingly, it is observed that vapO1mut decreases the amount of protein bound to 
DNA more significantly than vapO2mut, as C1 complex is less intense for the 
vapO1mut than vapO2mut. This is consistent with the observation that the protein 
complex has higher affinity for vapO1. It is also observed that when both sites are 
simultaneously mutated only a very weak C1 complex is detected, which is consistent 
with the weak C2 complex in the vapO1mut probe. This is most likely due to a in- 
complete disruption of the DNA binding in the vapO1mut mutation. To confirm these 
observations the effect of the binding site mutations on transcriptional repression with 
transcriptional vapBCLT2
D7A
-lacZ fusions, was tested (Figure 36C). As can be 
observed, both vapO1mut and vapO2mut independently allow repression to some 
degree compared to wt promoter. With a functional vapO1 (vapO2mut), ~ 0.5-fold up 
regulation is observed compared to wild type. This is more efficient than a functional 
vapO2 (vapO1mut) as ~ 1.5-fold up regulation is observed compared to wild type. 
When both operator sites are mutated (vapO12mut), ~4.6-fold up regulation is 
observed compared to wild type. This observation not only suggests that both operator 
sites contribute to transcriptional repression, but also that the sites independently can 
repress transcription. It is observed that vapO1 contributes more efficient to 
transcriptional repression than vapO2, which is consistent with the higher affinity of 
VapBCLT2 observed for this operator site. From the data presented it can not be 
excluded that an increase in transcription is caused by change in affinity of RNA 
polymerase for DNA in vapO mutants. However, the observed increase in 
transcription is consistent with the observed decrease in affinity of VapBLT2 for vapO 
mutants. In summary these observations indicate that the two inverted repeats may act 
as repressor sites independently and can be used isolated to investigate the DNA 
binding of VapBLT2.  
VapCLT2 toxin in excess disrupts DNA-binding of VapBLT2 to vapO1 and 
shows conditional repression in vitro and in vivo 
To test the repressor sites independently, EMSAs were performed using a DNA 
fragment containing only vapO1 (Figure 37A). Consistent with previous experiments, 
increasing the concentration of VapCLT2 in respect to VapBLT2, results in increased 
affinity of VapBLT2 for DNA (lanes 2-5). At a certain VapBLT2/VapCLT2 ratio however 
(1:8, lane 6), affinity for DNA gradually decreases with increased VapCLT2 
concentration. This can be reverted by changing the VapBLT2/VapCLT2 ratio by 
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addition of VapBLT2 to the reaction through which the affinity is regained (lanes 12-
14). This suggests that protein complex bound to single operator site can be liberated 
when VapCLT2 is in excess.   
To investigate the biological significance of the conditional repression in vivo, 
vapBCLT2 was transcriptionally fused to the lacZ gene encoding β-galactosidase and 
analysed in the presence of a plasmid expressing VapCLT2 in trans (Figure 37B). 
When inducing a non-toxic vapCLT2
D7A
 in trans on plates containing X-gal, the 
colonies are observed to be significantly more blue compared to an empty vector 
control, consistent with higher vapBCLT2 promoter activity. Up-regulation of 
vapBCLT2 was confirmed by quantitative PCR (Figure 37C). It is observed that after 
induction of vapCLT2
D7A
 the transcription of vapBCLT2 reaches a ~3-fold increase after 
 
Figure 37 The vapBCLT2 locus shows conditional DNA binding. A) Electrophoretic mobility shift 
assay with purified VapCLT2 and VapBLT2 with promoter DNA containing vapO1. (Left panel) 
VapBLT2 and VapCLT2 were mixed with radio labelled promoter DNA containing vapO1 binding 
site (36bp fragment, -14bp and +21bp of +1) in amount shown (nM) (lane 1-14). Protein-DNA 
complexes were separated by 6% native PAGE and analysed by phosphor imaging. U and C 
indicate position of unbound and bound DNA, respectively. (Right panel) Image J quantitated Band 
intensities plotted in a graph with C band intensity (%) as a function of the lane number. B) Ectopic 
induction of vapCLT2
D7A In vivo increases vapBCLT2 transcription. TB28 (MG1655 ∆lacIZYA) 
pKW512TFZD7A (vapBCLT2
D7A::lacZYA) containing either pKW3353HC 
(pBAD::SDopt::vapCLT2
D7A-H6) or pBAD33 were streaked to single colonies on LB plates 
containing X-gal and 0.2% arabinose. C) vapCLT2
D7A induced transcription as quantified by qPCR.  
TB28 (MG1655 ∆lacIZYA) pKW512TFZD7A (vapBCLT2
D7A::lacZYA) with pKW3353HC 
(pBAD::SDopt::vapCLT2
D7A-H6) or pBAD33 empty vector were grown exponential in LB medium at 
time zero 0.2% arabinose was added to induce transcription from pBAD promoter. Samples were 
taken at times indicated (min) and total RNA extracted. Quantitative PCR was performed and fold-
change in respect to house keeping gene rpsA was calculated by ∆∆Ct relative quantification 
method. 
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30 min of expression. Furthermore, no increase is observed when inducing empty 
vector which is consistent with Figure 37B. Summarising these observations, VapCLT2 
clearly seems to play an additional role by decreasing repression of transcription..  
To investigate the protein complex formed on vapO1 into more detail, the molecular 
weight (MW) of DNA-protein complex was estimated. The MW was determined by 
an EMSA based method in which the relative mobility (Rf) in different percentages of 
polyacrylamide (7-10%) is used to calculate the MW (Figure 38A-D).  The relative 
mobility of MW marker proteins and protein complex with DNA are plotted against 
the polyacrylamide concentration (Figure 38A and 38C). Slopes of the MW marker 
proteins were then plotted against their MW and the regression equation was used to 
calculate the MW of protein complex bound to DNA (Figure 38B and 38D).  
 
The MW of protein complex without DNA was calculated to be 91.74 kD. In a recent 
study on a VapC homologue, FitB from N. gonorrhoea, the crystal structure revealed 
a FitAB complex binding to DNA as an octamer of four FitAB heterodimers [FitA2-
FitB2]2 where FitB dimerisation mediates strong cooperative binding (Mattison et al., 
2006). The calculated MW of a [VapB2-VapC2]2 octamer is 93.2 kD, in accordance 
with the EMSA estimate for protein complex. In the EMSAs presented here 
(containing vapO1) no intermediate complex was observed even at low VapBCLT2 
concentrations, which if the proteins bind DNA as an [VapB2-VapC2]2 octamer are 
indicative of very strong cooperative binding. VapCLT2 may contribute to 
cooperativity by forming a bridge between VapBLT2 dimers bound to each half-site of 
vapO. However as observed VapCLT2 can also destroy DNA binding when in excess 
of VapBLT2. This suggests that VapCLT2 might regulate DNA binding by conditional 
cooperativity. In the FitAB crystal structure, FitA-FitB heterodimers are very similar 
and FitB does not contain any obvious low affinity binding sites for FitA as observed 
for CcdAB, RelBE and PhD-Doc TA complexes (De et al., 2009;Overgaard et al., 
2009;Garcia-Pino et al., 2010). This observation opens the possibility that VapBLT2 
and VapCLT2 forms an octameric complex and the mechanism of conditional 
cooperativity might lie in the dimerisation of VapCLT2. 
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Figure 38 Estimation of the Molecular weight (MW) of protein complex bound to vapO1 DNA. A) 
A graph showing the logarithm of the relative mobility (RF) of marker proteins; Lactalbumin 
(blue), Carbonic anhydrase (magenta), Ovalbumin (Yellow), BSA monomer (teal) and BSA dimer 
(purple) plotted as a function of polyacrylamide concentration (%). The calculated slopes of 
regression equations are shown on the right. B) The slopes of the marker protein regressions are 
plotted as a function of the molecular weight. The value of the regression equation of the plot is 
shown on the right. C)  A graph showing the logarithm of the relative mobility of protein-DNA 
complex of three independent experiments. The calculated slopes of regression equations of the 
three experiments are shown on the right. D) Table with the molecular weight of protein-DNA 
complexes and protein complex (subtracted with mass of promoter DNA fragment 22.106 kD) 
extrapolated according to the equation y = 0.0884x + 0.6332. The average mass of three 
experiments is 91.74 ± 10.09 kD.  
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VapCLT2 dimerisation is important for transcriptional repression and 
conditional cooperativity 
To investigate the possible role of VapCLT2 dimerisation in conditional cooperativity, 
a mutational analysis was performed on residues that could be important for 
dimerisation (Figure 40A). To select residues involved in dimerisation, the tertiary 
structure of VapCLT2 was predicted using PHYRE (Kelley and Sternberg, 2009) and 
the predicted structure superimposed onto FitB (Figure 39A). It can be observed that 
although VapCLT2 and FitB show limited similarity on the level of primary sequence 
(Figure 14) a high scoring model (FitB was used as a model by PHYRE) can be build 
which aligns with FitB  (Figure 39A). From the possible VapCLT2 dimer structure 
residues can be predicted which might be important for dimerisation (Figure 39B and 
Figure 40A). Putative residues involved in dimerisation were initially tested by 
substitution mutations in vapCLT2 in a transcriptional vapBCLT2-lacZ fusion by 
changing residues in VapCLT2 to either alanine or serine (Figure 40A and 40B). As 
dimerisation is crucial for cooperativity of FitAB DNA-binding, mutations that 
interfere with dimerisation of VapCLT2 should decrease the ability of the complex to 
repress transcription. It is observed that four residues are of particular interest; leucine 
43 to alanine (~ 5.2-fold up-regulation), isoleucine 44 to alanine (~ 1.4-fold up-
regulation), tyrosine 72 to alanine (~ 7-fold up-regulation) and alanine 76 to serine (~ 
1.9-fold up-regulation).  
 
Tyrosine 72 aligns perfectly with phenylalanine 78 in FitB, which has been shown to 
be a key residue for FitB dimerisation (Mattison et al., 2006) (Figure 39A). The 
transcriptional up-regulation observed when residues are mutated suggests that these 
residues might be important for VapCLT2 dimerisation as well.. Interestingly, 
mutations in the dimerisation interface that affect transcriptional repression also affect 
toxicity of VapCLT2 (Figure 42B). Particularly, L43A and Y72A decrease toxicity, 
however A76S also seem less toxic as small colonies are observed. This indicates that 
VapCLT2 dimerisation could also be important for toxicity, possibly by affecting the 
configuration of the acidic catalytic residues in the active site. The decrease in toxicity 
might also be caused by tertiary structure changes resulting from introducing 
mutations into VapCLT2.  
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Figure 39 Structural alignment of VapCLT2 with FitAB. A) The tertiary structure of VapCLT2 
(STM3033) from S. enterica LT2 was predicted using Protein Homology/analogY Recognition 
Engine (PHYRE  (Kelley and Sternberg, 2009), http://www.sbg.bio.ic.ac.uk/~phyre/index.cgi) the 
top scoring prediction had an E-value of 3.850249e-15 and was build on a model of FitB . The 
predicted VapC structure was aligned with the structure of N. gonorrhoea VapC homologue, FitB 
(2BSQ chain A) (Mattison et al., 2006) using PYMOL v1.3. Tyr72 of VapCLT2 and Phe78 of FitB 
is highlighted in red B) Proposed VapC dimer (Teal blue) aligned with FitB dimer (Violet) in 
FitAB complex bound to DNA inverted repeat. FitA dimers binding to DNA repeats are shown in 
green. The FitAB protein structure was obtained from the protein data bank PDB ID; 2BSQ. 
 
 
Figure 40 Isolation of mutants in the dimerisation interface that affect repression. A) Predicted 
tertiary and secondary structure of VapCLT2 dimer including positions of substitution mutations in 
predicted dimer interface. Helix 3 and 5 is marked in blue and red, respectively. B) Transcriptional 
activity of vapBCLT2 transcriptional fusion to lacZ with mutations in VapCLT2 dimer interface. 
TB28 (MG1655 ∆lacZIYA) containing pKW254BC (vapBCLT2::lacZYA) and substitution mutant 
derivatives were grown exponentially in LB medium at 37ºC. At OD600 of 0.5 samples were 
collected and the activity of β-galatactosidase (Units) measured. 
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However, mutants VapCLT2
L34A
, VapCLT2
Y72A
, VapCLT2
A76S
 and VapCLT2
I44A
 were 
initially purified from complex with His-tagged VapBLT2 which suggest that the 
mutations do not interfere with antitoxin binding and that the mutants, in that respect, 
are correctly folded. 
To investigate the importance of substitution Y72A in dimerisation and subsequent 
DNA-binding, EMSAs were performed using purified VapBLT2, VapCLT2 and 
VapCLT2
Y72A
 together with vapO1 DNA (Figure 41A).  VapCLT2 increases the affinity 
of VapBLT2 for DNA (lane 2-4) and at a certain VapBLT2/VapCLT2 ratio of ~1:8 (lane 
5) the affinity decreases with increasing VapCLT2 concentration. Interestingly, when 
 
Figure 41 VapCLT2
Y72A affects dimerisation and abolishes conditional cooperativety A) 
Electrophoretic mobility shift assay with purified VapCLT2, VapCLT2
Y72A and VapBLT2 with 
promoter DNA. (Left panel) VapBLT2 ,VapCLT2 or VapCLT2
Y72A were mixed with radio labelled 
promoter DNA containing vapO1 in amounts shown (nM) (lanes 1-7). Protein-DNA complexes 
were separated by 6% native PAGE and analysed by phosphor imaging. U and C indicate position 
of unbound and complex bound DNA, respectively. (Right panel). Image J quantitated Band 
intensities plotted in a graph with C band intensity (%) as a function of the lane number. B) In vitro 
crosslinking of VapCLT2 reveals Y72A mutant as being deficient in dimerisation. 5 pmol Purified 
VapCLT2 or VapCLT2
Y72A was in vitro cross linked by incubation with 0.7% formaldehyde or storage 
buffer for 15 min at 37ºC. Cross linked complexes were resolved by SDS-PAGE and subsequent 
silver staining. M is a molecular weight marker and position of monomer and dimer complexes are 
indicated with arrows. 
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VapCLT2
Y72A
 is incubated with VapBLT2, VapCLT2
Y72A
 increases the affinity of 
VapBLT2 for DNA (lanes 1-7). However, as it can be observed from the band intensity 
profiles (right panel), VapCLT2
Y72A
 only poorly contributes to DNA-binding compared 
to VapCLT2 at low concentrations.  
Furthermore, it can also be observed that VapCLT2
Y72A
 does not exhibit conditional 
cooperativity as it continues to increase the affinity of VapBLT2 for promoter DNA 
even at a VapBLT2/ VapCLT2
Y72A
 ratio of ~1:16 (lane 7). A possible explanation is that 
 
Figure 42 Effect of substitution mutations in VapCLT2 dimerisation interface on conditional 
cooperativity. A) Electrophoretic mobility shift assay with purified VapCLT2, VapCLT2
L43A 
VapCLT2
I44A VapCLT2
A76S and VapBLT2 with vapO1 DNA in amounts shown (nM). The proteins 
were mixed with radio labelled promoter DNA containing VapO1. Protein-DNA complexes were 
separated by 6% native PAGE and analysed by phosphor imaging. U and C indicate position of 
unbound and bound DNA, respectively. B) Toxicity of dimerisation mutants on plates. MG1655 
(E. coli K-12) containing pKW51(pA1/03/04:: SDopt::vapBLT2) and either pKW52 
(pBAD::SDopt::vapCLT2), pKW3352L43A (pBAD::SDopt::vapCLT2
L43A), pKW3352I44A 
(pBAD::SDopt::vapCLT2
I44A), pKW3352Y72A (pBAD::SDopt::vapCLT2
Y72A), pKW3352A76S 
(pBAD::SDopt::vapCLT2
A76S
), pKW3352I78A (pBAD::SDopt::vapCLT2
I78A
) were single colony streaked 
on NA plates containing 0.2% arabinose with or without 2 mM IPTG. 
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VapCLT2
Y72A
 has decreased affinity for VapBLT2. This however does not explain the 
lack of conditional cooperativity at high concentrations and that VapCLT2
Y72A 
can 
promote binding of more VapBLT2 to DNA. Consistent with weaker dimerisation, in 
vitro cross linking with formaldehyde, showed that VapCLT2
Y72A
 only weakly 
crosslinked, whereas VapCLT2 made stronger dimer sized crosslinks (Figure 41B). 
Similar to VapCLT2
Y72A
, dimerisation mutants of VapCLT2
L43A
, VapCLT2
I44A
 and 
VapCLT2
A76S
 were also analysed by EMSA and were also observed to lose the ability 
to exert conditional cooperativity at VapBLT2/VapCLT2 ratio of ~1:16 (Figure 42A). 
Consistent with the observed increase in vapBCLT2 transcription, mutants VapCLT2
L43A
 
and VapCLT2
A76S
 also significantly affected binding of VapBLT2 to DNA. The 
VapCLT2
I44A
 mutant did so to a lesser extent, which is also consistent with the subtle 
effect on transcription repression (Figure 40B). These observations support that 
dimerisation of VapCLT2 toxin is important for conditional cooperativity.  
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Discussion for Results Section II 
Previous studies on Toxin-Antitoxin systems such as Escherichia coli K-12 relBE 
locus have shown that, under steady-state growth, the relBE promoter is 
transcriptionally repressed (Christensen et al., 2001). Under conditions with decreased 
rate of translation, by treatment with chloramphenicol or amino acid starvation, 
transcription from relBE promoter is induced, which is dependent on Lon protease. 
This is due to a decrease in the RelB/RelE ratio as RelB levels are decreased under 
such conditions (Christensen et al., 2001;Overgaard et al., 2008).  
As demonstrated above amino acid starvation or treatment with chloramphenicol also 
increases transcription from the vapBCLT2 promoter and is also dependent on Lon 
protease (Figure 33A and 33B). Furthermore, it was observed that the increase in 
transcription could be linked to Lon-dependent decrease in the stability of antitoxin 
VapBLT2 (Figure 33C). Interestingly, vapBCLT2 transcript was also detected before 
addition of chloramphenicol, indicative of constitutive low level of transcription 
during steady state growth. A consequence of low basal transcription could suggest 
rapid turnover of VapBLT2 or the presence of a cellular pool of VapBCLT2 complex 
that does not repress transcription. Several studies have reported differential TA 
transcription within the same organism during steady state growth, whereas some TAs 
are repressed and others induced (Cooper et al., 2009;Ramage et al., 2009). 
S. enterica LT2 VapBLT2 contains a predicted N-terminal AbrB DNA-binding 
domain, similar to MazE antitoxin of E. coli K-12 MazEF toxin-antitoxin system. 
Transcription of mazEF was shown to occur primarily from a promoter (P2), which is 
located within an unusual inverted repeat which is DNase I protected by MazEF cell 
extracts (Marianovsky et al., 2001). The crystal structure of MazEF complex revealed 
a MazF2-MazE2-MazF2 hexamer of two heterotrimers in which both toxin MazF and 
antitoxin MazE dimerise and is proposed to bind DNA in a MazE:MazF ratio of 1:2 
(Zhang et al., 2003a;Kamada et al., 2003). Analysing the region flanking the 
identified vapBCLT2 promoter revealed two inverted repeats as potential VapBLT2 
binding sites (Figure 33D). When native purified VapBLT2 was incubated with 
promoter DNA, binding was only observed at high concentrations, indicating low 
affinity for DNA; however when VapBLT2 was added together with VapCLT2, the 
binding of VapBLT2 to DNA was observed at much lower concentrations (Figure 
34A). This indicates that VapCLT2 greatly increases the affinity of VapBLT2 for DNA. 
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DNase I protection by VapBLT2 bound at the inverted repeats 1 and 2 in the promoter 
region is also observed. This is consistent with protein complex binding to these sites 
(Figure 34B). For simplicity I rename the two inverted repeats, vapO1 and vapO2. 
Other homologues of VapBCLT2 have been characterised for their ability to bind 
promoter DNA. These include; FitAB from N. gonorrhoea, NtrPR from S. meliltoi, 
and more recently VapBC from M. smegmatis (Wilbur et al., 2005;Bodogai et al., 
2006;Robson et al., 2009). In the case of FitAB, it was shown that FitA antitoxin, 
which contains a Ribbon-helix-helix (RHH) DNA-binding domain, forms a 
homodimer which binds promoter DNA with low affinity and with high affinity when 
in complex with toxin FitB. This is in good accordance with the observations in this 
work. Interestingly, it was observed that NtrPR containing cell extracts, in which NtrP 
antitoxin contains an AbrB DNA-binding domain, seems to bind a direct repeat rather 
than an inverted repeat in the promoter region and therefore this complex might be 
different.  
It has recently been shown that toxins RelE and Doc can either positively or 
negatively regulate repression of transcription by a mechanism known as conditional 
cooperativity (Overgaard et al., 2008;Garcia-Pino et al., 2010). When VapCLT2 was in 
excess of VapBLT2, VapCLT2 decreased the affinity of VapBLT2 for DNA (Figure 
35A). The affinity of the VapBLT2 for DNA could be recovered by increasing the 
VapBLT2/VapCLT2 ratio, which confirmed that it likely is an active mechanism. 
Consistently it was observed that VapCLT2 in excess results in decreased DNAse I 
protection by VapBLT2; first in vapO2 and then in vapO1 indicating higher affinity of 
the protein complex for vapO1 (Figure 35B). The observed decrease in affinity of 
VapBLT2 for DNA when VapCLT2 is in excess is similar to the effect observed by RelE 
and Doc.  
To address the importance of the two operator sites for the conditional repression 
mechanism, EMSAs with VapBLT2, VapCLT2 and promoter fragments containing 
scrambled vapO1 and vapO2 were performed (Figure 36B). It was observed that 
mutations in these operator sites do indeed affect binding of  VapBLT2, confirming the 
DNase I protection by protein at these sites. This was also confirmed by 
transcriptional lacZ fusions in vivo as each site can contribute to repression of 
transcription, with vapO1 being more important than vapO2, which can be explained 
by higher affinity of VapBLT2 for the vapO1 site (Figure 36C). It can however not be 
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excluded that the transcriptional increase is caused by increased promoter activity in 
these mutants but is consistent with the in vitro observations. 
Nevertheless, it was observed that the conditional repression mechanism acts on both 
operator sites independently as protein complexes bound to either of the operator sites 
seem to decrease with increasing VapCLT2 concentration, suggesting that each 
inverted repeat is an independent functional repressor site. This was also confirmed 
by EMSAs of VapBLT2 and VapCLT2 with isolated vapO1 which also showed the 
conditional repression mechanism in excess of VapCLT2 and could be reverted by 
increasing the VapBLT2/VapCLT2 ratio (Figure 37A). In addition, VapCLT2 mediated 
increase transcription could also be observed in vivo as ectopic overexpression of non-
toxic VapCLT2
D7A
 increases transcription of vapBCLT2 (Figure 37B and 37C). 
The crystal structure of FitAB bound to DNA revealed an octamer of four 
heterodimers binding promoter DNA inverted repeat in a [FitA2-FitB2]2 complex 
(Mattison et al., 2006). In this complex FitB was found to dimerise forming a bridge 
between FitA bound to two different half sites of the inverted repeat. It would be 
expected that such bridging would result in strong cooperativity in DNA binding of 
FitA. The molecular weight of the protein complex bound to one operator site was 
estimated to be ~91.74kD which is in good accordance with DNA bound to a [VapB2-
VapC2]2-complex (Calculated MW 93.8kD, 4 VapBLT2 of 8.514 kD and 4 VapC of 
14.938 kD) (Figure 38A,B,C and D). It is observed that DNA binding of VapB to 
DNA with increasing VapCLT2 gives a cooperative saturation profile without binding 
intermediates (Figure 37A). Another observation which favours a strong cooperative 
binding of a [VapB2-VapC2]2-complex to DNA is observed when one half-site is 
scrambled in each of the inverted repeats which results in a complete loss of DNA-
binding (Figure 36B). 
The explanation for the observed conditional repression mechanism or conditional 
cooperativity could lie in the dimerisation bridge formed by VapCLT2 dimers, which 
would be crucial for this type of complex. Superimposing the predicted tertiary 
structure of VapCLT2 onto FitB dimer structure made it possible to predict residues 
involved in VapCLT2 dimerisation (Figure 39 and 40A). Mutations which interfere 
with VapCLT2 dimerisation are predicted to result in less stable [VapB2-VapC2]2-
complexes and will affect the ability of the complex to repress transcription. A 
mutational analysis of selected residues in VapCLT2 dimer interface was performed, 
which revealed residues L43A, I44A, Y72A and A76S to affect transcriptional 
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repression (Figure 40B). Especially, residues L43A and Y72A appeared to be 
important, as the mutations lead to strong decrease in transcriptional repression. 
Interestingly, it was also observed that these mutations seem to affect VapCLT2 
toxicity, which could be linked to the importance of dimerisation in configuring the 
active site of VapC (Figure 42B). This possibility has readily been discussed for 
crystal structures of VapCs from P. aerophilum; PAE2754, PAE0151 and FitAB of N. 
gonorrhoea (Arcus et al., 2004;Bunker et al., 2008;Mattison et al., 2006). However, 
this effect might also be caused by significant structural changes as a consequence of 
the substitution mutations. 
It has been shown that FitB has a dimer interface with extensive interactions between 
α-helix 3 in one dimer with α-helix 5 in the other dimer, which involves several 
hydrophobic residues. However, especially F78 seem to be the key residue forming 
several important hydrophobic interactions (Mattison et al., 2006). In the predicted 
VapCLT2 structure, Y72A aligns perfectly with F78 in FitB, which is interesting in 
respect to the observed effect on vapBCLT2 transcriptional repression (Figure 39A). To 
assess this, EMSAs with VapBLT2 and promoter DNA with increasing concentrations 
of VapCLT2 or VapCLT2
Y72A
 were performed (Figure 41A). Surprisingly, not only did 
VapCLT2
Y72A
 decrease the binding of complex to promoter DNA compared to 
VapCLT2 but also abolished the anti-repression mechanism, which is observed by 
VapCLT2 at VapBLT2/VapCLT2 ratio of ~1:16. This in turn resulted in even more 
VapBLT2 being bound to DNA at very high VapCLT2
Y72A
 amounts. Taking into 
consideration that the Y72A mutation does not significantly decrease the affinity of 
VapCLT2
Y72A
 for VapBLT2 it could indicate that a dimer/monomer equilibrium exists in 
solution in which the dimer favors DNA binding of the complex. The observed 
stimulation of VapBLT2 binding in the presence of high VapCLT2
Y72A
 concentrations is 
most likely due the fact that the interaction between toxin and antitoxin promotes the 
folding of the otherwise unstructured antitoxin. This in turn stimulates non-
cooperative DNA binding of the antitoxin to the operator sites. Binding is however 
only observed at very high VapCLT2
Y72A
 concentrations, which is in agreement with 
its poor ability to stimulate repression of transcription (Figure 40B). Interaction 
induced folding of the antitoxin has also previously been described for CcdA and Phd 
antitoxins (De et al., 2009;Garcia-Pino et al., 2010).  
That VapCLT2
Y72A
 might produce weaker dimers was also observed by in vitro cross 
linking whereas VapCLT2
Y72A
 showed no or low amounts of dimer (Figure 41B) This 
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observation could also be confirmed for other purified mutants of VapCLT2; 
VapCLT2
L43A
, VapCLT2
I44A
, and VapCLT2
A76S
, which had a similar effect on DNA 
binding of VapBLT2 (Figure 42A). These observations all suggest that VapCLT2 
dimerisation might be important for conditional cooperativity. 
It has been shown for CcdB, RelE and Doc that small changes in the antitoxin/toxin 
ratio results in rapid decrease in affinity of toxin-antitoxin complex for DNA (Afif et 
al., 2001;Overgaard et al., 2008;Garcia-Pino et al., 2010). For RelE and Doc this has 
been explained by the presence of a low and a high affinity antitoxin binding site in 
the toxin. Analysing the crystal structure of DNA bound FitAB reveals a complete 
symmetry in the FitB dimer interface which means that FitA most likely is bound to 
the same site in all FitB heterodimers (Figure 39B) (In FitA monomers 9-13 Amino 
acid  C-termini are not visible in the structure) (Mattison et al., 2006). This suggests 
two mechanisms by which excess VapCLT2 can break cooperative complex bound to 
DNA: (1) VapCLT2 in excess directly competes for antitoxin VapBLT2 in the DNA 
bound VapBCLT2 complex which could also result in loss cooperativity in the 
complex. This is highly unlikely since as the VapBLT2-VapCLT2 interaction is very 
strong and can only be broken using high amounts of urea during the purification 
process and is also the case for VapCLT2
Y72A
 which does not mediate conditional 
cooperativity. (2) A more likely mechanism is that VapCLT2 directly interferes with 
cooperativity by competing for dimerisation with VapCLT2 in the DNA bound 
VapBCLT2 complex, which would eventually lead to decreased DNA affinity by 
disruption of cooperativity (Figure 43). This mechanism would also predict that a 
higher concentration of VapCLT2 is needed to compete as a dimer equilibrium would 
not only exist in VapBCLT2 complex but also between free VapCLT2. This model is 
also consistent with the presence of a pool of VapBCLT2 complex in the cell during 
steady-state growth which does not inhibit transcription. 
The mechanism of conditional cooperativity allows cells which are inhibited by toxin 
to return from a dormant state to a state that permits growth. The outcome of a de-
repressed promoter on VapBLT2 and VapCLT2 production was investigated using a 
constitutive promoter which could mimic a de-repressed vapBCLT2 promoter (Figure 
32B and C). It is observed that VapCLT2 synthesis is limited by strict translational 
coupling from VapBLT2 both in vivo and in vitro, which indicates that if translation 
resumes by change in conditions, VapBLT2 will be synthesized in excess of VapCLT2 
and favour VapBCLT2 DNA-binding. Conditional cooperativity has previously been 
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reported for ccdAB, relBE and phd-doc (De et al., 2009; Overgaard et al., 2008: 
Garcia-Pino et al., 2010). In these systems, conditional cooperativity is mediated by 
the presence of two distinct antitoxin binding sites in the toxin. The antitoxin binds to 
these sites with different affinity which makes the complexes very sensitive to very 
small changes in the antitoxin/toxin ratio. The mechanism of conditional cooperativty 
presented here for vapBCLT2, depends on breaking of the dimerisation of VapCLT2 in 
the DNA bound [VapB2-VapC2]2-complex. Consistent with this interpretation the 
VapBCLT2 complex is less sensitive to changes in the VapBLT2/VapCLT2 ratio and 
complex breakage occurs gradually with increased VapCLT2, when VapCLT2 is in 
excess. Nevertheless, this study could represent an exciting new mechanism by which 
toxins can excert conditional cooperativity to regulate transcription.    
 
Figure 43 Model for how VapCLT2 in Excess can exert conditional cooperativity. (1)VapBLT2 
(salmon) and VapCLT2 dimer (teal and cyan) forms an octameric (VapB2-VapC2)2-complex which 
binds cooperatively to vapO1 and vapO2 operator sites and represses transcription. When the 
translation rate is decreased or protease activity is increased as a result of nutritional stress or 
treatment with antibiotics, VapBLT2 levels decrease and more stable VapCLT2 becomes in excess. 
(2) VapCLT2 forms a dimer in solution which exists in monomer/dimer equilibrium. (3) Free 
VapCLT2 monomer can interfere with the VapCLT2 dimer bound in complex, which abolishes 
cooperative binding to DNA. This in turn activates transcription, which will facilitate VapBLT2 
production, as VapBLT2 is produced in excess of VapCLT2. 
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Future Perspectives for Results Section II 
It is clear from the data presented in Results Section II that dimerisation of VapCLT2 is 
important not only for the cooperative binding of VapBLT2 to vapO but also for the 
mechanism of conditional cooperativity. To investigate this possibility further, a 
crystal structure of VapBCLT2 complex bound to DNA would give fundamental 
insights to the mechanism of regulation. Alternatively, a crystal structure of the 
complex formed when VapCLT2 is in excess would also give interesting clues to the 
mechanism of conditional cooperativity. Some of these questions might also be 
answered by analytical ultracentrifugation of the VapBCLT2 complex as well as 
information about the affinities between the antitoxin and the toxin. This could be 
done in parallel with mutant VapBCLT2
Y72A
 complex which would give interesting 
clues to the difference between wt and mutant.  
Alternatively, the affinities between antitoxin and toxin could be analysed by Surface 
Plasmon Resonance (SPR) with immobilised VapBLT2, VapCLT2 or VapCLT2
Y72A
. This 
experiment is however limited by the low solubility of the toxin proteins. However, 
the affinities of VapBCLT2 and VapBCLT2
Y72A
 for DNA could also be analysed by 
immobilising promoter DNA with a biotin tag as the complexes are more soluble. 
Finally, an interesting experiment would be to analyse the observed increase in 
affinity of VapBLT2 for DNA in the presence of high concentrations of VapCLT2
Y72A
 
mutants. This could be done by analysing the binding of VapBLT2 to a half operator 
site in the presence of VapCLT2 and VapCLT2
Y72A
. A half operator site would not allow 
cooperative binding to occur and if the toxin induces folding of the antitoxin upon 
interaction, VapCLT2 and VapCLT2
Y72A
 would do so to a similar extent. 
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Conclusion 
I demonstrate here that vapBC from Shigella flexneri 2a YSH6000 virulence plasmid 
pMYSH6000 and Salmonella enterica serovar Typhimurium LT2 is bona fide TA 
loci, which, like other Type II TAs, encodes an antitoxin vapB and toxin vapC. 
Furthermore, I show that vapB and vapC are translationally coupled which ensures 
that VapB is produced in excess of VapC. The vapBC locus is transcribed from a 
single promoter, which is repressed and transcribed only at low level during steady-
state growth.  
VapB contains an N-terminal DNA binding domain and forms a dimer which 
represses transcription by binding to two inverted repeats (vapO, operator sites) in the 
promoter region. The affinity of VapB for vapOs is greatly increased in the presence 
of VapC, which act as a co-repressor. The VapC toxin does so possibly by forming a 
complex with VapB by direct protein-protein interaction, which might not only 
neutralise the activity of VapC but also cooperatively enhance the binding of VapB to 
vapOs by forming VapC dimer bridge between two VapB dimers. 
Consistent with other Type II TAs, transcription of vapBC is increased during 
nutritional stress and treatment with antibiotics that is caused by decreased cellular 
levels of VapB, which is degraded by ATP-dependent Lon protease. The decrease in 
cellular levels of VapB leads to free VapC, which is activated to act on its cellular 
target. Apart from activation it also directly stimulates vapBC transcription as the 
cooperative binding of [VapB2-VapC2]2 complex to DNA is conditional and VapC in 
excess of VapB might interfere with VapC dimerisation in the DNA bound complex, 
which leads to de-repression of the promoter. Transcriptional induction ensures 
efficient VapB production when translation resumes by a change in the environment. 
The VapC toxin contains a PIN domain, which specifically cleaves tRNA
fMet
 between 
position +38 and +39 dependent on Mg
2+
. Hereby, VapC inhibits global translation at 
the step of translation initiation. This inhibition is bacteriostatic as cells rapidly 
recover by subsequent induction of VapB. The cleavage of tRNA
fMet
 results in a 
reduced growth rate and may be beneficial to translation fidelity during slow growth 
as the drain on charged pools of charged tRNA is adjusted to a slower growth rate, 
which results in increased translation fidelity. VapC activitation might also play 
another role by altering the proteome as decreased levels of tRNA
fMet
 result in 
increased competition by elongator tRNAs for P-site occupation which could lead to 
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translation initiation events to occur on elongator codons positioned in optimal 
distance to a Shine & Dalgarno sequence. The complete model for vapBC regulation 
and activity is shown in Figure 44. 
 
Figure 44 The complete model for vapBC regulation and activity. Two dimers of VapC (cyan) 
forms a complex with two dimers of VapB (salmon), which promotes cooperative binding to two 
operator sites (vapO) in the promoter region. This in turn represses transcription of the vapBC 
operon. VapB is an efficient Lon protease substrate. During environmental stress e.g. amino acid 
starvation, protease activity of Lon is increased, which leads to decreased cellular levels of VapB. 
This results in increased transcription as VapBLT2 is degraded and Free VapC interferes with the 
cooperative binding of the complex to DNA. Free VapC is also activated to act on its cellular target 
tRNAfMet, which leads to inhibition of global translation and results in decreased growth rate and 
drain on charged tRNA species with a consequent increase in fidelity of the translation machinery 
on mRNA which are translated.  A possibility is also that VapC might regulate the proteome as it 
might affect translation initiation, which could be beneficial to the cell under certain conditions. 
Environmental stress also induces ppGpp production (See Introduction Chapter 4), which helps the 
cell to adapt to the environment with a slower growth rate. Changes in the environment to more 
favourable conditions results in immediate toxin neutralisation as the synthesis of toxin is strictly 
coupled to the antitoxin.  
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Materials and Methods 
Bacterial Strains, Plasmids and Growth Conditions 
Bacterial cultures were grown in either Luria-Bertani medium (For 1L LB medium, 
10g Bacto-Tryptone, 5g Yeast Extract, 10g NaCl, PH 7.5) or AB minimal medium 
(For 1L AB medium, 0.4g (NH4)2SO4, 1.2g Na2HPO4, 0.6g KH2PO4, 0.6g NaCl, 
0.08mM CaCl2, 0.8mM MgCl2 and 2.4µM FeCl3) supplemented with 0.5% glycerol, 
1g/L thiamine and defined concentrations of amino acids. When appropriate, the 
medium was supplemented with 30 g/mL (low-copy) or 100g/mL (high-copy) 
ampicillin, 50 g/mL chloramphenicol, 25 g/mL kanamycin and 10 g/mL 
tetracycline. Amino acid starvation is induced by adding serine hydroxymate (SHT, 
purchased from Sigma Aldrich) to a final concentration 1 mg/mL. Transcription from 
LacI-regulated promoters was induced by the addition of 2 mM Isopropyl-β-D-1-
thiogalactopyranoside (IPTG). Transcription from AraC-regulated promoters was 
induced by the addition of 0.2% arabinose. 
Indicator plates were supplemented with X-gal (5-bromo-4-chloro-3-indoyl-b-D-
galactoside) to a final concentration of 40 µg/ml. Strains and plasmids constructed are 
listed in table 3 and 4, respectively. Oligonucleotides used in this study are listed in 
table 5. 
Standard procedures 
The molecular cloning work in this study was done according to (Sambrook et al., 
1989). Amplification of DNA fragments was performed using Phusion™ High-
Fidelity DNA polymerase (Finnzymes) and DNA purifications performed using 
illustra GFX PCR & gel band purification kit™ (GE healthcare). All other 
amplification was carried out using Gotaq
®
 Flexi DNA polymerase (Promega). 
Correct recombinant clones were confirmed by sequence obtained from DNA 
Sequencing & Services™, Dundee, Scotland. Plasmid preparations were carried out 
using QIAprep spin MiniPrep kit (Qiagen) and Nucleobond
®
 AX-100 (ClonTech). 
DNA restriction digestions and ligations were performed using enzymes purchased 
from Roche or Promega. 
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Table 3. Strains constructed and used in this study 
 
Table 4 Plasmids constructed and used in this study 
Plasmid Plasmid properties Reference 
pNDM71 Plasmid R1 derivative, bla Laboratory Collection 
pKW71512 pNDM71::vapBCLT2 This study 
pNDM220 R1 bla lacI
q
  pA1/O4/O3 
(Gotfredsen and Gerdes, 
1998) 
pRBJ200 R1 bla mcs-lacZYA (Jensen et al., 1995) 
pKW512 pRBJ200 vapBCLT2::lacZYA This work 
pMG25 pA1/O3/O4 Laboratory collection 
pKW512HB pA1/O3/O4::H6-vapBLT2-vapCLT2 This study 
pKW512HC pA1/O3/O4::vapBLT2-H6-vapCLT2 This study 
pBAD33 pBAD (Guzman et al., 1995) 
pKW3352HC pBAD::SDopt::vapCLT2
 
-H6 This study 
pKW3353HC pBAD::SDopt::vapCLT2
D7A 
-H6 This study 
pKW3354HC pBAD::SDopt::vapCLT2
D98A 
-H6 This Study 
pKW3382HC pBAD::SDopt::vapC-H6 This study 
pKW52 pBAD::SDopt::vapC This study 
pKW51 pA1/03/04:: SDopt::vapBLT2 This study 
pKW82 pBAD33 pBAD::vapC (mvpT) 
This study 
pKW81 pNDM220 pA1/O4/O3::vapB (mvpA) 
This study 
pKW3221 T7::tRNA
fMet
 This study 
pKW812HB pA1/O4/O3:H6-vapB-vapC This study 
pKW812HC pA1/O4/O3:vapB-H6-vapC This study 
pKW254812 pOU254::vapBC This study 
pKW254813 pOU254::vapBC
D7A
 This study 
pKP3035 pBAD::relE (Pedersen et al., 2002)  
pRB100 pBAD::yoeB (Christensen-Dalsgaard and 
Gerdes, 2008)  
pOU254 lacZYA transcrional fusion vector Laboratory collection 
pKW512TFZD7A pOU254, vapBCLT2
D7A
::lacZYA This study 
pKW512TFZD7A-1 pKW512TFZD7A, mutation in vapO1 This study 
pKW512TFZD7A-2 pKW512TFZD7A, mutation in vapO2 This study 
pKW512TFZD7A-1-2 pKW512TFZD7A, mutation in vapO1 and 
vapO2 
This study 
pKW254BC pOU254, vapBCLT2::lacZYA This study 
pKW254BCL40A pKW254BC, L40A substitution This study 
Strains Genotype Reference 
MG1655 Wild-type E. coli  K-12 Laboratory Collection 
KP1001 Wild-type S. enterica LT2 Laboratory Collection 
TB28 MG1655 ∆lacIZYA 
Laboratory Collection 
C41 BL21 derivative (DE3) 
Laboratory Collection 
SC301467 
MG1655 ΔmazF ΔchpB ΔrelBE ΔdinJ-yafQ 
ΔyefM-yoeB (Christensen et al., 2004) 
SC30 MG1655 ΔmazF (Christensen et al., 2003) 
SC31 MG1655 ΔchpB (Christensen et al., 2003) 
SC34 MG1655 ΔrelBE (Christensen et al., 2003) 
SC36 MG1655 ΔdinJ-yafQ (Christensen et al., 2004) 
SC37 MG1655 ΔyefM-yoeB (Christensen et al., 2004) 
MG1655 Δlon MO11, MG1655 ∆lon146::tet (Overgaard et al., 2008) 
KW10 ∆lon::kan This study 
KW11 ∆clp::kan This study 
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pKW254BCM41A pKW254BC, M41A substitution This study 
pKW254BCL43A pKW254BC, L43A substitution This study 
pKW254BCI44A pKW254BC, I44A substitution This study 
pKW254BCY45A pKW254BC, Y45A substitution This study 
pKW254BCE48A pKW254BC, E48A substitution This study 
pKW254BCK49A pKW254BC, K49A substitution This study 
pKW254BCY72A pKW254BC, Y72A substitution This study 
pKW254BCA76S pKW254BC, A76S substitution This study 
pKW254BCA77S pKW254BC, A77S substitution This study 
pKW254BCI78A pKW254BC, I78A substitution This study 
pKW254BCR89A pKW254BC, R89A substitution This study 
pOU253 lacZYA translational fusion vector Laboratory collection 
pKW253-1 pOU253, ptac::vapBCLT2
D7A
::lacZYA This study 
pKW253-2 pKW253-1, Start codon mutation This study 
pKW253-3 pKW253-1, Premature termination codon (PTC) This study 
pKW253-4 pKW253-1, Frameshift mutation This study 
pKW253-5  pOU253, ptac::vapBLT2::lacZYA This study 
pKW512HBL43A pKW512HB, with vapCLT2
L43A
 This study 
pKW512HBI44A pKW512HB, with vapCLT2
I44A
 This study 
pKW512HBY72A pKW512HB, with vapCLT2
Y72A
 This study 
pKW512HBA76S pKW512HB, with vapCLT2
A76S
 This study 
pKW3352L43A pBAD::SDopt::vapCLT2
L43A
 This study 
pKW3352I44A pBAD:: SDopt::vapCLT2
I44A
 This study 
pKW3352Y72A pBAD:: SDopt::vapCLT2
Y72A
 This study 
pKW3352A76S pBAD:: SDopt::vapCLT2
A76S
 This study 
pKW3352I78A pBAD:: SDopt::vapCLT2
I78A
 This study 
pKW254T pOU254 contains terminator from pMG25 
(Christensen-Dalsgaard et 
al., 2008) 
pKW25420T pKW254T dksA This work 
pKW25421T pKW254T dksA ATG→AAG
 
This work 
pKW25423T 
pKW254T dksA in frame TAA 2nd codon before 
stop codon
 
This work 
pKW25424T 
pKW254T dksA out of frame TAA before stop 
codon
 
This work 
pKW25425T 
pKW254T dksA out of frame TAA before stop 
codon This work 
pKW25427T pKW254T dksA –SD  This work 
pKW25428T pKW254T dksA –SD ATG→AAG This work 
pEQ AAA lucR lucF ATG→AAA (Kimura and Suzuki, 2010) 
pEQ AAG lucR lucF ATG→AAG This study 
pSC333  pGEM3, bla, T
7
::lpp  (Christensen and Gerdes, 
2003) 
pSC334  pGEM3, bla, T
7
::ssrA  (Christensen and Gerdes, 
2003) 
 
Table 5 Oligonucleotides used in this study 
Oligo name Sequence 
VAPC-1_LT2#1 CCCCCGCATGCGAATTCATGCAGAAATTAGCACCAGTCTTC 
VAPC-1_LT2#12 CCCCCGGTACCGGATCCAAAATAAGGAGGAAAAAAAAATGCTGAAATTCATGCTTGATAC 
VAPC-1_SF_#1 CCCCCAAGCTTGAATTCGATTTCTGATGAACAGGTCAGC 
VAPC-1_SF_#2 CCCCCGGTACCGGATCCGCAAGAAAGGGAGTCATTCTGA 
VAPB-1_LT2#1 CCCCCGCATGCGAATTCGCATCAAAATCCTTCCCGTTCC 
VAPB-1_LT2#12 CCCCCGGTACCGGATCCAAAATAAGGAGGAAAAAAAAATGCACACAACACTTTTTTTTAG 
VAPB-1_SF_#1 CCCCCAAGCTTGAATTCCTTCAGCATCAGAATGACTCCC 
VAPB-1_SF_#2 CCCCCGGTACCGGATCCCCACATAAGGAGGCAAATAATG 
VAPBC_LT2#2 CCCCCGAATTCGAATCCGGGGATAACATCTGA 
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VAPBC_LT2#1 CCCCCGGATCCGACAAGGATGCCCTGCGGAG 
VAPB_LT2#HIS61 CCCCCGAATTCAAAATAAGGAGGAAAAAAAAATGCACACAACACTTTTTTTTAG 
VAPB_LT1#HIS62 CCCCCGGATCCCAGCATCAAAATCCTTCCCG 
VAPC_LT2#HIS61 CCCCCGGATCCAAAATAAGGAGGAAAAAAAAATGCATCACCATCACCATCACCTG 
AAATTCATGCTTGATACCAA 
VAPC_LT2#HIS62 CCCCCAAGCTTGCAGAAATTAGCACCAGTCTTC 
TRANSTERM#CCW CCCCGAATTCGATTCAACCCCTTCTTCGATC 
DKSA_UAA1#UP CGAAAAACAGATGTAAGGCTAATTACAGC 
DKSA_UAA1#DOWN GCTGTAATTAGCCTTACATCTGTTTTTCG 
DKSA_UAA2#UP GCGAAAAACAGATTAATGGCTAATTACAG 
DKSA_UAA2#DOWN CTGTAATTAGCCATTAATCTGTTTTTCGC 
DKSA_UAA3#UP CGCGAAAAACAGATAACTGGCTAATTACAG 
DKSA_UAA3#DOWN CTGTAATTAGCCAGTTATCTGTTTTTCGCG 
rplN-3#CCW CGATAACTTCGTCATCACGACGG 
rpsJ-3#CCW2  CCAATCATTGTTTCAACCTCTC 
rrsA-1#up GGTGATCCAACCGCAGGTTCCCCTAC 
rnpB#up AGGTGAAACTGACCGATAAGCCGG 
pKW71D-3#PE GAGGTCATTACTGGATCTATCAAC 
T7/pmoA GGGCCTAATACGACTCACTATAGGGACCAGGTGTTATCTTTCGGAGCGGCCTGCGC 
pmoA-forw CGGCATAAGCCGAAGATATCGG 
dksA probe– f  CAACTTCCCGGACCCGGTAG 
dksA T7 probe- r GGGCCTAATACGACTCACTATAGGGGATGCACAGATCGGCTGTCG 
10SA-2 GCCCCTCGGCATGCATGCACC 
vapB-5#PE GGCAATCTGACTGCCTGGGTCC 
H6-VAPB#SF-DOWN CCCCCGAATTCAAAATAAGGAGGAAAAAAAAATGCATCACCATCACCATCACGAAACCACCGT
ATTTCTCAGCAAC 
H6-VAPB#SF-UP  CCCCCGGATCCCTTCAGCATCAGAATGACTCCC 
VAPB#SF-ECORI-DOWN CCCCCGAATTCAAAATAAGGAGGAAAAAAAAATGGAAACCACCGTATTTCTCAGCAAC 
VAPC#SF-UP    CCCCCAAGCTTGAATTCGATTTCTGATGAACAGGTCAGC 
H6C-down-BamHI-KpnI CCCCCGGATCCGGTACCAAAATAAGGAGGAAAAAAAAATGCTGAAATTCATGCTTGATACCAA
TAC 
H6C-up-HindIII CCCCCAAGCTTCAGAAATTAGTGATGGTGATGGTGATGGCACCAGTCTTCGATTCGGATAC 
VAPC#SF-DOWN CCCCCGGATCCGGTACCAAAATAAGGAGGAAAAAAAAATGCTGAAGTTTATGCTCGATACC 
VAPC-H6#SF-ECORI-
HINDIII-UP 
CCCCCGAATTCAAGCTTGTCAGTGATGGTGATGGTGATGGCTCCAGTCTTCAGTTCTCAG 
 
H6-VapC_SF_Down_N CCCCCGGTACCGGATCCAAAATAAGGAGGAAAAAAAAATGCATCACCATCACCATCAC 
CTGAAGTTTATGCTCGATAC 
H6C-down-D7A CATGCTTGCGACCAATACCTGTATTTTC 
D7A-up-N GTATTGGTCGCAAGCATGAATTTCAG 
H6C-down-D98A GCCTTATGCGCAGATGATTGCTGGC 
H6C-up-D98A CATCTGCGCATAAGGCCCGACAGG 
VapBC_SF_BamHI_Down CCCCCGGATCCGCACATAGTAATTATCCTTGTCG 
VapCpMYSHD7A-up  CAGATGTTGGTCGCGAGCATAAACTTCAGCAT 
VapCpMYSHD7A-down  GTTTATGCTCGCGACCAACATCTGCATTTTTAC 
T7-fMet-tRNA-f CCCCCGGTACCGAATTCGGGCCTAATACGACTCACTATAGACGCGGGGTGGAGCAGCCTG 
T7-fMet-tRNA-rv CCCCCGGATCCAAGCTTAGAAACAAAAAAACACCCGTTAGGGTG 
tRNAVal CCCTCCTTGTAAGGGAGG 
tRNAPhe GACACGGGGATTTTCAATC 
tRNAMet CCATCATTATGAGTGATGTG 
tRNA2Arg TCCGACCGCTCGGTTCGTAGC 
tRNAHis CACGACAACTGGAATCACAATCC 
tRNA1Leu GTAAGGACACTAACACCTGAAGC 
tRNA1Thr TGGGGACCTCACCCTTACCAA 
tRNAFmet CTTCGGGTTATGAGCCCGACGAGCTA 
tRNATyr CAGATTACAGTCTGCTCCCTTTGGCCGCTCGGGAACCCCAC 
Fmet-bio ATGAGTGATGTGCTCTAACCAACTGAG 
FMET-BIO-N CCCGACGAGCTACCAGGCTGCTCCAC 
FMET-BIO-3 GCCGGATTTGAACCGACGACCTTCGG 
dksA-bamHI-sacI#CW CCCCCGGATCCGAGCTCGTCGCGTGCGCAAATACGC 
TRANSTERM#CCW CCCCGAATTCGATTCAACCCCTTCTTCGATC              
dksA 1AAG-cw GTTAAGGAGAAGCAACAAGCAAGAAGGGCAAAAC 
dksA 1AAG-ccw GTTTTGCCCTTCTTGCTTGTTGCTTCTCCTTAAC 
dksA-antiSD-cw CGATAGTGCGTGTTATCCTCAAGCAACATGCAAGAAG 
dksA-antiSD-ccw CTTCTTGCATGTTGCTTGAGGATAACACGCACTATCG 
dksA-antiSD-1AAG-cw CGATAGTGCGTGTTATCCTCAAGCAACAAGCAAGAAG 
dksA-antiSD-1AAG- CTTCTTGCTTGTTGCTTGAGGATAACACGCACTATCG 
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ccw 
pKW71D-3#PE GAGGTCATTACTGGATCTATCAAC 
Fluc_AAG-AfeI-f CCCCCAGCGCTGTAAAGAGGAGAAATTAACCAAGGAAGACGCCAAAAACATAAAG 
Fluc_SphI-r  CCCCCGCATGCGAGAATCTGACGCAGGCAG 
Fmet-bio ATGAGTGATGTGCTCTAACCAACTGAG- TEG biotin 
VAPBC_LT2#1 CCCCCGGATCCGACAAGGATGCCCTGCGGAG 
VAPBC_LT2#2 CCCCCGAATTCGAATCCGGGGATAACATCTGA 
H6B-down-EcoRI CCCCCGAATTCAAAATAAGGAGGAAAAAAAAATGCATCACCATCACCATCACCACACAACACT
TTTTTTTAG 
VAPB_LT1#HIS62 CCCCCGGATCCCAGCATCAAAATCCTTCCCG  
VAPC-1_LT2#12 CCCCCGGTACCGGATCCAAAATAAGGAGGAAAAAAAAATGCTGAAATTCATGCTTGATAC 
VAPC_LT2#HIS62 CCCCCAAGCTTGCAGAAATTAGCACCAGTCTTC  
VAPB_LT2#HIS61 CCCCCGAATTCAAAATAAGGAGGAAAAAAAAATGCACACAACACTTTTTTTTAG 
VAPC_LT2#HIS61 CCCCCGGATCCAAAATAAGGAGGAAAAAAAAATGCATCACCATCACCATCACCTGAAATTCAT
GCTTGATACCAA 
vapBC_down#EcoRI CCCCGAATTCGACAAGGATGCCCTGCGGAG 
vapC-1_LT2up#BamHI CCCCGGATCCATGCAGAAATTAGCACCAGTCTTC 
H6C- down-D7A CATGCTTGCGACCAATACCTGTATTTTC 
D7A-up-N GTATTGGTCGCAAGCATGAATTTCAG 
pOU254_CW TAGGGGTTCCGCGCA 
pOU254_CCW TGTGGGATTAACTGC 
PBC-10_MUT_DOWN ATATACGCGTTGTATGATCAGAAAGGAGGCAGTTATGCAC 
PBC-10_MUT_UP CTGCCTCCTTTCTGATCATACAACGCGTATATCCATTATGAG 
PBC-35_MUT_DOWN GGATTATTTTTTCCTTACTATCTCTTTGACATATACATCGCCTC 
PBC-35_MUT_UP ATATGTCAAAGAGATAGTAAGGAAAAAATAATCCAGTCACATGACG 
VAPC-L40A-f CAGCTCCATCACCGCGATGGAGCTGATTTACGGTGC 
VAPC-L40A-rv GTAAATCAGCTCCATCGCGGTGATGGAGCTGATACAC 
VapC-M41A-f CAGCTCCATCACCTTAGCGGAGCTGATTTACGGTGCTG 
VapC-M41A-rv CACCGTAAATCAGCTCCGCTAAGGTGATGGAGCTGATAC 
VapC-L43A-f CATCACCTTAATGGAGGCGATTTACGGTGCTGAAAAAAG 
VapC-L43A-rv TTTCAGCACCGTAAATCGCCTCCATTAAGGTGATGGAGC 
VAPC-I44A-f CCTTAATGGAGCTGGCGTACGGTGCTGAAAAAAGCCTG 
VAPC-I44A-rv CTTTTTTCAGCACCGTACGCCAGCTCCATTAAGGTGATGG 
VAPC-Y45A-f CTTAATGGAGCTGATTGCGGGTGCTGAAAAAAGCCTGGC 
VAPC-Y45A-rv GCTTTTTTCAGCACCCGCAATCAGCTCCATTAAGGTGATG 
VapC-E48A-f CTGATTTACGGTGCTGCGAAAAGCCTGGCGCCGGAGCG 
VapC-E48A-rv CGGCGCCAGGCTTTTCGCAGCACCGTAAATCAGCTCC 
VapC-K49A-f GATTTACGGTGCTGAAGCGAGCCTGGCGCCGGAGCGTAATC 
VapC-K49A-rv CTCCGGCGCCAGGCTCGCTTCAGCACCGTAAATCAGCTC 
VapC-F72A-f GCCTTGAGGTTTTGGATGCGGATACACAGGCAGCGATAC 
VapC-F72A-rv TCGCTGCCTGTGTATCCGCATCCAAAACCTCAAGGCGG 
VAPC-A76S-f GGATTACGATACACAGTCGGCGATACATACCGGTCAAATC 
VAPC-A76S-rv GACCGGTATGTATCGCCGACTGTGTATCGTAATCCAAAAC 
VAPC-A77S-f TTACGATACACAGGCATCGATACATACCGGTCAAATCCG 
VAPC-A77S-rv TTTGACCGGTATGTATCGATGCCTGTGTATCGTAATCC 
VAPC-I78A-f GATACACAGGCAGCGGCGCATACCGGTCAAATCCGTGC 
VAPC-I78A-rv GATTTGACCGGTATGCGCCGCTGCCTGTGTATCGTAATC 
VapC-R89A-f CCGTGCCGAACTGGCCGCGAAGGGAACACCTGTCGGGCC 
VapC-R89A-rv GACAGGTGTTCCCTTCGCGGCCAGTTCGGCACGGATTTG 
BC_253-ECORI_DOWN CCCCCGAATTCGAGCTGTTGACAATTAATCATCGGCTCGTATAATGTGTGGACGCGTTGTATA
TCCAGAAAGGAGG 
BC_253-BAMHI-UP CCCCCGGATCCGCACCAGTCTTCGATTCGGATAC 
BC_253_PRESTOPB_DOW
N 
GCCAGTACTGATTTTTAAAGTACCAGAGAACAACCCGCAG 
BC_253_PRESTOPB_UP GTTGTTCTCTGGTACTTTAAAAATCAGTACTGGCGCCTTCGC 
BC_253_STARTB _DOWN CAGAAAGGAGGCAGTTAAGCACACAACACTTTTTTTTAGTAACCG 
BC_253_STARTB _UP CTAAAAAAAAGTGTTGTGTGCTTAACTGCCTCCTTTCTGGATATAC 
BC_253_STOPFB_DOWN ACGGGAAGGATTTTATGCTGAAATTCATGCTTGATACC 
BC_253_STOPFB_UP CATGAATTTCAGCATAAAATCCTTCCCGTTCCTGTAC 
BC_253_FUSB_UP CCCCCGGATCCCCGTTCCTGTACTGCGGGTTG 
H6C-down-BamhI-KpnI CCCCCGGATCCGGTACCAAAATAAGGAGGAAAAAAAAATGCTGAAATTCATGCTTGATACCAA
TAC 
VAPBC_T7_DOWN CGGGATCCTGTAATACGACTCACTATAGACGCGTTGTATATCCAGAAAGGAG 
VAPBC_T7_RRNBT1_UP CAAAAAACCCCTCAAGACCCGTTTAGAGGCCCCAAGGGGTTGATAACATCTGATGCAGAAATT
AGCAC 
vapBC_EMSA_down CAGAAGCCATGGGCACATATG 
vapBC_EMSA_up GATTTCGACATGTTTCACATCC 
VapBCbinding#small-
down 
CTCATAATGGATATACGCGTTGTATATCCAGAAAGG 
VapBCbinding#small-
up 
CCTTTCTGGATATACAACGCGTATATCCATTATGAG 
q-vapB-f GCAGTCAGATTGCCTAAATCG 
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q-vapB-rv AAATCAGTACTGGCGCCTTC 
rpsA qPCR-f CTGGGTCTGAAACAGTGCAA 
rpsA qPCR-r TCCAAGCCGATGAAGATACC 
171SR14 GGGGCAGCTGGCGAAAGGGGGATGTGCTGC 
171SR16 GGGGCAGCTGAATTTCACACAGGAAACAGCTA 
 
Strains Constructed 
KW10. The lon gene was deleted from the chromosome of MG1655 by P1 
transduction as described in (Sambrook et al., 1989). Insertion of kanamycin 
resistance cassette (Acquired from KEIO collection strain JW0429) into the correct 
location on the chromosome was confirmed by colony PCR using primers flanking 
the lon gene.  
 
KW11. the clpP gene was deleted from the chromosome of MG1655 by P1 
transduction as described in (Sambrook et al., 1989). Insertion of kanamycin 
resistance cassette (Acquired from KEIO collection strain JW0427) into the correct 
location on the chromosome was confirmed by colony PCR using primers flanking 
the clpP gene. 
Plasmids Constructed 
pKW52. vapCLT2 (STM3033) of S. enterica LT2 amplified by colony PCR with 
primers VAPC-1_LT2#1 and VAPC-1_LT2#12. The PCR product was digested with 
KpnI and SphI and inserted into pBAD33. Cells carrying pKW52 express VapCLT2 
upon addition of arabinose. 
 
pKW82. vapC (mvpT) of S. flexneri 2a strain YSH6000 virulence plasmid 
pMYSH6000 was amplified from purified total DNA of strain YSH6000 with primers 
VAPC-1_SF_#1 and VAPC-1_SF_#2. The PCR product was digested with KpnI and 
HindIII and inserted into pBAD33. Cells carrying pKW82 express VapC upon 
addition of arabinose. 
 
pKW51. vapBLT2 (STM3034) of S. enterica LT2 was amplified by colony PCR with 
primers VAPB-1_LT2#1 and VAPB-1_LT2#12. The PCR product was digested with 
BamHI and EcoRI and inserted into pNDM220. Cells carrying pKW51 express 
VapBLT2 upon addition of IPTG.  
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pKW81. vapB (mvpA) of S .flexneri 2a YSH6000 virulence plasmid pMYSH6000 was 
amplified from purified total DNA of strain YSH6000 with primers VAPB-1_SF_#1 
and VAPB-1_SF_#2. The PCR product was digested with BamHI and EcoRI and 
inserted into pNDM220. Cells carrying pKW81 express VapB upon addition of IPTG.  
 
pKW512. vapBC of S. enterica LT2 was amplified by colony PCR was amplified by 
colony PCR with primers VAPBC_LT2#1 and VAPBC_LT2#2. The PCR product 
was digested with BamHI and EcoRI and inserted into pRBJ200. Cells carrying 
pKW512 contains vapBCLT2 transcriptional fused to lacZYA. 
 
pKW3352HC. vapCLT2 (STM3033)-encoding DNA was synthesized by PCR using S. 
enterica LT2 template DNA and primers H6C-down-BamHI-KpnI and H6C-up-
HindIII. The resulting PCR product was digested with KpnI and HindIII and ligated 
into pBAD33. The resulting plasmid expresses C-terminal His-tagged (Six histidine 
residues) VapCLT2 upon addition of arabinose 
 
pKW3353HC. Two parts of vapCLT2 was PCR amplified from a pKW3352HC 
template using primers H6C-down-BamHI-KpnI and D7A-up-N, and primers H6C-
up-HindIII and H6C- down-D7A. The resulting two overlapping PCR products were 
used as templates in an additional amplification using primers primers H6C-down-
BamhI-KpnI and primers H6C-up-HindIII. The resulting PCR product was digested 
with KpnI and HindIII and ligated into pBAD33. The resulting plasmid expresses C-
terminal His-tagged VapCLT2 with Aspartate at +7 changed to Alanine upon addition 
of arabinose. 
 
pKW3354HC. Two parts of vapCLT2 was PCR amplified from a pKW3352HC 
template using primers H6C-down-BamHI-KpnI and H6C-up-D98A, and primers 
H6C-up-HindIII and H6C-down-D98A. The resulting two overlapping PCR products 
were used as templates in an additional amplification using primers primers H6C-
down-BamhI-KpnI and primers H6C-up-HindIII. The resulting PCR product was 
digested with KpnI and HindIII and ligated into pBAD33. The resulting plasmid 
expresses C-terminal His-tagged VapCLT2 with Aspartate at +98 changed to Alanine 
upon addition of arabinose. 
 
 132 
pKW3382HC. vapC (mvpT) of S. flexneri 2a strain YSH6000 virulence 
plasmid pMYSH6000 was amplified using strain YSH6000 DNA as a template with 
primers VAPC#SF-DOWN and VAPC-H6#SF-ECORI-HINDIII-UP. The PCR 
product was digested with KpnI and HindIII and inserted into pBAD33. Cells carrying 
pKW3382HC express C-terminal His-tagged (six histidine residues) VapC upon 
addition of arabinose. 
 
pKW3221. metV of E. coli K-12 was amplified from chromosomal DNA using 
primers T7-fMet-tRNA-f and T7-fMet-tRNA-rv. The resulting PCR product was 
digested with EcoRI and BamHI and ligated into pBR322. C41 (DE3) carries the T7 
RNA polymerase gene under plac control and C41 cells containing pKW3221 
therefore express tRNA
fMet
 upon addition of IPTG. 
 
pKW254812. vapBC (mvpT) of S. flexneri 2a strain YSH6000 virulence plasmid 
pMYSH6000 was amplified using strain YSH6000 DNA as a template with primers 
VAPC#SF-UP and VapBC_SF_BamHI_Down. The PCR product was digested with 
BamHI and EcoRI and inserted into pOU254. Cells carrying pKW254812 express 
vapBC from its native promoter. 
 
pKW254813. Two parts of vapBC were PCR amplified from a pKW254812 template 
using primers VapBC_SF_BamHI_Down and VapCpMYSHD7A-up, and VAPC#SF-
UP and VapCpMYSHD7A-down. The resulting two overlapping PCR products were 
used as templates in an additional amplification reaction using primers 
VapBC_SF_BamHI_Down and primer VAPC#SF-UP. The resulting PCR product 
was digested with BamHI and EcoRI and ligated into pOU254. Cells carrying 
pKW254813 express vapBC from its native promoter with VapC having an Aspartate 
at +7 changed to Alanine. 
 
pQE AAG. The Firefly luciferase gene (lucF) was amplified from purified plasmid 
pQE ATG with primers Fluc_AAG-AfeI-f and Fluc_SphI-r. The PCR product was 
then digested with AfeI and SphI and inserted into similarily digested pQE ATG. Cells 
carrying pQE AAG contains the dual luciferase plasmid with a start-codon 
substitution in lucF. 
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pKW25420T. The dksA gene of E. coli K-12 was amplified from chromosomal DNA 
with primers dksA-bamH1-sacI#CW and dksA-pmlI-xhoI#CCW. The PCR product 
was digested with BamH1 and XhoI and inserted into pKW254T. Cells carrying 
pKW25420T express dksA.  
 
pKW25421T. Two parts of the dksA gene of E. coli K-12 were amplified from 
purified pKW25420T with primers dksA-bamH1-sacI#CW and dksA 1AAG-ccw in 
addition to dksA 1AAG-cw and TRANSTERM#CCW. The two overlapping PCR 
products were used as a template in a second amplification with primers dksA-
bamHI-sacI#CW and TRANSTERM#CCW. The product was digested with BamHI 
and EcoRI and inserted into pOU254. Cells carrying pKW25421T express dksA 
mRNA with the start codon changed to AAG. 
 
pKW25423T. Two parts of the dksA gene of E. coli K-12 was amplified from purified 
pKW25420T with primers dksA-bamH1-sacI#CW and DKSA_UAA1#DOWN in 
addition to DKSA_UAA1#UP and TRANSTERM#CCW. These two overlapping 
PCR products were used as template in a second amplification with primers dksA-
bamH1-sacI#CW and TRANSTERM#CCW. The product was digested with BamHI 
and EcoRI and inserted into pOU254. Cells carrying pKW25423T express dksA with 
an in-frame UAA substitution and translation will terminate incorrectly.  
 
pKW25424T. Two parts of the dksA gene of E. coli K-12 was amplified from purified 
pKW25420T with primers dksA-bamH1-sacI#CW and DKSA_UAA2#DOWN in 
addition to DKSA_UAA2#UP and TRANSTERM#CCW. These two overlapping 
PCR products were used as template in a second amplification with primers dksA-
bamH1-sacI#CW and TRANSTERM#CCW. The product was digested with BamHI 
and EcoRI and inserted into pOU254. Cells carrying pKW25424T express dksA with 
an out-of frame UAA substitution and translation will terminate correctly.  
 
pKW25425T. Two parts of the dksA gene of E. coli K-12 was amplified from purified 
pKW25420T with primers dksA-bamH1-sacI#CW and DKSA_UAA3#DOWN in 
addition to DKSA_UAA3#UP and TRANSTERM#CCW. These two overlapping 
PCR products were used as template in a second amplification with primers dksA-
bamH1-sacI#CW and TRANSTERM#CCW. The product was digested with BamHI 
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and EcoRI and inserted into pOU254. Cells carrying pKW25425T express dksA with 
an out-of frame UAA substitution and translation will terminate correctly.  
 
pKW25427T. Two parts of the dksA gene of E. coli K-12 was amplified from purified 
pKW25420T with primers dksA-bamHI-sacI#CW and dksA-antiSD-ccw in addition 
to dksA-antiSD-cw and TRANSTERM#CCW. The two overlapping PCR products 
were used as a template in a second amplification with primers dksA-bamHI-
sacI#CW and TRANSTERM#CCW. The product was digested with BamHI and 
EcoRI and inserted into pOU254. Cells carrying pKW25427T express dksA mRNA 
with an inverted SD sequence. 
  
pKW25428T. Two parts of the dksA gene of E. coli K-12 was amplified from purified 
pKW25420T with primers dksA-bamHI-sacI#CW and dksA-antiSD-1AAG-ccw in 
addition to dksA-antiSD-1AAG-cw and TRANSTERM#CCW. The two overlapping 
PCR products were used as a template in a second amplification with primers dksA-
bamHI-sacI#CW and TRANSTERM#CCW. The product was digested with BamHI 
and EcoRI and inserted into pOU254. Cells carrying pKW25428T express dksA 
mRNA with an inverted SD sequence and the AUG start-codon changed to AAG. 
 
pKW71512. A DNA fragment containing vapBC from S. enterica LT2 was generated 
using primers VAPBC_LT2#1 and VAPBC_LT2#2. The PCR product was digested 
with BamHI and EcoRI and inserted in pNDM71, a mini R1cloning vector. 
pKW71512 contain vapBCLT2 under transcriptional control of its native promoter. 
 
pKW512HB. Two PCR products containing either vapB or vapC from S. enterica 
LT2 was generated using primers H6B-down-EcoRI and VAPB_LT1#HIS62 or 
VAPC-1_LT2#12 and VAPC_LT2#HIS62, respectively. PCR product containing 
vapBLT2 was digested with EcoRI and BamHI and PCR product containing vapCLT2 
was digested with BamHI and HindIII. The digests were then inserted into pMG25. 
pKW512HB produces VapBLT2 with a N-terminal tag of six histidines and VapCLT2 
upon addition of IPTG. 
 
pKW512HC. Two PCR products containing either vapB or vapC from S. enterica 
LT2 was generated using primers VAPB_LT2#HIS61 and VAPB_LT1#HIS62 or 
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VAPC_LT2#HIS61 and VAPC_LT2#HIS62, respectively. PCR product containing 
vapBLT2 was digested with EcoRI and BamHI and PCR product containing vapCLT2 
was digested with BamHI and HindIII. The digests were then inserted into pMG25. 
pKW512HC produces VapCLT2 with an N-terminal tag of six histidines and VapBLT2 
upon addition of IPTG. 
 
pKW812HB. Two PCR products, one encoding vapB and one encoding vapC were 
amplified from S. flexneri strain YSH6000 DNA as template and primers H6-
VAPB#SF-DOWN and H6-VAPB#SF-UP, and VAPC#SF-UP and VAPC#SF-
DOWN . The resulting PCR product containing vapB was digested with EcoRI and 
BamHI, whereas the PCR product containing vapC was digested with BamHI and 
HindIII. The products were ligated into pMG25, a pUC-derived vector that carries 
lacI
q
 and the synthetic LacI-regulated pA1/O3/O4 promoter. Cells containing 
pKW812HB express N-terminal His-tagged VapB and native VapC upon addition of 
IPTG. 
 
pKW812HC. Two PCR products, one containing vapB and one containing vapC were 
amplified from S. flexneri strain YSH6000 DNA as template and primers VAPB#SF-
ECORI-DOWN and H6-VAPB#SF-UP, and VAPC#SF-UP and H6-
VapC_SF_Down_N. The resulting PCR product encoding vapB was digested with 
EcoRI and BamHI, whereas the PCR product encoding vapC was digested with 
BamHI and HindIII. Digested products were ligated into pMG25. Cells containing 
pKW812HC express VapB and N-terminal His-tagged VapC upon addition of IPTG. 
 
pKW512TFZD7A. Two PCR products were generated using primers 
vapBC_down#EcoRI and D7A-up-N or vapBC-1LT2up#BamHI and H6C- down-
D7A using S. enterica LT2 as DNA template. The resulting products were then used 
as templates in a second round of PCR using primers vapBC_down#EcoRI and 
vapBC-1LT2up#BamHI. The PCR product was then digested with EcoRI and BamHI 
and inserted into pOU254. pKW512TFZD7A contains non-toxic vapBC
D7A
 in a 
transcriptional fusion to lacZYA. 
 
pKW512TFZD7A-1. Two PCR products were generated using primers pOU254_CW 
and PBC-10_MUT_UP, or PBC-10_MUT_DOWN and pOU254_CCW using 
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pKW512TFZD7A as template. Overlapping PCR products were then used as 
templates in a second round of PCR with primers pOU254_CW and pOU254_CCW. 
The PCR product was digested with BamHI and EcoRI and inserted in pOU254. 
pKW512TFZD7A-1 contains non-toxic vapBCLT2
D7A
 in a transcriptional fusion with 
lacZYA with ATC for GAT substitution mutation in promoter 
 
pKW512TFZD7A-2. Two PCR products were generated using primers pOU254_CW 
and PBC-35_MUT_UP, or PBC-35_MUT_DOWN and pOU254_CCW using 
pKW512TFZD7A as template. Overlapping PCR products were then used as 
templates in a second round of PCR with primers pOU254_CW and pOU254_CCW. 
The PCR product was digested with BamHI and EcoRI and inserted in pOU254. 
pKW512TFZD7A-2 contains non-toxic vapBCLT2
D7A
 in a transcriptional fusion with 
lacZYA with GTA for TAC substitution mutation in promoter 
 
pKW512TFZD7A-1-2. Two PCR products were generated using primers 
pOU254_CW and PBC-10_MUT_UP, or PBC-10_MUT_DOWN and pOU254_CCW 
using pKW512TFZD7A-2 as template. Overlapping PCR products were then used as 
templates in a second round of PCR with primers pOU254_CW and pOU254_CCW. 
The PCR product was digested with BamHI and EcoRI and inserted in pOU254. 
pKW512TFZD7A-1-2 contains non-toxic vapBCLT2
D7A
 in a transcriptional fusion 
with lacZYA with GTA for TAC  and ATC for GAT substitution mutation in promoter 
 
pKW254BC. A DNA fragment containing vapBC from S. enterica LT2 was generated 
using primers vapBC_down#EcoRI and vapC-1_LT2up#BamHI. The PCR product 
was digested with BamHI and EcoRI and inserted in pOU254. pKW254BC contains 
vapBCLT2 in a transcriptional fusion with lacZYA. 
 
pKW254BCL40A. Two PCR products were generated using primers 
vapBC_down#EcoRI and VAPC-L40A-rv or vapC-1_LT2up#BamHI 
and VAPC-L40A-f using S. enterica LT2 as DNA template. The resulting products 
were then used as templates in a second round of PCR using primers 
vapBC_down#EcoRI and vapC-1_LT2up#BamHI. The PCR product was then 
digested with EcoRI and BamHI and inserted into pOU254. pKW254BCL40A 
contains vapBCLT2
L40A
 in a transcriptional fusion to lacZYA. 
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pKW254BCM41A. Two PCR products were generated using primers 
vapBC_down#EcoRI and VAPC-M41A-rv or vapC-1_LT2up#BamHI and VAPC-
M41A-f using S. enterica LT2 as DNA template. The resulting products were then 
used as templates in a second round of PCR using primers vapBC_down#EcoRI and 
vapC-1_LT2up#BamHI. The PCR product was then digested with EcoRI and BamHI 
and inserted into pOU254. pKW254BCM41A contains vapBCLT2
M41A
 in a 
transcriptional fusion to lacZYA. 
 
pKW254BCL43A. Two PCR products were generated using primers 
vapBC_down#EcoRI and VAPC-L43A-rv or vapC-1_LT2up#BamHI and VAPC-
L43A-f using S. enterica LT2 as DNA template. The resulting products were then 
used as templates in a second round of PCR using primers vapBC_down#EcoRI and 
vapC-1_LT2up#BamHI. The PCR product was then digested with EcoRI and BamHI 
and inserted into pOU254. pKW254BCL43A contains vapBCLT2
L43A
 in a 
transcriptional fusion to lacZYA. 
 
pKW254BCI44A. Two PCR products were generated using primers 
vapBC_down#EcoRI and VAPC-I44A-rv or vapC-1_LT2up#BamHI and VAPC-
I44A-f using S. enterica LT2 as DNA template. The resulting products were then used 
as templates in a second round of PCR using primers vapBC_down#EcoRI and vapC-
1_LT2up#BamHI. The PCR product was then digested with EcoRI and BamHI and 
inserted into pOU254. pKW254BCI44A contains vapBCLT2
I44A
 in a transcriptional 
fusion to lacZYA. 
 
pKW254BCY45A. Two PCR products were generated using primers 
vapBC_down#EcoRI and VAPC-Y45A-rv or vapC-1_LT2up#BamHI and VAPC-
Y45A-f using S. enterica LT2 as DNA template. The resulting products were then 
used as templates in a second round of PCR using primers vapBC_down#EcoRI and 
vapC-1_LT2up#BamHI. The PCR product was then digested with EcoRI and BamHI 
and inserted into pOU254. pKW254BCY45A contains vapBCLT2
Y45A
 in a 
transcriptional fusion to lacZYA. 
 
 138 
pKW254BCE48A. Two PCR products were generated using primers 
vapBC_down#EcoRI and VAPC-E48A-rv or vapC-1_LT2up#BamHI and VAPC-
E48A-f using S. enterica LT2 as DNA template. The resulting products were then 
used as templates in a second round of PCR using primers vapBC_down#EcoRI and 
vapC-1_LT2up#BamHI. The PCR product was then digested with EcoRI and BamHI 
and inserted into pOU254. pKW254BCE48A contains vapBC
E48A
 in a transcriptional 
fusion to lacZYA. 
 
pKW254BCK49A. Two PCR products were generated using primers 
vapBC_down#EcoRI and VAPC-K49A-rv or vapC-1_LT2up#BamHI and VAPC-
K49A-f using S. enterica LT2 as DNA template. The resulting products were then 
used as templates in a second round of PCR using primers vapBC_down#EcoRI and 
vapC-1_LT2up#BamHI. The PCR product was then digested with EcoRI and BamHI 
and inserted into pOU254. pKW254BCK49A contains vapBC
K49A
 in a transcriptional 
fusion to lacZYA. 
 
pKW254BCY72A. Two PCR products were generated using primers 
vapBC_down#EcoRI and VAPC-Y72A-rv or vapC-1_LT2up#BamHI and VAPC-
Y72A-f using S. enterica LT2 as DNA template. The resulting products were then 
used as templates in a second round of PCR using primers vapBC_down#EcoRI and 
vapC-1_LT2up#BamHI. The PCR product was then digested with EcoRI and BamHI 
and inserted into pOU254. pKW254BCY72A contains vapBC
Y72A
 in a transcriptional 
fusion to lacZYA. 
 
pKW254BCA76S. Two PCR products were generated using primers 
vapBC_down#EcoRI and VAPC-A76S-rv or vapC-1_LT2up#BamHI and VAPC-
A76S-f using S. enterica LT2 as DNA template. The resulting products were then 
used as templates in a second round of PCR using primers vapBC_down#EcoRI and 
vapC-1_LT2up#BamHI. The PCR product was then digested with EcoRI and BamHI 
and inserted into pOU254. pKW254BCA76S contains vapBC
A76S
 in a transcriptional 
fusion to lacZYA. 
 
pKW254BCA77S. Two PCR products were generated using primers 
vapBC_down#EcoRI and VAPC-A77S-rv or vapC-1_LT2up#BamHI and VAPC-
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A77S-f using S. enterica LT2 as DNA template. The resulting products were then 
used as templates in a second round of PCR using primers vapBC_down#EcoRI and 
vapC-1_LT2up#BamHI. The PCR product was then digested with EcoRI and BamHI 
and inserted into pOU254. pKW254BCA77S contains vapBCLT2
A77S
 in a 
transcriptional fusion to lacZYA. 
 
pKW254BCI78A. Two PCR products were generated using primers 
vapBC_down#EcoRI and VAPC-I78A-rv or vapC-1_LT2up#BamHI and VAPC-
I78A-f using S. enterica LT2 as DNA template. The resulting products were then used 
as templates in a second round of PCR using primers vapBC_down#EcoRI and vapC-
1_LT2up#BamHI. The PCR product was then digested with EcoRI and BamHI and 
inserted into pOU254. pKW254BCI78A contains vapBCLT2
I78A
 in a transcriptional 
fusion to lacZYA. 
 
pKW254BCR89A. Two PCR products were generated using primers 
vapBC_down#EcoRI and VAPC-R89A-rv or vapC-1_LT2up#BamHI and VAPC-
R89A-f using S. enterica LT2 as DNA template. The resulting products were then 
used as templates in a second round of PCR using primers vapBC_down#EcoRI and 
vapC-1_LT2up#BamHI. The PCR product was then digested with EcoRI and BamHI 
and inserted into pOU254. pKW254BCR89A contains vapBCLT2
R89A
 in a 
transcriptional fusion to lacZYA. 
 
pKW253-1. A DNA fragment containing vapBC from S. enterica LT2 was generated 
using primers BC_253-ECORI_DOWN and BC_253-BAMHI-UP using 
pKW512TFZD7A as template. The PCR product was digested with BamHI and 
EcoRI and inserted in pOU253. pKW253-1 contains vapBCLT2
D7A
 with a ptac promoter 
in a translational fusion with lacZYA. 
 
pKW253-2. Two PCR products were generated using primers BC_253-
ECORI_DOWN and BC_253_PRESTOPB_UP or BC_253-BAMHI-UP and 
BC_253_PRESTOPB_DOWN using pKW512TFZD7A as template. The resulting 
products were then used as templates in a second round of PCR using primers 
BC_253-ECORI_DOWN and BC_253-BAMHI-UP. The PCR product was then 
digested with EcoRI and BamHI and inserted into pOU253. pKW253-2 contains 
 140 
vapBCLT2
D7A
 with a premature termination codon in vapBLT2 in a translational fusion 
with lacZYA under the control of a constitutive ptac promoter. 
 
pKW253-3. Two PCR products were generated using primers BC_253-
ECORI_DOWN and BC_253_STARTB _UP or BC_253-BAMHI-UP and 
BC_253_STARTB _DOWN using pKW512TFZD7A as template. The resulting 
products were then used as templates in a second round of PCR using primers 
BC_253-ECORI_DOWN and BC_253-BAMHI-UP. The PCR product was then 
digested with EcoRI and BamHI and inserted into pOU253. pKW253-3 contains 
vapBCLT2
D7A
 with a start codon mutation in vapBLT2 in a translational fusion with 
lacZYA under the control of a constitutive ptac promoter. 
 
pKW253-4. Two PCR products were generated using primers BC_253-
ECORI_DOWN and BC_253_STOPFB_UP or BC_253-BAMHI-UP and 
BC_253_STOPFB_DOWN using pKW512TFZD7A as template. The resulting 
products were then used as templates in a second round of PCR using primers 
BC_253-ECORI_DOWN and BC_253-BAMHI-UP. The PCR product was then 
digested with EcoRI and BamHI and inserted into pOU253. pKW253-4 contains 
vapBCLT2
D7A
 with a frameshift  mutation in vapBLT2 in a translational fusion with 
lacZYA under the control of a constitutive ptac promoter. 
 
pKW253-5. A DNA fragment containing vapB from S. enterica LT2 was generated 
using primers BC_253-ECORI_DOWN and BC_253_FUSB_UP using 
pKW512TFZD7A as template. The PCR product was digested with BamHI and 
EcoRI and inserted in pOU253. pKW253-5 contains vapBLT2 with a ptac promoter in a 
translational fusion with lacZYA.  
 
pKW512HBL43A. A PCR product containing vapC from S. enterica LT2 was 
generated using primers H6C-down-BamhI-KpnI and VAPC_LT2#HIS62 using 
pKW254BCL43A as template. PCR product containing vapC
L43A
 was digested with 
BamHI and HindIII and inserted into BamHI and HindIII digested pKE512HB. 
pKW512HBL43A produces VapBLT2 with a N-terminal tag of six histidines and 
VapCLT2
L43A
 upon addition of IPTG. 
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pKW512HBI44A. A PCR product containing vapC from S. enterica LT2 was 
generated using primers H6C-down-BamhI-KpnI and VAPC_LT2#HIS62 using 
pKW254BCI44A as template. PCR product containing vapC
I44A
 was digested with 
BamHI and HindIII and inserted into BamHI and HindIII digested pKE512HB. 
pKW512HBI44A produces VapBLT2 with a N-terminal tag of six histidines and 
VapCLT2
I44A
 upon addition of IPTG. 
 
pKW512HBY72A. A PCR product containing vapC from S. enterica LT2 was 
generated using primers H6C-down-BamhI-KpnI and VAPC_LT2#HIS62 using 
pKW254BCY72A as template. PCR product containing vapC
Y72A
 was digested with 
BamHI and HindIII and inserted into BamHI and HindIII digested pKE512HB. 
pKW512HBY72A produces VapBLT2 with a N-terminal tag of six histidines and 
VapCLT2
Y72A
 upon addition of IPTG. 
 
pKW512HBA76S. A PCR product containing vapC from S. enterica LT2 was 
generated using primers H6C-down-BamhI-KpnI and VAPC_LT2#HIS62 using 
pKW254BCA76S as template. PCR product containing vapC
A76S
 was digested with 
BamHI and HindIII and inserted into BamHI and HindIII digested pKE512HB. 
pKW512HBA76S produces VapBLT2 with a N-terminal tag of six histidines and 
VapCLT2
A76S
 upon addition of IPTG. 
 
pKW3352L43A. A PCR product containing vapC from S. enterica LT2 was 
generated using primers VAPC-1_LT2#12 and VAPC_LT2#HIS62 using 
pKW254BCL43A as template. PCR product containing vapCLT2
L43A
 was digested 
with kpnI and HindIII and inserted into pBAD33 pKW3352L43A produces 
VapCLT2
L43A
 upon addition of arabinose. 
 
pKW3352I44A. A PCR product containing vapC from S. enterica LT2 was generated 
using primers VAPC-1_LT2#12 and VAPC_LT2#HIS62 using pKW254BCI44A as 
template. PCR product containing vapCLT2
I44A
 was digested with kpnI and HindIII and 
inserted into pBAD33. pKW3352I44A produces VapCLT2
I44A
 upon addition of 
arabinose. 
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pKW3352Y72A. A PCR product containing vapC from S. enterica LT2 was 
generated using primers VAPC-1_LT2#12 and VAPC_LT2#HIS62 using 
pKW254BCY72A as template. PCR product containing vapCLT2
Y72A
 was digested 
with kpnI and HindIII and inserted into pBAD33. pKW3352Y72A produces 
VapCLT2
Y72A
 upon addition of arabinose. 
 
pKW3352A76S. A PCR product containing vapC from S. enterica LT2 was generated 
using primers VAPC-1_LT2#12 and VAPC_LT2#HIS62 using pKW254BCA76S as 
template. PCR product containing vapCLT2
A76S
 was digested with kpnI and HindIII 
and inserted into pBAD33. pKW3352A76S produces VapCLT2
A76S
 upon addition of 
arabinose. 
 
pKW3352I78A. A PCR product containing vapC from S. enterica LT2 was generated 
using primers VAPC-1_LT2#12 and VAPC_LT2#HIS62 using pKW254BCI78A as 
template. PCR product containing vapCLT2
I78A
 was digested with kpnI and HindIII and 
inserted into pBAD33. pKW3352I78A produces VapCLT2
I78A
 upon addition of 
arabinose. 
Rates-of protein, RNA and DNA synthesis 
Cells were grown in AB minimal at 37ºC supplemented with 0.5% glycerol and 1X 
FN18 amino acid mix (For 200mL 20x FN18 mix, 0.710g Ala, 0.700g Arg, 0.310g 
His, 0.580g His, 0.580g His, 0.580g Lys, 0.460g Pro, 0.480g Thr, 0.600g Gly, 0.530g 
Asn, 0.870 Gln, 0.520g Iso, 0.240g Phe, 0.360g Tyr, 0.700g Val, 0.530g Asp, 0.880 
Glu, 0.120 Cys, 10g Ser, 0.200 Trp) to an optical density OD450= 0.5. Cultures were 
the diluted to OD450 of 0.05 and at an OD450 of 0.3 cultures were induced by adding 
0.2% arabinose. Samples of 0.5 mL were taken out at time points 0, 5, 10, 30, 60 min 
and added to preheated  5 Ci of [35S]methionine (protein synthesis), 2 Ci 
[
3
H]uridine (RNA synthesis) or 2 Ci [methyl-3H]thymidine (DNA synthesis). After 1 
min of pulse incorporation, samples were chased for 10 min with 0.5 mg cold 
methionine, 0.5 mg uridine or 0.5 mg thymidine, respectively. Protein, RNA and 
DNA was precipitated by addition of 100 L ice-cold 40% trichloracetic acid (TCA) 
and centrifuged at 14.300 rpm for 30 min at 4ºC. Samples were then washed twice in 
cold 96% ethanol. Precipitates were transferred to scintillations vials and the amount 
of radioactivity incorporated counted in a liquid scintillation counter. 
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RNA purification 
Cells were grown in LB at 37ºC. At an OD450 of 0.5 the cultures were diluted an OD 
of 0.05 and grown to an OD of 0.5 and transcription of the toxin was induced by 
appropriate inducer. Translation was inhibited by adding 50g/mL chloramphenicol. 
15 mL samples were taken at appropriate time points (see text) and immediately 
cooled, harvested and stored at -80ºC. 
Total RNA purification 
Sample cell pellets were resuspended in 200 L ice cold solution 1 [0.3 M sucrose, 
0.01 M Na-Ac (pH 4.5)] and transferred to 1.5 mL microfuge tubes containing 200 L 
solution 2 [2% SDS, 0.01 M Na-Ac (pH 4.5)]. 400L of RNA phenol [saturated with 
0.03M Na-Ac (pH 4.5), 0.1% 8-hydroxyquinoline] is then added to the cell 
suspension and it is heated at 65ºC for 3 min. The solution was then frozen in liquid 
nitrogen for 15 s and spun at max-speed for 5 min. at room temperature. The aqueous 
phase is transferred into a new microfuge tube and extraction is repeated. The 
extraction is completed by addition of 200 L phenol and 200 L chloroform. The 
RNA was then precipitated ON in 900 L 96% ethanol and 80 L 1.5 M K-Ac (pH 
4.8). In the final step the precipitated RNA was pelleted by centrifugation at 20.000 g 
for 20 min at 4 ºC and washed with 70% ethanol. The RNA was then dried in a speed-
vac for 5 min and resuspended in appropriate amounts of TE-buffer (10 mM Tris-HCl 
and 1 mM EDTA, pH 8) or nuclease free dH2O. Alternatively, total RNA was purified 
using the RNAeasy
®
 minprep kit (Qiagen) according to manufactures instructions. 
The RNA was then quantified at OD260 and the quality checked by agarose gel 
electrophoresis and ethidium bromide (EtBr) staining 
tRNA purification 
Total tRNA was purified according to (Varshney et al., 1991). Cell pellets of 10 mL 
samples were resuspend 0.3 ml of 0.3 M Na-Ac (pH 4.5) and 10 mM Na2EDTA, 
transferred to 1.5-ml Eppendorf tubes, and subjected to two extractions with equal 
volumes of phenol. The aqueous layer was transferred to new 
tubes, mixed with 2.5 volumes of ethanol, and left on ice for 1-2 h. Total nucleic acids 
were recovered by centrifugation for 15 min. The pellet was dissolved in 60 µL of 0.3 
M Na-Ac (pH 4.5). Nucleic acids were re-precipitated with 2.5 volumes of ethanol, 
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left on ice for 2-3 h, and recovered by centrifugation for 15 min. The pellet was 
dissolved in 20 µl of 10 mM Na-Ac (pH 4.5) and 1 mM 
Na,EDTA. The RNA was then quantified at OD260 and the quality checked by agarose 
gel electrophoresis and EtBr staining. 
Preparation of VapC and VapB 
VapC and VapCLT2 was purified from complex with N-terminal His-tagged VapB 
essentially as described for RelE (Pedersen et al., 2002) with some modifications. 
Strain C41 containing either pKW512HB (h6-vapBLT2-vapCLT2) or pKW812HB (h6-
vapB-vapC) were grown under aeration in LB at 37ºC. At OD450 = 0.5 expression was 
induced by addition of 2 mM IPTG. After 3 h of growth, the cultures were harvested 
and resuspended in ice-cold lysis buffer (50mM  NaH2PO4, 0.3M NaCl, 10mM 
imidazole, 5mM β-mercaptoethanol pH8 supplemented with EDTA-free protease 
inhibitor, Roche). Cells were disrupted using a Constant Cell disruption system and 
lysate cleared by centrifugation at 15,000 rpm for 30 min at 4ºC. The cleared lysates 
were then incubated with Ni-NTA agarose (Qiagen) for at least 2 h at 4ºC and 
subsequently loaded onto a gravity column. The columns were then washed 
extensively in wash buffer (50mM NaH2PO4, 0.3M NaCl, 35mM imidazole, 5mM β-
mercaptoethanol pH8). VapCLT2 or VapC could then be separated and isolated from 
VapBC complex under denaturing conditions by incubating the column overnight 
(ON) at room-temperature in 10 column volumes of denaturing buffer (100mM   
NaH2PO4, 10mM Tris-HCl, 9.8M Urea, pH8). Denatured protein was collected 
refolded by four step dialysis; (1) 1 x PBS 0.1% Triton X-100 5mM DTT, (2) 1 x PBS 
5mM DTT, (3) 1 x PBS 5mM DTT, and (4) 1 X PBS 20% glycerol 5 mM DTT. The 
authenticity and purity analysed by SDS-PAGE. VapBLT2, VapB or VapCLT2 mutants 
were purified in a similar way using strain C41 carrying pKW512HC (vapBLT2-h6-
vapCLT2), pKW812HC (vapB-h6-vapC), pKW512HBL43A (h6-vapBLT2- 
vapCLT2
L43A
), pKW512HBI44A (h6-vapBLT2- vapCLT2
I44A
), pKW512HBA76S (h6-
vapBLT2- vapCLT2
A76S
) and pKW512HBY72A (h6-vapBLT2- vapCLT2
Y72A
). 
Inhibition of in vitro translation extract 
Purified VapC was tested for inhibition of MS2 RNA translation in a cell-free E. coli 
S30 in vitro translation Extract (Promega).  
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VapC activity assay 
Each reaction contained the following: 6 μL Premix, 4.5 μL S30 Extract, 1.5 μL 
amino acid mix without methionine, 0.5 μL 35S-methionine and 4.5 pmol VapC with 
and without pre-incubation with 30 pmol VapB. The reaction was incubated for 5 min 
at 37ºC before addition of 1 μL MS2 RNA (~0.7 pmol) (Roche). The reactions were 
incubated for 1 h at 37ºC before termination of the reaction by acetone precipitation. 
The protein products were separated on a 12% SDS-PAGE and visualised by 
phosphor imaging. 
Resuming translation in a VapC inhibited extract 
Each reaction contained the following: 20 μL Premix, 15 μL S30 Extract, 5 μL amino 
acid mix without methionine, and with 9 pmol VapC or storage buffer. The reaction 
was incubated for 5 min at 37ºC before addition of either VapB (~60 pmol) or storage 
buffer. The incubation was continued for 5 min at 37ºC. Finally, 2 μL MS2 RNA 
(~1.4 pmol, Roche) template was added together with 1µL 
35
S-methionine with or 
without 8 pmol of fMet-tRNA
fMet
 (A generous gift from Daniel Castro-Roa, Nikolay 
Zenkin‟ lab, Newcastle University) and incubation was continued for 10 min at 37ºC. 
A 20 μL sample was taken and reaction terminated by acetone precipitation. The 
proteins synthesized by the in vitro translation reactions were separated on a 12% 
SDS-PAGE gel and visualised by phosphor imaging. 
In vitro RNA cleavage analysis 
VapC tRNase activity was tested in vitro by incubating 2.5 pmol or 5 pmol of purified 
VapC with 2 pmol of purified tRNA
fMet
, tRNA
Val
 or tRNA
Phe
 (Sigma-Aldrich) in 
cleavage buffer (10 mM HEPES pH7.5, 15 mM KCl, 3 mM MgCl2 and a final 
glycerol concentration of 10%.) for 15 min at 37ºC. VapC activity was counteracted 
by either pre-incubation with 30 pmol of VapB or by addition of 12.5mM of EDTA. 
Reactions were stopped by the addition of formamide buffer (FD, 10mL Formamide, 
0.1 mM EDTA, 0.1% xylene cyanol, 0.1% bromphenol blue) and tRNAs could be 
separated by 8% PAGE (1:37.5) containing 8M Urea in 1 x TBE (for 1L 5 x TBE 
stock; 54g Tris, 27.5g boric acid and 20 mL 0.5M EDTA pH 8) and subsequent 
Ethidium bromide (EtBr) staining. 
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In vitro cleavage site mapping 
The cleavage site of VapC was identified by incubation with either 5‟-end or 3‟-end 
radio-labelled tRNA
fMet. 5‟-end labelling was achieved by phosphorylating 
dephosphorylated tRNA
fMet
 using T4 polynucleotide kinase (NEB) and [γ-
32
P]-ATP, 
whereas 3‟-end labelling of tRNAfMet was achieved by ligation of radiolabelled pCp 
using T4 RNA ligase (NEB). A hydroxyl ladder was created by incubating 1 pmol of 
tRNA
fMet
 in ladder buffer (50 mM NaCO3 pH9.2, 1mM EDTA) for 5 min at 95ºC. An 
RNase T1 ladder was created by incubating 1 pmol tRNA
fMet
 with 4U of RNase T1 
(Fermentas) for 3 min at 37ºC in RNase T1 buffer (50 mM Tris-HCl pH7.5, 2 mM 
EDTA). VapC cleavage was performed in cleavage buffer containing 1 pmol 
tRNA
fMet
 and 0.01 pmol, 0.025 pmol and 0.05 pmol of VapC for 15 min at 37ºC. In 
the cleavage control, VapC was omitted. The reactions were stopped by addition of 
FD buffer and the tRNA separated on a 10% PAGE (1:37.5) gel containing 8M Urea 
in 1 x TBE and visualised by subsequent phosphor imaging.  
Analysis of the in vivo cleavage site in tRNAfMet  
To determine the cleavage site in vivo, tRNA
fMet
 was isolated from total tRNA by 
hybridization to tRNA
fMet
 specific biotinylated DNA probes Fmet-bio, FMET-BIO-N 
or FMET-BIO-3 (see Table 5). Five micrograms of dephosphorylated total tRNA was 
mixed with 5 pmol of Fmet-bio oligo in 10 µL RNA buffer (10 mM HEPES pH 7.5, 
15 mM KCl). The mixture was denatured at 80 ºC for 10 min and incubated on ice for 
5 min. The hybrid was added to 20 µL of Streptavidin Sepharose HP (GE Healthcare) 
and incubated for 5 min at room temperature during gentle mixing. The sepharose was 
then washed three times in RNA buffer to remove non-specific hybridization. The 
sepharose beads were resuspended in 15 µL RNA buffer with 2 µL polynucleotide 
kinase buffer, 1µL kinase was added together with 2 µL [γ-32P]-ATP. The solution 
was incubated for 30 min at 37 ºC. Finally, the sepharose was washed three times in 
RNA buffer to remove excess un-incorporated [
32
P]-ATP and the reaction stopped by 
addition of FD buffer. The fragments could be resolved by 10% Urea PAGE (1:37.5) 
in 1 x TBE and visualized by phosphor imaging. 
Ribosome Profiles generated by ultracentrifugation  
Ribosome profiles and subsequent Western analysis was done according to (Liu et al., 
2008), however with modifications. MG1655∆lon containing either pKW3352HC 
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(pBAD33::vapCLT2-H6) or pKW3382HC (pBAD33::vapC-H6) were grown 
exponentially in 400mL of LB. At OD450 = 0.4, transcription was induced by the 
addition of 0.2% arabinose and expression was allowed to continue for 20‟ before the 
cultures were harvested. Pellets were washed in Ribosome buffer (10 mM MgCl2 50 
mM NH4Cl 10 mM Tris, pH 7.4 and 5 mM DTT) and stored at -80ºC. Pellet was then 
resuspended in 5 mL ice-cold Ribosome buffer with EDTA-free protease inhibitor 
and 5U of RNase-free DNase (Roche). The Cells were lysed by passing trough Cell 
Disrupter at 16.000 bar once and the lysate cleared by centrifugation at 15,000 rpm 
for 20 min. 500µL of cleared lysate was loaded onto at 5-40% continuous sucrose 
gradient in Ribosome buffer and centrifuged either at 35.000 rpm for 3.5 h or at 
28,000 rpm for 12 hr at 4ºC in a Beckman SW40Ti rotor. Gradients were fractionated 
in 500 µL fractions and visualized in a 1% agarose gel stained with EtBr. In an 
attempt to separate ribosomal subunits, 1 mL of lysate was initially centrifuged 
through a 1.1 M sucrose cushion in ribosome buffer at 35,000 rpm for 14hr at 4ºC. 
The clear ribosome pellet, which appeared was then washed gently with low 
magnesium ribosome buffer (1 mM MgCl2 50 mM NH4Cl 10 mM Tris, pH 7.4 and 5 
mM DTT) and resuspended in 1 mL low magnesium ribosome buffer by gentle 
agitation on ice. 500µL of the resuspend ribosome solution was then loaded onto a 5-
40% continuous sucrose gradient in low magnesium ribosome buffer and centrifuged 
at 28,000 rpm for 12hr at 4ºC. Gradients were then fractionated in 500 µL fraction 
and visualized in a 1% agarose gel stained with EtBr. 
Luciferase activity assays 
The assay was carried out in accordance with (Kimura and Suzuki, 2010), however 
with modifications. E. coli K-12 MG1655∆lon containing pKW3352HC 
(BAD::vapCLT2) with pQE AAA or pQE AAG were grown exponentially in LB 
medium at 37ºC. At OD450 = 0.4, 0.2% arabinose was added and after 30 min of 
expression, 0.5 mL samples were harvested by centrifugation. The cell pellet was then 
resuspended in 100 µL of luciferase lysis buffer (50 mM HEPES pH 7.5, 100 mM 
KCl, 10 mM MgCl2, 7 mM β-Mercaptoethanol and 400 µM lysozyme). The 
suspension was then shock-frozen in liquid nitrogen and thawed on ice. The lysate 
was cleared by centrifugation and 10 µL of lysate was used in the Dual-Luciferase® 
Reporter Assay System (Promega) in accordance with manufactures protocol. The 
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translation efficiency on the start codon of lucF was determined as the LucF/LucR 
ratio.  
Northern blot analysis 
Northern analysis was used for detection and quantification of mRNA and tRNA 
levels.  
mRNA Northern blot analysis 
For mRNA quantification 10 g of total RNA was fractionated in a 5% PAGE 
(1:37.5) gel containing 1x TBE and 8M Urea and electroblotted to a Zeta-probe nylon 
membrane (Bio Rad) and hybridized with a single-stranded 
32
P-labelled riboprobe, 
complementary to the RNA in PerfectHyb
TM
 Plus hybridization buffer (Sigma) ON at 
65 ºC. The riboprobes for lpp and tmRNA were generated using pstI linerized pSC333 
and pSC334 as template. The dksA and ompA specific riboprobes were generated with 
a PCR product template including a T7 promoter made with primers dksA probe-f and 
dksA T7 probe-r and T7/pmoA and pmoA-forw, respectively. Templates were in vitro 
transcribed for 2 h at 37ºC [T7 RNA polymerase (Promega); 0.1 M DTT;1x transc. 
buffer; 2.5 mM of ATP, GTP and UTP; 0.2g template; [32Pα]-CTP (50 mCi); 
100M CTP; RNase inhibitor]. DNA template was removed by adding DNase. The 
membranes were washed in 2 x SSC (0.3M NaCl, 0.03M Na-citrate, pH 7) with 0.1 % 
SDS twice at room temperature, to wash increase stringency, membrane were 
additionally washed one – two times for 30 min in 0.5 x SSC with 0.1% SDS at 
hybridisation temperature. Finally the blot was detected by phosphor imaging  
tRNA Northern blot analysis 
Northern blot analysis was also applied to determine the stability of different tRNA 
species after VapC or VapCLT2 expression. Five micrograms of purified tRNA was 
mixed with loading buffer (0.1 M Na-Acetate pH 5, 8 M Urea, 0.05% bromphenol 
blue and 0.05% xylene cyanol) and separated in an 8% PAGE (1:37.5) gel containing 
8 M urea and 0.1 M Na-acetate pH 5. The part of the gel containing tRNA of interest 
was then electroblotted onto a Hybond-N membrane (GE Healthcare) in transfer 
buffer (40 mM Tris-Acetate, 2 mM EDTA pH 8.1). The separated tRNA was UV-
crosslinked. The membrane was pre-hybridized in PerfectHyb
TM
 Plus hybridization 
buffer (Sigma) for 5 min at 42 ºC following addition of an appropriate 
32
P-labelled 
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DNA oligo probe; tRNA
Val
, tRNA
Phe
, tRNA
Met
, tRNA
Arg2
, tRNA
His
, tRNA
Leu1
, 
tRNA
Thr1
, tRNA
fMet
 or tRNA
Tyr
 (see the oligonucleotide list) and subsequent 
hybridization for at least 4 h at 42 ºC. After hybridization, the membrane was washed 
two - three times 5 min in 2 x SSC with 0.1% SDS at room temperature and the blot 
was analysed by phorsphor imaging.  
Primer extension analysis 
Primer extension analysis was used semi-quantitatively, and to identify mRNA 5‟-
ends generated either as transcript 5‟-ends or by mRNA interferase cleavage. 
Identification of the transcriptional start site of the vapBCLT2 promoter 
To map the promoter vapBCLT2 from S. enterica LT2, primer extension analysis was 
performed on total RNA from KP1001 S. typimurium LT2 or E. coli K-12 variants 
containing a plasmid with vapBC operon. The vapB-5#PE primer (4 pmol) which is 
specific to vapB in vapBC mRNA was labelled in a reaction with 4µL [γ-32P]-ATP 
and T4 polynucleotide kinase (NEB) for 30 min at 37ºC. Labelled primer (0.2 pmol) 
was hybridized with 10 µg of total RNA. Hybridization with primer was followed by 
reverse transcription using 0.1 U of SuperScript II Reverse transcriptase (Invitrogen) 
in 1 x FirstStrand buffer, 10 mM DTT and 1 mM dNTP for 1 h at 42ºC. Radiolabelled 
cDNA was separated in a 6% PAGE (1:37.5) gel containing 8 M Urea with 1 x TBE 
and visualized by phosphor imaging.  
Identification of cleavage sites generated by YoeB mRNA interferase 
To identify the cleavage sites of ribosome dependent YoeB mRNase, primer 
extension analysis was performed on genetically modified versions of the dksA 
mRNA. The pKW71D-3#PE primer (4 pmol) which is specific to the 3‟-end of dksA 
mRNA deriving from pKW25420T (dksA with native promoter), pkW25421T (dksA, 
ATG→AAG), pKW25423T (dksA, in frame premature termination codon, 
pKW25424T (dksA, out of frame TAA), pKW25425T (dksA, out of frame TAA), 
pKW25427T (dksA without SD sequence) and pKW25428T (dksA, ATG→AAG, 
without SD sequence) was labelled in a reaction with 4µL [γ-32P]-ATP and T4 
polynucleotide kinase (NEB) for 30 min at 37ºC. Labelled primer (0.2 pmol) was 
hybridized with 20 µg of total RNA isolated from E. coli K-12 expressing dksA 
derivates together with vapC, vapCLT2 or YoeB. The hybridization was followed by 
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reverse transcription using 0.1 U of SuperScript II Reverse transcriptase (Invitrogen) 
in 1 x FirstStrand buffer, 10 mM DTT and 1 mM dNTP. The tmRNA 5‟-end and the 
small reading frame was mapped using primer 10SA-2. Radiolabelled cDNA was 
fractionated in a 6% PAGE (1:37.5) gel containing 8 M Urea with 1 x TBE and 
visualized by phosphor imaging.  
Western blot analysis 
Western blot analysis was used to detect specific proteins in protein samples either 
using protein specific or tag specific antibodies 
Degradation of VapBLT2 in the cell 
The stability of VapBLT2 after addition of chloramphenicol was determined by 
Western Blot Analysis. The vapBLT2 transcription was induced from pKW51, a low 
copy plasmid, by addition of 1 mM IPTG for 10min to exponentially growing 
MG1655, KW10 (MG1655 ∆lon) and KW11 (MG1655 ∆clp). Translation was 
inhibited by addition of 50µg/mL choramphenicol and 1 mL samples were taken at 
time points indicated. Samples were rapidly harvested at 4ºC and cell pellet resuspend 
in 50 µL leammli buffer (Buffer stock, 4mL 50% glycerol, 1mL Mercaptoethanol, 
5.75mL 10% SDS, 2.5mL 0.5M Tri-HCl pH 6.8 and 1mL 0.1% Bromophenol blue)  
and boiled for 2 min. Proteins from 10 µL samples were separated by SDS-PAGE and 
electroblotted onto a PVDF transfer membrane (GE healthcare) and membrane 
blocked 1hr at ambient temperature in PBS-T (Phosphate Buffered Saline (Oxoid) 
with 0.1% Tween) with 5% milk powder. The membrane was briefly washed in PBS-
T and then incubated for at least 1 h at room temperature with VapBLT2 polyclonal 
antibodies (Eurogentec) in PBS-T and 2% milk powder. After 2 x 5 min washing 
steps in PBS-T was followed by incubation with HRP (Horseradish Peroxidase) 
conjugated anti-rabbit IgG antibodies (Sigma) in PBS-T with 2% milk powder for 1 h 
at room temperature. The membrane was then washed 2 x 5 min and 15 min in PBS-T 
and the blot detected by chemiluminescense using ECL plus western blotting 
detection system (GE Healthcare). 
Western blot analysis on ribosome fractions 
VapC-H6 and VapCLT2-H6 were detected in sucrose gradient fractions by western blot 
analysis. 10 µL relevant ribosome gradient fractions were mixed with 10 µL of 
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laemmli buffer and proteins separated in a 4-12% SDS-PAGE gel (Invitrogen). 
Proteins were then electro blotted onto a PVDF transfer membrane (GE healthcare) at 
115mA for 60 min and membrane blocked ON at 4ºC in PBS-T (PBS with 0.1% 
Tween) and 5% milk powder. The membrane was then incubated for at least 3 h at 
4ºC with Penta-His monoclonal antibodies (Qiagen) in PBS-T and 2% milk powder. 
The membrane was then briefly washed in PBS-T followed by incubation with HRP 
conjugated mouse IgG antibodies (Sigma) for 2 h at 4ºC. The membrane was finally 
washed in PBS-T and the blot detected using ECL plus western blotting detection 
system (GE Healthcare).       
Electrophoretic mobility shift assays and DNase I footprinting 
DNA fragments containing either one binding site, vapO1  (using hybridised oligos 
VapBCbinding#small-down and VapBCbinding#small-up), or two binding sites, 
vapO1 and vapO2 (PCR product with oligos vapBC_EMSA_down and 
vapBC_EMSA_up), were 5‟-end-labelled with [γ-32P]ATP using T4 polynucleotide 
Kinase (NEB). Binding site mutations in vapO1 or vapO2 were introduced by PCR 
using primers PBC-10_MUT_DOWN and PBC-10_MUT_UP for vapO1mut and 
PBC-35_MUT_DOWN and PBC-35_MUT_UP for vapO2mut. Binding Control DNA 
(199bp) was amplified from pUC plasmid DNA using primer 171SR14 and 171SR16 
and was 5‟-labelled as described above. 
Labelled probes (0.5-2nM) were incubated with purified proteins in binding buffer 
(20 mM Tris-HCl pH 7.5,100 mM KCl, 2 mM MgCl2, 1 mM DTT, 50 µg/mL BSA 
and 10% glycerol) in a volume of 20uL or 30uL. To avoid unspecific DNA binding 
sonicated salmon sperm DNA (ssDNA) was added to a final concentration 0.1 mg/ml. 
Reactions were incubated for 20 min at 37ºC before DNA bound complexes were 
separated by native PAGE in 5% or 6% acrylamide gels (1:37.5) with 0.5x TBE for 
two and one binding site probes, respectively. The separation was followed by 
phosphor imaging. 
DNase I footprinting 
For DNase I footprinting, binding reactions prepared as described above, were 
incubated with 0.01 U/µl DNase I and 1 x DNase I buffer (Roche) at 37°C for 2 min, 
followed by addition of 100 µl of Stop buffer (2 M ammonium acetate, 20 mM 
EDTA, 10 mg/ml ssDNA). The resulting DNA fragments were extracted once in 
 152 
phenol, once in chloroform, precipitated in ethanol equalized for total radioactivity 
and separated on an 8% PAGE gel (1:37.5) containing 8M Urea in 1 x TBE along 
with a dideoxyNTP sequencing ladder. The digestion pattern was detected by 
phosphor imaging. 
MW estimation of VapBCLT2 complex bound to DNA 
The molecular weight (MW) of VapBCLT2 bound to DNA was estimated according to 
an EMSA-based method (Orchard and May, 1993). 50 pmol of VapCLT2 was 
incubated with 50 pmol of VapBLT2 and 5 pmol DNA probe (containing vapO1) in 
binding buffer as described above. The binding reactions were analyzed on a series of 
polyacrylamide gels (7%-10%) including four molecular weight markers (Lactal 
Albumin, 14.2kD, Carbonic Anhydrase, 29kD, Ovoalbumin, 44kD, Bovine Serum 
Albumin, 66kD). The gels were silver stained and the distance from the well to 
stained protein band was measured and divided by the bromophenol blue migration 
distance to give the relative mobility (Rf). The logarithm of the Rf values for protein 
complex and molecular weight marker was plotted against the gel acrylamide 
concentration and a best-line fit was obtained. The negative slopes of these fits were 
plotted against the molecular weights of the protein standards on a double-logarithmic 
scale and a best-line fit was obtained. The slope of VapBCLT2 bound to DNA could 
then extrapolated according to the equation (y = 0.0884x + 0.6332) and the MW of 
the DNA (22.116 kD) was subtracted to give MW of VapBCLT2.   
β-galactosidase assays 
Overnight cultures were diluted to an OD600 ~ 0.05 in LB supplemented with 
appropriate antibiotics and grown at 37°C to an OD600 of 0.5 and diluted to OD600 of 
0.05. At OD600 of 0.4-0.5 samples of 500 µL were taken.  Activity of the fusion was 
measured by monitoring β-galactosidase activity (Units) in samples from cells 
carrying pOU254 and pOU253 derivatives using the chloroform protocol variant as 
described (Miller, 1972). Experiments were carried out in triplicates.  
Quantitative PCR 
Total RNA was extracted from cell samples using RNeasy mini kit (Qiagen). After 
elution, RNA was treated with DNase in an additional step to ensure that RNA was 
completely DNA free. Total RNA was converted to cDNA in 20 uL standard 
 153 
reactions with 0.32 µg of RNA and random primers using MultiScribe™ reverse 
transcriptase (AppliedBiosystems) according to manufactures instructions.  The 
cDNA was diluted 100-fold and 6 µL used in 20 uL standard reactions containing 2 
uL of each primer and 10 µL 2x Sybr Green PCR mastermix (Qiagen). Primers used 
were q-vapB-f and q-vapB-rv for vapB mRNA and rpsA qPCR-f and rpsA qPCR-rv 
for internal reference gene (rpsA). The cDNA was amplified in a Rotor-Gene Q real-
time PCR cycler (Qiagen) and the quantification performed using Rotor-Gene Q 
software by the ∆∆Ct relative quantification method (Livak and Schmittgen, 2001). 
Standard curves for primer efficiencies were performed using 10, 100, 10
3
 and 10
4
 
dilutions of cDNA and was taken into consideration in the Ct values obtained.  
In vitro translation of vapBCLT2 mRNA 
The vapBCLT2 mRNA variants were purified as T7 transcripts from DNA templates. 
For wild type vapBC mRNA primers VAPBC_T7_DOWN and 
VAPBC_T7_RRNBT1_UP were used. PCR products using 
BC_253_PRESTOPB_DOWN and BC_253_PRESTOPB_UP or BC_253_STARTB 
_DOWN and BC_253_STARTB _UP were used as templates in a PCR with 
VAPBC_T7_DOWN and VAPBC_T7_RRNBT1_UP to create T7 templates for 
vapBCLT2 mRNA containing premature stop codon in vapBLT2 and vapBLT2 start 
codon mutation, respectively. The DNA templates were transcribed using T7 RNA 
polymerase (Promega) in accordance with manufactures instructions. T7 transcripts 
were purified by extraction from denaturing PAGE gel. Transcripts were then in vitro 
translated using a cell free in vitro translation S30 extract (Promega). Each reaction 
contained 8 µL S30 premix, 2 µL amino acid mix, 5 µL S30 extract, 1 µL 
35
S-
methionine which was preincubated for 5 min at 37ºC before addition of 1 pmol of 
mRNA. Incubation was continued for 25 min before reaction was terminated by 
acetone precipitation. Protein product was visualized by SDS-PAGE and phosphor 
imaging. 
In vitro cross-linking of purified VapCLT2 
The presence of VapCLT2 dimer in solution was verified by in vitro cross linking with 
formaldehyde. 5 pmol Purified VapCLT2 or VapCLT2
Y72A
 mutant was incubated with 
0.7% formaldehyde in storage buffer (PBS + 20% glycerol) for 15 min at 37ºC. The 
cross linking reaction was terminated by addition of glycine to final concentration of 
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0.25M and leammli buffer. The cross linked complexes were separated by 4-12% 
SDS-PAGE and visualised by silver staining. 
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